0000275053-22-000017.txt : 20220809 0000275053-22-000017.hdr.sgml : 20220809 20220809171135 ACCESSION NUMBER: 0000275053-22-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURES SUNSHINE PRODUCTS INC CENTRAL INDEX KEY: 0000275053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870327982 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34483 FILM NUMBER: 221149380 BUSINESS ADDRESS: STREET 1: 2901 WEST BLUEGRASS BLVD. STREET 2: SUITE 100 CITY: LEHI STATE: UT ZIP: 84043 BUSINESS PHONE: (801) 341-7900 MAIL ADDRESS: STREET 1: 2901 WEST BLUEGRASS BLVD. STREET 2: SUITE 100 CITY: LEHI STATE: UT ZIP: 84043 FORMER COMPANY: FORMER CONFORMED NAME: AMTEC INDUSTRIES INC DATE OF NAME CHANGE: 19821108 10-Q 1 natr-20220630.htm 10-Q natr-20220630
0000275053false2022Q2--12-3111.2500002750532022-01-012022-06-3000002750532022-07-22xbrli:shares00002750532022-06-30iso4217:USD00002750532021-12-31iso4217:USDxbrli:shares00002750532022-04-012022-06-3000002750532021-04-012021-06-3000002750532021-01-012021-06-300000275053us-gaap:CommonStockMember2021-12-310000275053us-gaap:RetainedEarningsMember2021-12-310000275053us-gaap:NoncontrollingInterestMember2021-12-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000275053us-gaap:CommonStockMember2022-01-012022-03-3100002750532022-01-012022-03-310000275053us-gaap:RetainedEarningsMember2022-01-012022-03-310000275053us-gaap:NoncontrollingInterestMember2022-01-012022-03-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000275053us-gaap:CommonStockMember2022-03-310000275053us-gaap:RetainedEarningsMember2022-03-310000275053us-gaap:NoncontrollingInterestMember2022-03-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100002750532022-03-310000275053us-gaap:CommonStockMember2022-04-012022-06-300000275053us-gaap:RetainedEarningsMember2022-04-012022-06-300000275053us-gaap:NoncontrollingInterestMember2022-04-012022-06-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000275053us-gaap:CommonStockMember2022-06-300000275053us-gaap:RetainedEarningsMember2022-06-300000275053us-gaap:NoncontrollingInterestMember2022-06-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000275053us-gaap:CommonStockMember2020-12-310000275053us-gaap:RetainedEarningsMember2020-12-310000275053us-gaap:NoncontrollingInterestMember2020-12-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100002750532020-12-310000275053us-gaap:CommonStockMember2021-01-012021-03-3100002750532021-01-012021-03-310000275053us-gaap:RetainedEarningsMember2021-01-012021-03-310000275053us-gaap:NoncontrollingInterestMember2021-01-012021-03-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000275053us-gaap:CommonStockMember2021-03-310000275053us-gaap:RetainedEarningsMember2021-03-310000275053us-gaap:NoncontrollingInterestMember2021-03-310000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100002750532021-03-310000275053us-gaap:CommonStockMember2021-04-012021-06-300000275053us-gaap:RetainedEarningsMember2021-04-012021-06-300000275053us-gaap:NoncontrollingInterestMember2021-04-012021-06-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000275053us-gaap:CommonStockMember2021-06-300000275053us-gaap:RetainedEarningsMember2021-06-300000275053us-gaap:NoncontrollingInterestMember2021-06-300000275053us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000002750532021-06-300000275053natr:AccruedSeveranceandRentCostsMember2022-06-300000275053natr:AccruedSeveranceandRentCostsMember2021-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2017-07-110000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-06-23natr:borrowing0000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2022-06-232022-06-23xbrli:pure0000275053natr:BankofAmericaCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2022-06-300000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-06-232022-06-230000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-12-310000275053natr:BankofAmericaCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-06-300000275053natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMemberus-gaap:LineOfCreditMember2020-04-210000275053natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMemberus-gaap:LineOfCreditMember2020-11-190000275053natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMembernatr:IndicativeIndexMemberus-gaap:LineOfCreditMember2022-06-300000275053natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMemberus-gaap:LineOfCreditMember2020-11-192020-11-19natr:payment0000275053natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMemberus-gaap:LineOfCreditMember2022-06-3000002750532021-04-052021-04-0500002750532021-03-1000002750532022-03-080000275053natr:A2012IncentivePlanMember2012-12-310000275053natr:A2012IncentivePlanMember2015-01-012015-12-310000275053natr:A2012IncentivePlanMember2021-05-052021-05-050000275053srt:MaximumMembernatr:TimeBasedStockOptionsMember2022-01-012022-06-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2022-01-012022-06-300000275053us-gaap:EmployeeStockOptionMember2021-12-310000275053us-gaap:EmployeeStockOptionMember2022-01-012022-06-300000275053us-gaap:EmployeeStockOptionMember2022-06-300000275053us-gaap:EmployeeStockOptionMember2022-04-012022-06-300000275053us-gaap:EmployeeStockOptionMember2021-04-012021-06-300000275053us-gaap:EmployeeStockOptionMember2021-01-012021-06-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2021-12-310000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember2022-06-300000275053srt:MinimumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053srt:MaximumMembernatr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053natr:A2012IncentivePlanMembersrt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053natr:A2012IncentivePlanMembersrt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-300000275053natr:A2012IncentivePlanMembersrt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2021-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2021-12-310000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053natr:A2012IncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2022-06-300000275053natr:A2012IncentivePlanMembernatr:TimeBasedRestrictedStockUnitsRSUsMember2022-01-012022-06-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMembernatr:A2012IncentivePlanMember2022-01-012022-06-300000275053natr:NetSalesandOperatingIncomeTargetsMembernatr:PerformanceBasedRestrictedStockUnitsRSUsMembernatr:A2012IncentivePlanMember2022-01-012022-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2022-06-300000275053us-gaap:RestrictedStockUnitsRSUMember2021-12-310000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMember2022-04-012022-06-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMember2021-04-012021-06-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMember2022-01-012022-06-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMember2021-01-012021-06-300000275053natr:PerformanceBasedRestrictedStockUnitsRSUsMembersrt:MaximumMember2022-06-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMembersrt:MinimumMember2022-01-012022-06-300000275053natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMembersrt:MaximumMember2022-01-012022-06-30natr:segment0000275053natr:AsiaSegmentMember2022-04-012022-06-300000275053natr:AsiaSegmentMember2021-04-012021-06-300000275053natr:AsiaSegmentMember2022-01-012022-06-300000275053natr:AsiaSegmentMember2021-01-012021-06-300000275053natr:EuropeSegmentMember2022-04-012022-06-300000275053natr:EuropeSegmentMember2021-04-012021-06-300000275053natr:EuropeSegmentMember2022-01-012022-06-300000275053natr:EuropeSegmentMember2021-01-012021-06-300000275053natr:NorthAmericaSegmentMember2022-04-012022-06-300000275053natr:NorthAmericaSegmentMember2021-04-012021-06-300000275053natr:NorthAmericaSegmentMember2022-01-012022-06-300000275053natr:NorthAmericaSegmentMember2021-01-012021-06-300000275053natr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053country:CN2022-04-012022-06-300000275053country:CN2022-01-012022-06-300000275053country:CN2021-04-012021-06-300000275053country:CN2021-01-012021-06-300000275053country:US2022-04-012022-06-300000275053country:US2021-04-012021-06-300000275053country:US2022-01-012022-06-300000275053country:US2021-01-012021-06-300000275053country:KR2022-04-012022-06-300000275053country:KR2021-04-012021-06-300000275053country:KR2022-01-012022-06-300000275053country:KR2021-01-012021-06-300000275053country:TW2022-04-012022-06-300000275053country:TW2021-04-012021-06-300000275053country:TW2022-01-012022-06-300000275053country:TW2021-01-012021-06-300000275053natr:OtherCountriesMember2022-04-012022-06-300000275053natr:OtherCountriesMember2021-04-012021-06-300000275053natr:OtherCountriesMember2022-01-012022-06-300000275053natr:OtherCountriesMember2021-01-012021-06-300000275053natr:GeneralHealthProductsMembernatr:AsiaSegmentMember2022-04-012022-06-300000275053natr:GeneralHealthProductsMembernatr:AsiaSegmentMember2021-04-012021-06-300000275053natr:GeneralHealthProductsMembernatr:AsiaSegmentMember2022-01-012022-06-300000275053natr:GeneralHealthProductsMembernatr:AsiaSegmentMember2021-01-012021-06-300000275053natr:ImmunityProductsMembernatr:AsiaSegmentMember2022-04-012022-06-300000275053natr:ImmunityProductsMembernatr:AsiaSegmentMember2021-04-012021-06-300000275053natr:ImmunityProductsMembernatr:AsiaSegmentMember2022-01-012022-06-300000275053natr:ImmunityProductsMembernatr:AsiaSegmentMember2021-01-012021-06-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2022-04-012022-06-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2021-04-012021-06-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2022-01-012022-06-300000275053natr:AsiaSegmentMembernatr:CardiovascularProductsMember2021-01-012021-06-300000275053natr:DigestiveProductsMembernatr:AsiaSegmentMember2022-04-012022-06-300000275053natr:DigestiveProductsMembernatr:AsiaSegmentMember2021-04-012021-06-300000275053natr:DigestiveProductsMembernatr:AsiaSegmentMember2022-01-012022-06-300000275053natr:DigestiveProductsMembernatr:AsiaSegmentMember2021-01-012021-06-300000275053natr:PersonalCareProductsMembernatr:AsiaSegmentMember2022-04-012022-06-300000275053natr:PersonalCareProductsMembernatr:AsiaSegmentMember2021-04-012021-06-300000275053natr:PersonalCareProductsMembernatr:AsiaSegmentMember2022-01-012022-06-300000275053natr:PersonalCareProductsMembernatr:AsiaSegmentMember2021-01-012021-06-300000275053natr:WeightManagementProductsMembernatr:AsiaSegmentMember2022-04-012022-06-300000275053natr:WeightManagementProductsMembernatr:AsiaSegmentMember2021-04-012021-06-300000275053natr:WeightManagementProductsMembernatr:AsiaSegmentMember2022-01-012022-06-300000275053natr:WeightManagementProductsMembernatr:AsiaSegmentMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:GeneralHealthProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:GeneralHealthProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:GeneralHealthProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:GeneralHealthProductsMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:ImmunityProductsMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:CardiovascularProductsMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:DigestiveProductsMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:PersonalCareProductsMember2021-01-012021-06-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2022-04-012022-06-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2021-04-012021-06-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2022-01-012022-06-300000275053natr:EuropeSegmentMembernatr:WeightManagementProductsMember2021-01-012021-06-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2022-04-012022-06-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2021-04-012021-06-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2022-01-012022-06-300000275053natr:GeneralHealthProductsMembernatr:NorthAmericaSegmentMember2021-01-012021-06-300000275053natr:ImmunityProductsMembernatr:NorthAmericaSegmentMember2022-04-012022-06-300000275053natr:ImmunityProductsMembernatr:NorthAmericaSegmentMember2021-04-012021-06-300000275053natr:ImmunityProductsMembernatr:NorthAmericaSegmentMember2022-01-012022-06-300000275053natr:ImmunityProductsMembernatr:NorthAmericaSegmentMember2021-01-012021-06-300000275053natr:NorthAmericaSegmentMembernatr:CardiovascularProductsMember2022-04-012022-06-300000275053natr:NorthAmericaSegmentMembernatr:CardiovascularProductsMember2021-04-012021-06-300000275053natr:NorthAmericaSegmentMembernatr:CardiovascularProductsMember2022-01-012022-06-300000275053natr:NorthAmericaSegmentMembernatr:CardiovascularProductsMember2021-01-012021-06-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2022-04-012022-06-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2021-04-012021-06-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2022-01-012022-06-300000275053natr:DigestiveProductsMembernatr:NorthAmericaSegmentMember2021-01-012021-06-300000275053natr:NorthAmericaSegmentMembernatr:PersonalCareProductsMember2022-04-012022-06-300000275053natr:NorthAmericaSegmentMembernatr:PersonalCareProductsMember2021-04-012021-06-300000275053natr:NorthAmericaSegmentMembernatr:PersonalCareProductsMember2022-01-012022-06-300000275053natr:NorthAmericaSegmentMembernatr:PersonalCareProductsMember2021-01-012021-06-300000275053natr:WeightManagementProductsMembernatr:NorthAmericaSegmentMember2022-04-012022-06-300000275053natr:WeightManagementProductsMembernatr:NorthAmericaSegmentMember2021-04-012021-06-300000275053natr:WeightManagementProductsMembernatr:NorthAmericaSegmentMember2022-01-012022-06-300000275053natr:WeightManagementProductsMembernatr:NorthAmericaSegmentMember2021-01-012021-06-300000275053natr:GeneralHealthProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:GeneralHealthProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:GeneralHealthProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:GeneralHealthProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053natr:ImmunityProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:ImmunityProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:ImmunityProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:ImmunityProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053natr:CardiovascularProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:CardiovascularProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:CardiovascularProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:CardiovascularProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053natr:DigestiveProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:DigestiveProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:DigestiveProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:DigestiveProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053natr:PersonalCareProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:PersonalCareProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:PersonalCareProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:PersonalCareProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053natr:WeightManagementProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-04-012022-06-300000275053natr:WeightManagementProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-04-012021-06-300000275053natr:WeightManagementProductsMembernatr:LatinAmericaAndOtherSegmentMember2022-01-012022-06-300000275053natr:WeightManagementProductsMembernatr:LatinAmericaAndOtherSegmentMember2021-01-012021-06-300000275053country:US2022-06-300000275053country:US2021-12-310000275053natr:OtherCountriesMember2022-06-300000275053natr:OtherCountriesMember2021-12-310000275053natr:AsiaSegmentMember2022-06-300000275053natr:AsiaSegmentMember2021-12-310000275053natr:EuropeSegmentMember2022-06-300000275053natr:EuropeSegmentMember2021-12-310000275053natr:NorthAmericaSegmentMember2022-06-300000275053natr:NorthAmericaSegmentMember2021-12-310000275053natr:LatinAmericaAndOtherSegmentMember2022-06-300000275053natr:LatinAmericaAndOtherSegmentMember2021-12-310000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2022-06-30natr:claim0000275053natr:NonIncomeTaxMember2022-06-300000275053natr:NonIncomeTaxMember2021-12-310000275053natr:NonIncomeTaxMembersrt:MinimumMember2022-06-300000275053natr:NonIncomeTaxMembersrt:MaximumMember2022-06-300000275053us-gaap:PendingLitigationMember2021-12-310000275053us-gaap:PendingLitigationMember2022-06-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember2022-01-012022-06-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MinimumMember2022-06-300000275053natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMembersrt:MaximumMember2022-06-300000275053natr:ChinaJointVentureMember2022-06-300000275053natr:ChinaJointVentureMember2021-06-300000275053natr:ChinaJointVentureMembernatr:FosunPharmaMember2021-06-300000275053natr:ChinaJointVentureMembernatr:FosunPharmaMember2022-06-300000275053srt:SubsidiariesMembernatr:ChinaJointVentureMemberus-gaap:NotesReceivableMember2022-01-012022-06-300000275053srt:SubsidiariesMembernatr:ChinaJointVentureMemberus-gaap:NotesReceivableMember2022-04-012022-06-300000275053srt:SubsidiariesMembernatr:ChinaJointVentureMemberus-gaap:NotesReceivableMember2021-01-012021-06-300000275053srt:SubsidiariesMembernatr:ChinaJointVentureMemberus-gaap:NotesReceivableMember2021-04-012021-06-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2022-06-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMember2021-12-310000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2022-06-300000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMembernatr:CompanysJointVenturePartnerMember2021-12-310000275053natr:NaturesSunshineProductsChinaMembersrt:SubsidiariesMemberus-gaap:NotesReceivableMember2022-01-012022-06-300000275053us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000275053us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000275053us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000275053us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000275053us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000275053us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-31natr:loyalty_pointnatr:product_category0000275053srt:MaximumMember2022-01-012022-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
_________________________________________________________________
 
FORM 10-Q 
(Mark One)
 
     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the quarterly period ended June 30, 2022
 
OR
 
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the transition period from            to            .
 
Commission File Number: 001-34483
natr-20220630_g1.jpg 
NATURE’S SUNSHINE PRODUCTS, INC.
(Exact name of Registrant as specified in its charter) 
Utah 87-0327982
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
 
2901 Bluegrass Boulevard, Suite 100
Lehi, Utah 84043
(Address of principal executive offices and zip code)
 
(801) 341-7900
(Registrant’s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valueNATR
Nasdaq Capital Market

 
Indicate by check mark whether the registrant; (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ý  No  o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ý  No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  o
 
Accelerated filer  ☒
   
Non-accelerated filer  o
 
Smaller reporting company 
  
Emerging growth company  
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes    No  ý.
 
The number of shares of Common Stock, no par value, outstanding on July 22, 2022, was 19,224,999 shares.



NATURE’S SUNSHINE PRODUCTS, INC.
FORM 10-Q
 
For the Quarter Ended June 30, 2022
 
Table of Contents
 
    
 
    
  
  
  
  
  
  
    
 
    
 
    
 
    
    
 
    
 
    
 
    
 
    
 
    
 
    
 

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
Certain information included or incorporated herein by reference in this report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. For example, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are more fully described in this report, including the risks set forth under “Risk Factors” in Item 1A, and in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, but include the following:

extensive government regulations to which the Company’s products, business practices and manufacturing activities are subject;
registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
legal challenges to the Company’s direct selling program or to the classification of its independent consultants;
laws and regulations regarding direct selling may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
liabilities and obligations arising from improper activity by the Company’s independent consultants;
product liability claims;
impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
the Company’s ability to attract and retain independent consultants;
the loss of one or more key independent consultants who have a significant sales network;
the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;
the effect of fluctuating foreign exchange rates;
failure of the Company’s independent consultants to comply with advertising laws;
changes to the Company’s independent consultants compensation plans;
geopolitical issues and conflicts;
adverse effects caused by the ongoing coronavirus pandemic;
negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
risks associated with the manufacturing of the Company’s products;
supply chain disruptions, manufacturing interruptions or delays, or the failure to accurately forecast customer demand;
failure to timely and effectively obtain shipments of products from our manufacturers and deliver products to our independent consultants and customers;
world-wide slowdowns and delays related to supply chain, ingredient shortages and logistical challenges;
uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
changes in tax laws, treaties or regulations, or their interpretation;
cybersecurity threats and exposure to data loss;
the storage, processing, and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
reliance on information technology infrastructure; and
the sufficiency of trademarks and other intellectual property rights.

All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report. Throughout this report, we refer to Nature’s Sunshine Products, Inc., together with our subsidiaries, as "we," "us," "our," "our Company" or “the Company.”

3

PART I FINANCIAL INFORMATION
 
Item 1. FINANCIAL STATEMENTS
 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
 June 30,
2022
December 31,
2021
Assets  
Current assets:  
Cash and cash equivalents$56,344 $86,184 
Accounts receivable, net of allowance for doubtful accounts of $525 and $143, respectively
10,540 8,871 
Inventories70,643 60,852 
Prepaid expenses and other9,618 8,760 
Total current assets147,145 164,667 
Property, plant and equipment, net49,099 50,857 
Operating lease right-of-use assets18,060 18,349 
Investment securities - trading743 964 
Deferred income tax assets7,794 13,590 
Other assets10,218 10,447 
Total assets$233,059 $258,874 
Liabilities and Shareholders’ Equity  
Current liabilities:  
Accounts payable$9,423 $9,702 
Accrued volume incentives and service fees23,199 23,131 
Accrued liabilities26,842 31,600 
Deferred revenue1,829 3,694 
Related party notes payable 302 
Income taxes payable2,227 2,647 
Current portion of operating lease liabilities4,336 4,350 
Current portion of note payable1,263 1,244 
Total current liabilities69,119 76,670 
Long-term portion of operating lease liabilities15,871 15,919 
Long-term note payable537 1,174 
Deferred compensation payable743 964 
Deferred income tax liabilities1,212 1,566 
Other liabilities1,098 1,177 
Total liabilities88,580 97,470 
Shareholders’ equity:  
Common stock, no par value, 50,000 shares authorized, 19,259 and 19,724 shares issued and outstanding, respectively
121,623 133,382 
Retained earnings32,591 35,025 
Noncontrolling interest3,902 3,202 
Accumulated other comprehensive loss(13,637)(10,205)
Total shareholders’ equity144,479 161,404 
Total liabilities and shareholders’ equity$233,059 $258,874 
 
See accompanying notes to condensed consolidated financial statements.

4


NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited) 
 Three Months Ended
June 30,
 20222021
Net sales$104,161 $108,978 
Cost of sales29,471 28,463 
Gross profit74,690 80,515 
Operating expenses:  
Volume incentives32,069 35,443 
Selling, general and administrative36,866 35,586 
Operating income5,755 9,486 
Other income (loss), net(442)529 
Income before provision for income taxes5,313 10,015 
Provision for income taxes4,361 3,221 
Net income952 6,794 
Net income attributable to noncontrolling interests436 254 
Net income attributable to common shareholders$516 $6,540 
Basic and diluted net income per common share:  
Basic earnings per share attributable to common shareholders$0.03 $0.33 
Diluted earnings per share attributable to common shareholders$0.03 $0.32 
Weighted average basic common shares outstanding19,386 19,999 
Weighted average diluted common shares outstanding19,594 20,503 
 
See accompanying notes to condensed consolidated financial statements.

5

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share information)
(Unaudited) 
 Six Months Ended
June 30,
 20222021
Net sales$214,655 $211,399 
Cost of sales63,931 55,442 
Gross profit150,724 155,957 
Operating expenses:  
Volume incentives66,171 69,698 
Selling, general and administrative77,489 69,138 
Operating income7,064 17,121 
Other loss, net(756)(1,404)
Income before provision for income taxes6,308 15,717 
Provision for income taxes8,042 4,771 
Net income (loss)(1,734)10,946 
Net income attributable to noncontrolling interests700 390 
Net income (loss) attributable to common shareholders$(2,434)$10,556 
Basic and diluted net income per common share:  
Basic earnings (loss) per share attributable to common shareholders$(0.12)$0.53 
Diluted earnings (loss) per share attributable to common shareholders$(0.12)$0.52 
Weighted average basic common shares outstanding19,479 19,897 
Weighted average diluted common shares outstanding19,479 20,340 
Dividends declared per common share$ $1.00 

See accompanying notes to condensed consolidated financial statements.
6

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Amounts in thousands)
(Unaudited) 
 Three Months Ended
June 30,
 20222021
Net income$952 $6,794 
Foreign currency translation loss (net of tax)(2,457)(45)
Total comprehensive income (loss)$(1,505)$6,749 
 
Six Months Ended
June 30,
 20222021
Net income (loss)$(1,734)$10,946 
Foreign currency translation loss (net of tax)(3,432)(166)
Total comprehensive income (loss)$(5,166)$10,780 
 
See accompanying notes to condensed consolidated financial statements.
 
7

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands)
(Unaudited) 
 Common StockRetained EarningsNoncontrolling
Interest
Accumulated
Other
Comprehensive
Loss
Total
 SharesAmount
Balance at December 31, 202119,724 $133,382 $35,025 $3,202 $(10,205)$161,404 
Share-based compensation expense— 801 — — — 801 
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax218 (795)— — — (795)
Repurchase of common stock(451)(7,971)— — — (7,971)
Net income (loss)— — (2,950)264 — (2,686)
Other comprehensive loss— — — — (975)(975)
Balance at March 31, 202219,491 $125,417 $32,075 $3,466 $(11,180)$149,778 
Share-based compensation expense— 540 — — — 540 
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax58 (334)— — — (334)
Repurchase of common stock(290)(4,000)— — — (4,000)
Net income— — 516 436 — 952 
Other comprehensive loss— — — — (2,457)(2,457)
Balance at June 30, 202219,259 $121,623 $32,591 $3,902 $(13,637)$144,479 

Common StockRetained EarningsNoncontrolling
Interest
Accumulated
Other
Comprehensive
Loss
Total
SharesAmount
Balance at December 31, 202019,697 $139,311 $26,030 $1,848 $(9,955)$157,234 
Share-based compensation expense— 1,005 — — — 1,005 
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax218 (914)— — — (914)
Cash dividends ($1.00 per share)
— — (19,858)— — (19,858)
Net income— — 4,016 136 — 4,152 
Other comprehensive loss— — — — (121)(121)
Balance at March 31, 202119,915 $139,402 $10,188 $1,984 $(10,076)$141,498 
Share-based compensation expense— 1,066 — — — 1,066 
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax152 (660)— — — (660)
Repurchase of common stock(77)(1,500)— — — (1,500)
Net income— — 6,540 254 — 6,794 
Other comprehensive loss— — — — (45)(45)
Balance at June 30, 202119,990 $138,308 $16,728 $2,238 $(10,121)$147,153 

See accompanying notes to condensed consolidated financial statements.
8

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited) 
 Six Months Ended
June 30,
 20222021
CASH FLOWS FROM OPERATING ACTIVITIES:  
Net income (loss)$(1,734)$10,946 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:  
Provision for doubtful accounts417  
Depreciation and amortization5,451 5,541 
Non-cash lease expense2,785 2,626 
Share-based compensation expense1,341 2,071 
Loss on sale of property, plant and equipment 12 
Deferred income taxes5,338 1,753 
Purchase of trading investment securities(19)(24)
Proceeds from sale of trading investment securities69 175 
Realized and unrealized gains (losses) on investments170 (67)
Foreign exchange losses803 1,572 
Changes in assets and liabilities:  
Accounts receivable(2,801)(2,755)
Inventories(11,910)(3,777)
Prepaid expenses and other current assets(1,357)(918)
Other assets(33)(108)
Accounts payable(80)1,079 
Accrued volume incentives and service fees1,045 483 
Accrued liabilities(4,001)(5,473)
Deferred revenue(1,718)(111)
Lease liabilities(2,503)(2,487)
Income taxes payable(386)261 
Liability related to unrecognized tax benefits (87)
Deferred compensation payable(220) 
Net cash provided by (used in) operating activities(9,343)10,712 
CASH FLOWS FROM INVESTING ACTIVITIES:  
Purchases of property, plant and equipment(3,757)(2,898)
Net cash used in investing activities(3,757)(2,898)
CASH FLOWS FROM FINANCING ACTIVITIES:  
Payments of cash dividends (19,858)
Principal payments of long-term debt(618)(698)
Proceeds from revolving credit facility15,645  
Principal payments of revolving credit facility(15,645) 
Principal payments of related party borrowing(300) 
Payments related to tax withholding for net-share settled equity awards(1,129)(1,574)
Repurchase of common stock(11,971)(1,500)
Net cash used in financing activities(14,018)(23,630)
Effect of exchange rates on cash and cash equivalents(2,722)(1,351)
Net decrease in cash and cash equivalents(29,840)(17,167)
Cash and cash equivalents at the beginning of the period86,184 92,069 
Cash and cash equivalents at the end of the period$56,344 $74,902 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:  
Cash paid for income taxes, net of refunds$4,173 $2,582 
Cash paid for interest113 111 
 
See accompanying notes to condensed consolidated financial statements.
9

NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
(1)    Basis of Presentation
 
We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.
 
Principles of Consolidation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.
 
These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.

The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions.

Noncontrolling Interests

Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.7 million for the three and six months ended June 30, 2022, respectively. Net income attributable to the noncontrolling interests was $0.3 million and $0.4 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, noncontrolling interests were $3.9 million and $3.2 million, respectively.

Restructuring Related Accruals and Expenses

We recorded $0 and $0.3 million of restructuring related expenses during the three and six months ended June 30, 2022, respectively. We recorded $0 and $48,000 of restructuring related expenses during the three and six months ended June 30, 2021, respectively. Accrued severance and restructuring related costs were $5,000 and $0.2 million as of June 30, 2022 and December 31, 2021, respectively.

Recent Accounting Pronouncements
 
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the
10

potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

(2)    Inventories
 
The composition of inventories is as follows (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Raw materials$27,680 $22,494 
Work in progress1,930 1,746 
Finished goods41,033 36,612 
Total inventories$70,643 $60,852 

(3)    Investment Securities - Trading
 
Our trading securities portfolio totaled $0.7 million at June 30, 2022, and $1.0 million at December 31, 2021, and generated losses of $0.1 million and gains of $0.1 million for the three months ended June 30, 2022 and 2021, respectively, and losses of $0.2 million and gains of $0.1 million for the six months ended June 30, 2022 and 2021, respectively.
 
(4)    Revolving Credit Facility and Other Obligations

On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022 the credit agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each. The amendment to the credit agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (3.10 percent as of June 30, 2022), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. At June 30, 2022 and December 31, 2021, there was no outstanding balance under the Credit Agreement.

The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of June 30, 2022, we were in compliance with the debt covenants set forth in the Credit Agreement.

On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in 36 monthly payments, of $0.1 million. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of June 30, 2022, there was $1.8 million outstanding balance under the Capital Credit Agreement, of which $1.3 million was classified as current.

(5)    Net Income Per Share
 
Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.

11

Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net income (loss) attributable to common shareholders$516 $6,540 $(2,434)$10,556 
Basic weighted average shares outstanding19,386 19,999 19,479 19,897 
Basic earnings (loss) per share attributable to common shareholders$0.03 $0.33 $(0.12)$0.53 
Diluted shares outstanding:    
Basic weighted-average shares outstanding19,386 19,999 19,479 19,897 
Stock-based awards208 504  443 
Diluted weighted-average shares outstanding19,594 20,503 19,479 20,340 
Diluted earnings (loss) per share attributable to common shareholders$0.03 $0.32 $(0.12)$0.52 
Dilutive shares excluded from diluted-per-share amounts:    
Stock options341 563  563 
Anti-dilutive shares excluded from diluted-per-share amounts:    
Stock options25  341 (1) 
_________________________________________

(1)     As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.

Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.
 
(6)    Capital Transactions
 
Dividends

On March 10, 2021, we announced a special non-recurring cash dividend of $1.00 per common share in an aggregate amount of $19.9 million that was paid on April 5, 2021, to shareholders of record on March 29, 2021. In accordance with the provisions of our 2012 Stock Incentive Plan (the "2012 Incentive Plan"), as a result of the special dividend we are required to make the participant's original grant whole by preventing either dilution or enlargement of the benefits or potential benefits intended by the original grant. The 2012 Incentive Plan provides our Compensation Committee with the discretion to meet this requirement. See further discussion in the Share-Based Compensation section of this Note.

The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors.

12

Share Repurchase Program

On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the six months ended June 30, 2022 and 2021, we repurchased 741,000 and 77,000 shares of our common stock for $12.0 million and $1.5 million, respectively. At June 30, 2022, the remaining balance available for repurchases under the program was $25.6 million.

Share-Based Compensation
 
During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.
 
Stock Options
 
Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.
 
Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Exercise
Price Per Share
Weighted Average
Grant Date
Fair Value
Options outstanding at December 31, 2021172 $12.13 $5.05 
Granted   
Forfeited or canceled   
Exercised(29)9.17 3.92 
Options outstanding at June 30, 2022143 $12.72 $5.28 

There was no share-based compensation expense for the three- and six-month periods ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, there was no unrecognized share-based compensation expense related to the grants described above.

At June 30, 2022, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 143,000 shares of common stock was $41,000. At December 31, 2021, the aggregate intrinsic value of outstanding and exercisable options to purchase 172,000 shares of common stock was $1.1 million.

For the six-month periods ended June 30, 2022 and 2021, we issued 29,000 and 50,000 shares of common stock upon the exercise of stock options at an average exercise price of $9.17 and $12.00 per share, respectively. The aggregate intrinsic value of options exercised during the six-month periods ended June 30, 2022 and 2021, was $0.3 million and $0.4 million, respectively. For the six-month periods ended June 30, 2022 and 2021, the Company recognized $0.1 million and $0.2 million of tax benefits from the exercise of stock options, respectively.

As of June 30, 2022 and December 31, 2021, we did not have any unvested performance-based stock options outstanding.
13

 
Restricted Stock Units
 
Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2022 and December 31, 2021, there were 68,000 and 88,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period.

Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Grant Date
Fair Value
Restricted Stock Units outstanding at December 31, 2021830 $9.46 
Granted164 8.87 
Forfeited(68)5.39 
Issued(329)7.50 
Restricted Stock Units outstanding at June 30, 2022597 10.84 
 
During the six-month period ended June 30, 2022, we granted 164,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $6.01 per share and vest upon achieving share-priced targets over a three-year period from the grant date.

Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.9 percent for a common share.

Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50.1 percent, and a risk-free rate of 3.3 percent.

Share-based compensation expense related to time-based RSUs for the three-month periods ended June 30, 2022 and 2021, was approximately $0.3 million and $0.6 million, respectively. Share-based compensation expense related to time-based RSUs for the six-month periods ended June 30, 2022 and 2021, was approximately $0.9 million and $1.0 million, respectively. As of June 30, 2022 and December 31, 2021, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.4 million and $1.6 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.3 years.
 
Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2022 and 2021, was $0.2 million and $0.5 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2022 and 2021, was $0.5 million and $0.9 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would, and expect to, recognize up to $2.4 million of potential share-based compensation expense.

The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 80,000 and 121,000 shares for the six-month periods ended June 30, 2022 and 2021, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above. 

14

(7)    Segment Information
 
We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.

Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.

Reportable business segment information is as follows (dollar amounts in thousands):

 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
Asia$47,382 $43,536 $93,492 $79,291 
Europe17,099 21,455 38,876 43,655 
North America34,082 37,372 70,063 75,134 
Latin America and Other5,598 6,615 12,224 13,319 
Total net sales104,161 108,978 214,655 211,399 
Contribution margin (1):    
Asia21,432 18,463 43,371 33,782 
Europe6,595 6,588 10,968 13,384 
North America12,300 16,259 25,019 31,699 
Latin America and Other2,294 3,762 5,195 7,394 
Total contribution margin42,621 45,072 84,553 86,259 
Selling, general and administrative expenses (2)36,866 35,586 77,489 69,138 
Operating income5,755 9,486 7,064 17,121 
Other income (loss), net(442)529 (756)(1,404)
Income before provision for income taxes$5,313 $10,015 $6,308 $15,717 
_________________________________________

(1)    Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2)    Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses.

15

From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
United States$31,483 $34,378 $64,712 $69,298 
South Korea14,465 17,546 28,118 32,355 
Taiwan11,933 4,730 21,683 7,499 
Other46,280 52,324 100,142 102,247 
 $104,161 $108,978 $214,655 $211,399 

16

Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Asia    
General health$12,319 $12,698 $25,305 $23,990 
Immune781 382 2,125 585 
Cardiovascular13,242 12,260 26,872 22,163 
Digestive10,990 7,747 20,026 14,618 
Personal care2,083 5,290 4,626 7,814 
Weight management7,967 5,159 14,538 10,121 
 47,382 43,536 93,492 79,291 
Europe    
General health$7,328 $9,667 $16,524 $19,139 
Immune1,443 1,818 4,074 3,834 
Cardiovascular2,150 2,836 4,783 5,828 
Digestive4,481 5,567 10,072 11,107 
Personal care1,209 999 2,442 2,425 
Weight management488 568 981 1,322 
 17,099 21,455 38,876 43,655 
North America    
General health$14,954 $16,349 $30,268 $32,619 
Immune4,061 4,101 8,933 8,975 
Cardiovascular3,893 4,010 7,735 8,235 
Digestive9,044 10,016 17,638 19,479 
Personal care1,389 1,834 3,564 3,653 
Weight management741 1,062 1,925 2,173 
 34,082 37,372 70,063 75,134 
Latin America and Other    
General health$1,597 $1,873 $3,415 $3,848 
Immune755 697 1,516 1,508 
Cardiovascular455 425 812 903 
Digestive2,551 3,001 5,392 5,872 
Personal care80 398 721 743 
Weight management160 221 368 445 
 5,598 6,615 12,224 13,319 
 $104,161 $108,978 $214,655 $211,399 

From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
 June 30,
2022
December 31,
2021
Property, plant and equipment:  
United States$45,036 $46,595 
Other4,063 4,262 
Total property, plant and equipment, net$49,099 $50,857 

17

Total assets per segment is set forth below (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Assets:  
Asia$91,762 $104,659 
Europe14,771 15,486 
North America119,018 131,207 
Latin America and Other7,508 7,522 
Total assets$233,059 $258,874 

(8)    Income Taxes
 
For the three months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 82.1 percent and 32.2 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 127.5 percent and 30.4 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2022, was primarily attributed to recording a valuation allowance against deferred tax assets which are expected to expire before utilization.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2021, was primarily attributed to transfer pricing adjustments and foreign losses during those periods that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items.

The difference between the effective tax rate for the three and six months ended June 30, 2022 compared to June 30, 2021 is primarily caused by recording a valuation allowance in the current period against deferred tax assets which are expected to expire before utilization.

Our U.S. federal income tax returns for 2018 through 2020 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2016 through 2021.
 
As of June 30, 2022 and December 31, 2021, we do not have any amounts accrued for unrecognized tax positions.
 
Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.
 
(9)    Commitments and Contingencies
 
Legal Proceedings
 
We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim.
 
Non-Income Tax Contingencies
 
We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are
18

recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.8 million.
 
Other Litigation
 
We are a party to various other legal proceedings and disputes in the United States and foreign jurisdictions. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.5 million, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, but either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.4 million.
 
(10)     Related Party Transactions

During the three and six months ended June 30, 2022 and 2021, our joint venture in China, owned 80 percent by us and 20 percent by a wholly owned subsidiary of Fosun Pharma, did not borrow any amounts from the Company or our joint venture partner. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from the Company were $0 and $1.2 million, respectively. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from our joint venture partner were $0 and $0.3 million, respectively. These notes were payable in less than one year and bore interest of 3.0 percent. The notes between NSP China and the Company eliminated in consolidation. In March 2022 the outstanding principal and interest amounts were repaid.

(11)    Fair Value Measurements
 
The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
 
Level 1: Quoted market prices in active markets for identical assets or liabilities.
 
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
 
Level 3: Unobservable inputs that are not corroborated by market data.
 
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2022 (dollar amounts in thousands):
 
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$743 $ $ $743 
Total assets measured at fair value on a recurring basis$743 $ $ $743 
 
19

The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2021 (dollar amounts in thousands):
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$964 $ $ $964 
Total assets measured at fair value on a recurring basis$964 $ $ $964 
 
Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets.
 
For the six months ended June 30, 2022 and for the year ended December 31, 2021, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3).
 
The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the six months ended June 30, 2022 and 2021, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

(12)    Revenue Recognition

Revenue Recognition

Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year.

A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive.

From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation.

Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales.

Contract Liabilities - Customer Loyalty Programs

Historically, we have offered loyalty point programs which allowed customers to earn loyalty points on personal orders. Loyalty points were recorded as contract liabilities in deferred revenue. These programs were accounted for as a reduction in the transaction price and generally recognized as points that were redeemed for additional products. During the year ended December 31, 2020 these programs were discontinued. As of June 30, 2022, there were no outstanding loyalty points.

20

Disaggregation of Revenue

Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category.

Practical Expedients and Exemptions

We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.

We generally expense volume incentives when incurred because the amortization period would have been one year or less.

All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.
21


Item 2.                            MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following Management’s Discussion and Analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included in this report, as well as the consolidated financial statements, the notes thereto, and management’s discussion and analysis included in our Annual Report on Form 10-K for the year ended December 31, 2021, and our other reports filed since the date of such Form 10-K.
 
OVERVIEW
 
We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who resell our products to consumers.

Our independent consultants market and sell our products to customers and sponsor other independent consultants who also market our products to customers. Because a significant amount of revenue is generated through the sales or our independent consultants, our revenue can be impacted by the number and productivity of our independent consultants. We seek to motivate and provide incentives to our independent consultants by offering high quality products, product support, training seminars, and financial incentives, among other considerations.

COVID-19

In or about December 2019, a novel strain of coronavirus, SARS-CoV-2 “COVID-19”, began aggressively spreading throughout the world, including all the primary markets where we conduct business. As COVID-19 has spread throughout the world, it has impacted our markets differently. At various times during the course of the pandemic and throughout our markets, governments have issued orders and restrictions that have limited the ability of our consultants to meet with consumers, put downward pressure on our sales in many of our markets and added substantial uncertainties to our global supply chain. Different variants of COVID-19 continue to arise and spread in various places around the world. We continue to take actions to mitigate the effects COVID-19 may have on our business, such actions may ultimately be insufficient to avoid substantial impact on the consolidated financial statement or material health of the Company. At this time, the duration of any business disruption and related financial impact cannot be reasonably estimated.

Eastern Europe

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. Our consultants in our Russia and Other market, a market within our Europe business segment that includes Russia, Ukraine, Belarus and other Common Independent States in the region, continue to operate their independent businesses, albeit at a reduced level than prior to the start of the conflict. For the six months ended June 30, 2022, we have recorded a pretax charge of $3.1 million, primarily related to the impairment of inventory, as well as accruals for contractual obligations related to Russian operations. We expect that this will continue to impact our business for the foreseeable future. We will continue monitoring the social, political, regulatory and economic environment in Ukraine and Russia, and will consider further actions as appropriate.

Net sales related to Russia and Other for the three and six months ended June 30, 2022, were $11.1 million and $25.6 million, respectively, compared to $14.0 million and $28.3 million for the same periods in 2021. Operating income related to Russia and Other for the three and six months ended June 30, 2022, was $1.0 million and $2.2 million, respectively, prior to the charges noted above, compared to $1.4 million and $2.7 million for the same periods in 2021. As of June 30, 2022, Russia and Other had assets of $5.2 million, net of working capital reserves, which primarily consisted of inventories and accounts receivable.

More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope, including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures and supply chain cost increases or the geographic proximity of the war relative to the rest of Europe.

22

Inflation

In 2021, the inflation rate in the U.S. began to increase significantly. In 2022, the inflation rate increase accelerated and during the six months ended June 30, 2022, was the highest in 40 years. Europe and other areas in which we do business are also experiencing higher levels of inflation. Our operations have been, and may continue to be, adversely impacted by inflation, primarily from higher costs of raw materials, labor, production, distribution and transportation costs.

In the second quarter of 2022, we experienced a decrease in our consolidated net sales of 4.4 percent (or an increase of 0.5 percent in local currencies) compared to the same period in 2021. Asia net sales increased approximately 8.8 percent (or 18.8 percent in local currencies) compared to the same period in 2021. Europe net sales decreased approximately 20.3 percent (or 16.2 percent in local currencies) compared to the same period in 2021. North America net sales decreased approximately 8.8 percent (or 8.5 percent in local currencies) compared to the same period in 2021. Latin America and Other net sales decreased approximately 15.4 percent (or 15.0 percent in local currencies) compared to the same period in 2021. The strengthening of the U.S. dollar versus the local currencies, primarily in our Asian and European markets, resulted in an approximate 4.9 percent, or $5.4 million, decrease of our net sales during the quarter.

Cost of sales increased $1.0 million during the three months ended June 30, 2022, compared to the same period in 2021, and as a percentage of net sales were 28.3 percent and 26.1 percent for the three months ended June 30, 2022 and 2021, respectively. The increase in cost of sales percentage is primarily due to changes in inventory valuation reserves, changes in market mix, heightened inflation, and increases in raw materials, production and transportation costs. For the six months ended June 30, 2022, we had incremental valuation charges of $5.0 million related to inventory. Of that amount $2.7 million related to the conflict between Russia and Ukraine, and $2.3 million related to changes in forecast demand and production issues, among other factors.

In absolute terms, selling, general and administrative expenses increased $1.3 million during the three months ended June 30, 2022, compared to the same period in 2021, and as a percentage of net sales were 35.4 percent and 32.7 percent for the three months ended June 30, 2022 and 2021, respectively. The dollar increase was primarily related to higher service fees that resulted from growth in China's net sales, increased selling costs and direct marketing spend intended to drive growth, increase in expected level of convention and distributor events, as well as growth in markets with higher variable costs.

As an international business, we have significant sales and costs denominated in currencies other than the U.S. Dollar. We expect foreign markets with functional currencies other than the U.S. Dollar will continue to represent a substantial portion of our overall sales and related operating expenses. Accordingly, changes in foreign currency exchange rates could materially affect sales and costs or the comparability of sales and costs from period to period as a result of translating foreign markets financial statements into our reporting currency.

23

RESULTS OF OPERATIONS
 
The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the three months ended June 30, 2022 and 2021 (dollar amounts in thousands):

 
 Three Months Ended
June 30, 2022
Three Months Ended
June 30, 2021
Change
 Total
dollars
Percent of
net sales
Total
dollars
Percent of
net sales
Total
dollars
Percentage 
Net sales$104,161 100.0 %$108,978 100.0 %$(4,817)(4.4)%
Cost of sales29,471 28.3 28,463 26.1 1,008 3.5 
Gross profit74,690 71.7 80,515 73.9 (5,825)(7.2)
Volume incentives32,069 30.8 35,443 32.5 (3,374)(9.5)
SG&A expenses36,866 35.4 35,586 32.7 1,280 3.6 
Operating income5,755 5.5 9,486 8.7 (3,731)(39.3)
Other income (loss), net(442)(0.4)529 0.5 (971)(183.6)
Income before income taxes
5,313 5.1 10,015 9.2 (4,702)(46.9)
Provision for income taxes4,361 4.2 3,221 3.0 1,140 35.4 
Net income$952 0.9 %$6,794 6.2 %$(5,842)(86.0)%

The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the six months ended June 30, 2022 and 2021 (dollar amounts in thousands):

 
 Six Months Ended
June 30, 2022
Six Months Ended
June 30, 2021
Change
 Total
dollars
Percent of
net sales
Total
dollars
Percent of
net sales
Total
dollars
Percentage 
Net sales$214,655 100.0 %$211,399 100.0 %$3,256 1.5 %
Cost of sales63,931 29.8 55,442 26.2 8,489 15.3 
Gross profit150,724 70.2 155,957 73.8 (5,233)(3.4)
Volume incentives66,171 30.8 69,698 33.0 (3,527)(5.1)
SG&A expenses77,489 36.1 69,138 32.7 8,351 12.1 
Operating income7,064 3.3 17,121 8.1 (10,057)(58.7)
Other loss, net(756)(0.4)(1,404)(0.7)648 46.2 
Income before income taxes
6,308 2.9 15,717 7.4 (9,409)(59.9)
Provision for income taxes8,042 3.7 4,771 2.3 3,271 68.6 
Net income (loss)$(1,734)(0.8)%$10,946 5.2 %$(12,680)(115.8)%

 Net Sales
 
International operations have provided, and are expected to continue to provide, a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the U.S. dollar against foreign currencies. In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, in addition to comparing the percent change in net sales from one period to another in U.S. dollars, we present net sales excluding the impact of foreign exchange fluctuations. We compare the percentage change in net sales from one period to another period by excluding the effects of foreign currency exchange as shown below. Net sales excluding the impact of foreign exchange fluctuations is not a U.S. GAAP financial measure and removes from net sales in U.S. dollars the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries, by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period. We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. However, net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Throughout the last five years, foreign currency exchange rates have fluctuated significantly. See Item 3. Quantitative and Qualitative Disclosures about Market Risk.
24


The following table summarizes the changes in net sales by operating segment with a reconciliation to net sales excluding the impact of currency fluctuations for the three months ended June 30, 2022 and 2021 (dollar amounts in thousands): 
 Net Sales by Operating Segment
 Three Months Ended
June 30, 2022
Three Months Ended
June 30, 2021
Percent
Change
Impact of
Currency
Exchange
Percent
Change
Excluding
Impact of
Currency
Asia$47,382 $43,536 8.8 %$(4,358)18.8 %
Europe17,099 21,455 (20.3)(887)(16.2)
North America34,082 37,372 (8.8)(102)(8.5)
Latin America and Other5,598 6,615 (15.4)(25)(15.0)
 $104,161 $108,978 (4.4)%$(5,372)0.5 %

The following table summarizes the changes in net sales by operating segment with a reconciliation to net sales excluding the impact of currency fluctuations for the six months ended June 30, 2022 and 2021 (dollar amounts in thousands): 

 Net Sales by Operating Segment
 Six Months Ended
June 30, 2022
Six Months Ended
June 30, 2021
Percent
Change
Impact of
Currency
Exchange
Percent
Change
Excluding
Impact of
Currency
Asia$93,492 $79,291 17.9 %$(6,208)25.7 %
Europe38,876 43,655 (10.9)(1,441)(7.6)
North America70,063 75,134 (6.7)(103)(6.6)
Latin America and Other12,224 13,319 (8.2)(87)(7.6)
 $214,655 $211,399 1.5 %$(7,839)5.2 %
 
Consolidated net sales for the three and six months ended June 30, 2022, were $104.2 million and $214.7 million, respectively, compared to $109.0 million and $211.4 million for the same period in 2021, which represents decreases of 4.4 percent and increases of 1.5 percent, respectively. The decrease for the three months ended June 30, 2022, was primarily related to product sales declines in our Europe, North America, and Latin America and Other operating segments. The increase for the six months ended June 30, 2022, was primarily related to notable product sales growth in our Asia operating segment. Excluding the impact of foreign currency exchange rate fluctuations, consolidated net sales for the three and six months ended June 30, 2022, increased 0.5 percent and 5.2 percent, respectively, from the same periods in 2021.

Asia

Net sales related to Asia for the three and six months ended June 30, 2022, were $47.4 million and $93.5 million, respectively, compared to $43.5 million and $79.3 million for the same periods in 2021, or increases of 8.8 percent and 17.9 percent, respectively. In local currency, net sales for the three and six months ended June 30, 2022, increased 18.8 percent and 25.7 percent, respectively, compared to the same periods in 2021.
Notable activity in the following markets contributed to the results of Asia:

In our South Korea market, net sales decreased $3.1 million and $4.2 million, or 17.6 percent and 13.1 percent, for the three and six months ended June 30, 2022, respectively, compared to the same periods in 2021. In local currency, net sales for the three and six months ended June 30, 2022, decreased 7.6 percent and 4.2 percent, respectively, compared to the same periods in 2021. The decrease in local currency for the three and six months ended June 30, 2022, was primarily the result of government restrictions in the market intended to slow the spread of COVID-19, which were not lifted until the second quarter.

In our Taiwan market, net sales increased $7.2 million and $14.2 million, or 152.3 percent and 189.1 percent, for the three and six months ended June 30, 2022, compared to the same periods in 2021. In local currencies, net sales for the three and six months ended June 30, 2022, increased 163.7 percent and 195.9 percent, compared to the same periods in 2021. We
25

attribute the growth in net sales primarily to product promotions intended to stimulate activity as well as an increase in demand for nutritional supplements.

In our Japan market, net sales increased $1.5 million and $3.1 million, or 17.5 percent and 19.1 percent, for the three and six months ended June 30, 2022, respectively, compared to the same periods in 2021. In local currencies, net sales for the three and six months ended June 30, 2022, increased 38.0 percent and 35.5 percent, respectively, compared to the same periods in 2021. We attribute the growth in net sales primarily to product promotions intended to stimulate activity as well as an increase in demand for nutritional supplements.

In our China market, net sales decreased $0.8 million and increased $3.1 million, or decreased 7.9 percent and increased 16.7 percent, for the three and six months ended June 30, 2022, respectively, compared to the same periods in 2021. In local currencies, net sales for the three and six months ended June 30, 2022, increased decreased 5.7 percent and increased 16.8 percent, respectively, compared to the same periods in 2021. The decrease in net sales for the three months ended June 30, 2022, was primarily the result of additional government restrictions in the market intended to slow the spread of COVID-19, which included lockdowns during the second quarter. We attribute the growth in net sales for the six months ended June 30, 2022, primarily to initiatives designed to increase independent service providers’ engagement levels and gain market share.

Europe

Net sales related to Europe for the three and six months ended June 30, 2022, were $17.1 million and $38.9 million, respectively, compared to $21.5 million and $43.7 million for the same periods in 2021, or decreases of 20.3 percent and 10.9 percent, respectively. In local currency, net sales for the three and six months ended June 30, 2022, decreased 16.2 percent and 7.6 percent, respectively, compared to the same periods in 2021. The functional currency for many of these markets is the U.S. Dollar which reduces the effect from foreign currency fluctuations. Fluctuations in foreign exchange rates had unfavorable impacts on net sales of $0.9 million and $1.4 million for the three and six months ended June 30, 2022, respectively. Net sales decreased primarily as a result of conflict between Russia and Ukraine which has placed significant financial pressures on the surrounding Western and Eastern Europe markets, and customer sensitivity due to inflationary pressures, among other factors.

North America

Net sales related to North America for the three and six months ended June 30, 2022, were $34.1 million and $70.1 million, respectively, compared to $37.4 million and $75.1 million for the same periods in 2021, or decreases of 8.8 percent and 6.7 percent, respectively. In local currency, net sales for the three and six months ended June 30, 2022, decreased 8.5 percent and 6.6 percent, respectively, compared to the same periods in 2021.

In the United States, net sales decreased $2.9 million and $4.6 million, or 8.4 percent and 6.6 percent, for the three and six months ended June 30, 2022, respectively, compared to the same periods in 2021. The decrease in sales was due primarily to stock outs of certain products as a result of supply chain challenges, and a reduction in the average order size attributed to customer sensitivity due to inflationary pressures, among other factors.

Latin America and Other

Net sales related to Latin America and Other markets for the three and six months ended June 30, 2022, were $5.6 million and $12.2 million, respectively, compared to $6.6 million and $13.3 million for the same periods in 2021, or decreases of 15.4 percent and 8.2 percent, respectively. In local currency, net sales for the three and six months ended June 30, 2022, decreased 15.0 percent and 7.6 percent, respectively, compared to the same periods in 2021. Fluctuations in foreign currency had unfavorable impacts on net sales of $25,000 and $0.1 million for the three and six months ended June 30, 2022, respectively. The decrease in sales was due primarily to stock outs of certain products as a result of supply chain challenges, and a reduction in the average order size attributed to customer sensitivity due to inflationary pressures, among other factors.

Further information related to our Asia, Europe, North America, and Latin America and Other business segments is set forth in Note 7 to the Unaudited Condensed Consolidated Financial Statements in Part 1, Item 1 of this report.

26

Cost of Sales
 
Cost of sales as a percent of net sales was 28.3 percent and 29.8 percent for the three and six months ended June 30, 2022, compared to 26.1 percent and 26.2 percent for the same periods in 2021. The increase in cost of sales percentage is primarily due to changes in inventory valuation reserves as a result of the conflict between Russia and Ukraine, as well as reserves for other markets, changes in market mix, persistent inflation, and increases in raw materials, production and transportation costs. For the six months ended June 30, 2022, we had incremental valuation charges of $5.0 million related to inventory. Of that amount $2.7 million related to the conflict between Russia and Ukraine, and $2.3 million related to changes in forecast demand and production issues, among other factors.
 
Volume Incentives

Volume incentives expense as a percent of net sales was 30.8 percent and 30.8 percent for the three and six months ended June 30, 2022, respectively, compared to 32.5 percent and 33.0 percent for the same periods in 2021. These payments are designed to provide incentives for reaching certain sales levels. Volume incentives vary slightly, on a percentage basis, by product due to pricing policies and commission plans in place in our various operations. We do not pay volume incentives in China, instead we pay independent service fees which are included in selling, general and administrative expenses. Volume incentives as a percentage of net sales can fluctuate based on promotional activity and mix of sales by market. The decrease in volume incentives as a percent of net sales for the three and six months ended June 30, 2022 is primarily due to change in market mix, reflecting growth in markets where volume incentives as a percentage of net sales are lower than the consolidated average, and the growth in NSP China. The decrease also reflects cost savings from the September 2020 launch of our new consultant sales and compensation plan in North America and LATAM.
 
Selling, General and Administrative
 
Selling, general and administrative expenses represent operating expenses, components of which include labor and benefits, sales events, professional fees, travel and entertainment, marketing, occupancy costs, communications costs, bank fees, depreciation and amortization, independent services fees paid in China, and other miscellaneous operating expenses.

Selling, general and administrative expenses increased by $1.3 million and $8.4 million, respectively, to $36.9 million and $77.5 million for the three and six months ended June 30, 2022, respectively, compared to the same periods in 2021. Selling, general and administrative expenses were 35.4 percent and 36.1 percent of net sales for the three and six months ended June 30, 2022, compared to 32.7 percent and 32.7 percent for the same periods in 2021. The dollar increase in selling, general and administrative expenses was primarily related to higher service fees that resulted from growth in China's net sales, increased selling costs and direct marketing spend intended to drive growth, increase in expected level of convention and distributor events, as well as growth in markets with higher variable costs.

Other Income (Loss), Net
 
Other income (loss), net, for the three and six months ended June 30, 2022, were losses of $0.4 million and $0.8 million, respectively, compared to gains of $0.5 million and losses of $1.4 million during the same periods in 2021, respectively. Other income (loss), for the three and six months ended June 30, 2022 primarily consisted of foreign exchange gains and losses as a result of net changes in foreign currencies primarily in Asia, Europe and Latin America.
 
Income Taxes

For the three months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 82.1 percent and 32.2 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 127.5 percent and 30.4 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2022, was primarily attributed to recording a valuation allowance against deferred tax assets which are expected to expire before utilization.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2021, was primarily attributed to an increase in tax liability associated with transfer pricing adjustments, nondeductible
executive compensation, and net unfavorable foreign tax related items, partially offset by favorable deductions for stock compensation.
27


The difference between the effective tax rate for the three and six months ended June 30, 2022 compared to June 30, 2021 is primarily caused by recording a valuation allowance in the current period against deferred tax assets which are expected to expire before utilization.

Our U.S. federal income tax returns for 2018 through 2020 are open to examination for federal tax purposes. We have several foreign tax jurisdictions that have open tax years from 2016 through 2021.
 
As of June 30, 2022 and December 31, 2021, we do not have any amounts accrued for unrecognized tax positions.

Product Categories
 
Our line of over 700 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. We purchase herbs and other raw materials in bulk and, after quality control testing, we formulate, encapsulate, tablet or concentrate them, label and package them for shipment. Most of our products are manufactured at our facility in Spanish Fork, Utah. Contract manufacturers produce some of our products in accordance with our specifications and standards. We have implemented quality control procedures to verify that our contract manufacturers have complied with our specifications and standards.

See Note 7, Segment Information, for a summary of the U.S. dollar amounts from the sale of general health, immune, cardiovascular, digestive, personal care and weight management products for the three and six months ended June 30, 2022 and 2021, by business segment.
 
Distribution and Marketing
 
We market our products primarily through our network of independent consultants, who market our products to customers through direct selling techniques and sponsor other independent consultants who also market our products to customers. We seek to motivate and provide incentives to our independent consultants by offering high quality products and providing independent consultants with product support, training seminars, sales conventions, travel programs and financial incentives.

Our products sold in the United States are shipped directly from our manufacturing and warehouse facilities located in Spanish Fork, Utah, as well as from our regional warehouses located in Georgia, Ohio and Texas. Many of our international operations maintain warehouse facilities and inventory to supply their independent consultants. However, in foreign markets where we do not maintain warehouse facilities, we have contracted with third-parties to distribute our products and provide support services to our force of independent consultants.

In the United States, we generally sell our products on a cash or credit card basis. From time to time, our U.S. operations extend short-term credit associated with product promotions. For certain of our international operations, we use independent distribution centers and offer credit terms that are generally consistent with industry standards within each respective country.

We pay sales commissions, or “volume incentives” to our independent consultants based upon their own product sales and the product sales of their sales organization. As an exception, in NSP China, we do not pay volume incentives; rather, we pay independent service fees, which are included in selling, general and administrative expenses. These volume incentives are recorded as an expense in the year earned. The amounts of volume incentives that we expensed during the quarters ended June 30, 2022 and 2021, are set forth in the Condensed Consolidated Financial Statements in Item 1 of this report. In addition to the opportunity to receive volume incentives, independent Managers who attain certain levels of monthly product sales are eligible for additional incentive programs including automobile allowances, sales convention privileges and travel awards.
 
LIQUIDITY AND CAPITAL RESOURCES
 
Our principal use of cash is to pay for operating expenses, including volume incentives, inventory and raw material purchases, capital assets and funding of international expansion. As of June 30, 2022, working capital was $78.0 million, compared to $88.0 million as of December 31, 2021. At June 30, 2022, we had $56.3 million in cash, of which $4.9 million was held in the U.S. and $51.4 million was held in foreign markets and may be subject to various withholding taxes and other restrictions related to repatriation before becoming available to be used along with the normal cash flows from operations to fund any unanticipated shortfalls in future cash flows.
 
28

Our net consolidated cash inflows (outflows) are as follows (in thousands):
 Six Months Ended June 30,
 20222021
Operating activities$(9,343)$10,712 
Investing activities(3,757)(2,898)
Financing activities(14,018)(23,630)
 
Operating Activities
 
For the six months ended June 30, 2022, operating activities used cash of $9.3 million, compared to providing cash of $10.7 million in the same period in 2021. Operating cash flows decreased primarily due to increased inventory purchases before any changes in reserves and timing of payments on accounts payable, deferred revenue, and income taxes payable partially offset by the timing of accrued volume incentives and service fees, and accrued liabilities.

Investing Activities
 
For the six months ended June 30, 2022, investing activities used $3.8 million, compared to $2.9 million for the same period in 2021, which consisted of capital expenditures related to the purchase of equipment, computer systems and software.

Financing Activities
 
For the six months ended June 30, 2022, financing activities used $14.0 million, compared to $23.6 million in cash for the same period in 2021.

During the six months ended June 30, 2022, we used cash to repurchase 741,000 shares of our common stock under the share repurchase program for $12.0 million. At June 30, 2022, the remaining balance available for repurchases under the program was $25.6 million.

We maintain a revolving credit agreement with Bank of America, N.A (the “Credit Agreement”), as well as a credit agreement with Banc of America Leasing and Capital, LLC (the "Capital Credit Agreement"). At June 30, 2022, there was no outstanding balance under the Credit Agreement. During the six months ended June 30, 2022 we made monthly payments of $0.1 million pursuant to the Capital Credit Agreement. As of June 30, 2022, there was $1.8 million outstanding balance under the Capital Credit Agreement, $1.3 million of which was classified as current. Our debt obligations are discussed in greater detail in Note 4, Revolving Credit Facility and Other Obligations, to our Condensed Consolidated Financial Statements in Item 1, Part 1 of this report.

We believe that cash generated from operations, along with available cash and cash equivalents, will be sufficient to fund our normal operating needs, including capital expenditures, on both a short- and long-term basis.

In addition, other things such as a prolonged economic downturn, a decrease in demand for our products, an unfavorable settlement of our unrecognized tax positions or non-income tax contingencies could adversely affect our long-term liquidity.

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements.
 
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
 
Our consolidated financial statements have been prepared in accordance with U.S. GAAP and form the basis for the following discussion and analysis on critical accounting policies and estimates. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations. We have discussed the development, selection and disclosure of these estimates with the Board of Directors and our Audit Committee.

29

A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2021. We believe the critical accounting policies and estimates described below reflect our more significant estimates and assumptions used in the preparation of the consolidated financial statements. The impact and any associated risks on our business that are related to these policies are also discussed throughout this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” where such policies affect reported and expected financial results.
 
Revenue Recognition
 
Our revenue recognition practices are discussed in Note 12, Revenue Recognition, to our Condensed Consolidated Financial Statements in Item 1, Part 1 of this report.
 
Inventories
 
Inventories are adjusted to lower of cost and net realizable value, using the first-in, first-out method. The components of inventory cost include raw materials, labor and overhead. To estimate any necessary adjustments, various assumptions are made in regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production planning and market conditions. If future demand and market conditions are less favorable than our assumptions, additional inventory adjustments could be required.

Incentive Trip Accrual
 
We accrue for expenses associated with our direct sales program, which rewards independent consultants with paid attendance for incentive trips, including our conventions and meetings. Expenses associated with incentive trips are accrued over qualification periods as they are earned. We specifically analyze incentive trip accruals based on historical and current sales trends as well as contractual obligations when evaluating the adequacy of the incentive trip accrual. Actual results could generate liabilities more or less than the amounts recorded.

Contingencies
 
We are involved in certain legal proceedings and disputes. When a loss is considered probable in connection with litigation or non-income tax contingencies and when such loss can be reasonably estimated with a range, we record our best estimate within the range related to the contingency. If there is no best estimate, we record the minimum of the range. As additional information becomes available, we assess the potential liability related to the contingency and revise the estimates. Revision in estimates of the potential liabilities could materially affect our results of operations in the period of adjustment. Our contingencies are discussed in further detail in Note 10, “Commitments and Contingencies”, to the Notes of our Condensed Consolidated Financial Statements, of Item 1, Part 1 of this report.
 
Income Taxes
 
Our provision for income taxes, deferred tax assets and liabilities and contingent reserves reflect management’s best assessment of estimated future taxes to be paid. We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments and estimates are required in determining our consolidated provision for income taxes.

Deferred income taxes arise from temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating our ability to recover our deferred tax assets, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. In projecting future taxable income, we develop assumptions including the amount of future state, federal and foreign pretax operating income, the reversal of temporary differences, and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income, and are consistent with the plans and estimates that we are using to manage the underlying businesses. Valuation allowances are recorded as reserves against net deferred tax assets by us when it is determined that net deferred tax assets are not likely to be realized in the foreseeable future.

Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on our results of operations, cash flows or financial position.

30

The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized.

Item 3            QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We conduct business in several countries and intend to grow our international operations. Net sales, operating income and net income are affected by fluctuations in currency exchange rates, interest rates and other uncertainties inherent in doing business and selling product in more than one currency. In addition, our operations are exposed to risks associated with changes in social, political and economic conditions inherent in international operations, including changes in the laws and policies that govern international investment in countries where we have operations, as well as, to a lesser extent, changes in U.S. laws and regulations relating to international trade and investment. For further information, see Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2021.
 
Item 4.         CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
Our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) are designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC, and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2022. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2022, at the reasonable assurance level.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

31

PART II OTHER INFORMATION
 
Item 1.                     LEGAL PROCEEDINGS
 
None.
 
Item 1A.            RISK FACTORS
 
In addition to the information set forth in this report, you should carefully consider the risks discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, which could have a material adverse effect on our business or consolidated financial statements, results of operations, and cash flows. Additional risks not currently known, or risks that are currently believed to be not material, may also impair business operations. There have been no material changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2021, except as set forth below.

Geopolitical issues, conflicts and other global events could adversely affect our results of operations and financial condition.

Because a substantial portion of our business is conducted outside of the United States, our business is subject to global political issues and conflicts. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.

Russia’s invasion of Ukraine and the continuing war between Russia and Ukraine has negatively impacted our operations in both countries and the region. In fiscal 2021, operations in our Russia and Other market, a market within our Europe business segment that includes Russia, Ukraine, Belarus and other Common Independent States in the region, accounted for 13.8% of net sales. As of June 30, 2022, Russia and Other had assets of $5.2 million which primarily consisted of inventories and accounts receivable. We are unable to estimate future impacts to our business due to the high level of uncertainty as to how the war will evolve, its duration, and its ultimate resolution. Within Ukraine, there is a possibility of loss of life, physical damage and destruction of property, and loss of earning opportunities for many of our independent distributors and dealers. We may not be able to operate in many areas due to damage and safety concerns. Within Russia, we may need to further reduce our operations due to sanctions and counter sanctions, currency or payment controls, and supply chain challenges. Certain suppliers, vendors, independent distributors and customers are all impacted by the war and their ability to successfully maintain their operations could also impact our results of operations or product sales throughout the world.

The ongoing coronavirus pandemic and the responses thereto around the world could adversely impact our business and operating results.

Throughout the COVID-19 pandemic, governments around the world have issued orders restricting travel, the number of people who may gather, or for their citizens to shelter-in-place to slow the spread of COVID-19. Such orders, restrictions and recommendations have resulted in widespread closures of businesses not deemed “essential,” work stoppages, limitations on the number of people allowed to gather in one location, slowdowns and delays in world-wide supply chains, work-from-home policies, travel restrictions and cancellation of events, among other effects. In particular, travel and logistics restrictions, shelter-in-place orders and other measures, including working remotely, social distancing and other policies implemented in foreign and domestic sites to protect the health and safety of employees, have resulted in, and are expected to continue to result in, transportation disruptions (such as reduced availability of air transport, port closures, and increased border controls or closures), production delays and capacity limitations at our facilities and some of our customers and suppliers, as well as reduced workforce availability or productivity. These and other adverse impacts on our supply chain could limit our ability to obtain required materials in a timely manner, maintain adequate inventory levels, and respond to changes in customer demand, which could adversely affect our business and result of operations.

The duration and extent of COVID-19’s impact on our business are difficult to assess or predict. Conditions vary significantly by geography, and the continued rise of COVID-19 variants and associated spread have resulted in additional disruptions, government lockdowns, and other restrictive measures. For example, late in the first quarter of 2022, and into the second quarter, an increase in COVID-19 cases in certain parts of China resulted in the re-imposition of widespread lock-downs and restrictions. Stay-at-home and quarantine mandates have disrupted or halted our operations in certain parts of China and may continue to impact our business in the near term. Further quarantines, government reactions or shutdowns could disrupt or halt our operations and materially harm our business, financial condition and results of operations. Our manufacturing personnel and other employees could also be affected by COVID-19, potentially reducing their availability, and a widespread
32

outbreak of COVID-19 among our manufacturing or supply-chain employees could disrupt or halt our operations. Further, restrictions on gatherings of individuals may limit the ability of our independent consultants to sell our products. Additionally, the procedures we take to mitigate the effect of COVID-19 on our workforce, including but not limited to, social distancing and additional sanitizing measures, could reduce the efficiency of our operations, increase our operating costs or prove insufficient to protect our employees.

High inflation and other difficult economic conditions could adversely affect our results of operations and financial condition.

Consumer spending, including spending for our products, is affected by, among other things, prevailing economic conditions, including, among others, unemployment rates, inflation, fuel prices, salaries and wages, the availability of consumer credit, consumer confidence and consumer perception of economic conditions. The rate of inflation has recently reached its highest level in the U.S. in over forty years. Europe and other areas in which we do business are also experiencing higher than desired inflation. Inflation may require consumers to reconsider purchases of items they consider nonessential and, as a result, consumers may purchase fewer of our products if they consider our products nonessential. We believe high levels of inflation in the U.S. and other regions in which we do business have resulted, and will continue to result, in increased input costs and lower net sales of our products. We may not be able to pass any inflation-related increases on to customers without adversely affecting net sales. A prolonged period of high inflation, recession, and other unfavorable economic conditions that adversely affect the ability of consumers to pay for our products could have a material adverse effect on our business, financial condition, cash flows, and results of operations.

Item 2.                     UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
The following table summarizes the purchases of our common stock during the fiscal quarter ended June 30, 2022:

PeriodsTotal Number of Shares Purchased
(in thousands)
Average Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs
 (in thousands)
Maximum Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(1)
(in thousands)
April 1, 2022 to April 31, 202276 $16.86 76 
May 1, 2022 to May 31, 2022130 13.21 130 
June 1, 2022 to June 30, 202284 $11.84 84 
Total290 290 $25,604 

(1)    On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. We purchased 290,000 shares of our common stock during the quarter ended June 30, 2022 under the terms of this Board approved plan.

The actual timing, number, and value of common shares repurchased under our board-approved plan will be determined at our discretion and will depend on a number of factors, including, among others, general market and business conditions, the trading price of common shares, and applicable legal requirements. We have no obligation to repurchase any common shares under the authorization, and the repurchase plan may be suspended, discontinued, or modified at any time for any reason.
 
Item 3.                     DEFAULTS UPON SENIOR SECURITIES
 
None.
 
Item 4.                     MINE SAFETY DISCLOSURES

Not applicable.
 
Item 5.                     OTHER INFORMATION
 
None.
33

Item 6.                     EXHIBITS
 
a)             Index to Exhibits
 
Item No. Exhibit
10.1 (1)
10.2 (2)
10.3 (2)
31.1(2) 
31.2(2) 
32.1(2) 
32.2(2) 
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
104Cover page Interactive Data File (the cover page XBRL tags are embedded within iXBRL (Inline Extensible Business Reporting Language) document)
_________________________________________

(1)    Previously filed as Exhibit 99.1 to the Current Report on Form 8-K filed on August 17, 2021 and incorporated by reference herein.

(2)    Filed currently herewith.

34

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Natures Sunshine Products, Inc.
  
Date:August 9, 2022/s/ Terrence O. Moorehead
 Terrence O. Moorehead,
President and Chief Executive Officer
(Principal Executive Officer)
Date:August 9, 2022/s/ Joseph W. Baty
 Joseph W. Baty,
Executive Vice President, Chief Financial Officer and Treasurer
(Principal Financial Officer)


35
EX-10.2 2 formrsuawardagreement-2022.htm EX-10.2 Document

[GRANT NAME]
NATURE'S SUNSHINE PRODUCTS, INC.
AMENDED AND RESTATED 2012 STOCK INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
This RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”) is made effective as of [DATE], by and between Nature’s Sunshine Products, Inc., a Utah corporation (the “Company”), and [NAME], an individual (“Participant”).
1.                  Award»
The Company hereby grants to Participant a restricted stock unit award covering [XXXX] shares (the “Shares”) of Common Stock of the Company according to the terms and conditions set forth herein and in the Nature’s Sunshine Products, Inc. Amended and Restated 2012 Stock Incentive Plan (the “Plan”).  Each restricted stock unit (a “Unit”) represents the right to receive one Share, subject to the vesting requirements of this Agreement and the terms of the Plan. The Units are granted under Section 6(c) of the Plan. A copy of the Plan will be furnished upon request of Participant.
For purposes of this Agreement, the following terms shall have the definitions set forth below:
(a)        “Grant Date” shall mean [DATE].           
(b)        “Change in Control” shall mean any one of the transactions or events described in subparagraphs (i) through (v) below, provided any such transaction or event must also constitute a “change in control event” as defined in Treasury Regulation §1.409A-3(i)(5).
(i)      approval by the stockholders of the Company of a plan of complete dissolution or liquidation of the Company;
(ii)     consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or any of its subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination:  (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of at least 90% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities (as defined in subparagraph (iv)) that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation) is or becomes the beneficial owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation), and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors (as defined in subparagraph (v)) at the time of the approval by the Company’s board of directors (the “Board”) of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”);
(iii)    consummation of a sale of all or substantially all of the Company’s business and/or assets to a person or entity which is not a subsidiary;
(iv)    any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more (an “Acquiring Person”) of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this subparagraph (iv) shall not be deemed to be a Change in Control Event by virtue of any of the following acquisitions:  (A) by the Company or any subsidiary, (B) by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) pursuant to a Non-Qualifying Transaction, as defined in subparagraph (ii); or
(v)     during any period not longer than two consecutive years, individuals who at the beginning of such period constituted the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority thereof, provided that any person becoming a director subsequent to the beginning of such period whose election or



nomination for election was approved by a vote of a least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director, provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director.
(c)        “Disability” shall mean a determination by the Company that the Participant is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, unable to engage in any substantial gainful activity.
(d)       “Distribution Date” as to any particular Unit shall mean the earliest to occur of the following events:  (i) the Participant’s Separation from Service; (ii) the Participant’s Disability; (iii) a Change in Control; or (iv) with respect to the Vesting Schedule.
(e)        “Separation from Service” shall mean a complete severance of the Participant’s relationship as an employee, officer, consultant, independent contractor, advisor, or director of the Company; provided, however, that a Participant may have a Separation from Service upon resignation or removal as a director even if the director then becomes an officer or employee of the Company. For the sake of clarity, a Separation of Service shall not be deemed to have occurred unless such separation qualifies as a “separation of service” as determined under Section 409A of the Internal Revenue Code.
(f)        “Specified Employee” shall mean an individual who meets the definition of “specified employee,” as defined in Section 409A(a)(2)(B)(i) of the  Internal Revenue Code.
2.                  Vesting
Except as otherwise provided in this Agreement, the Units shall vest as follows: 
Vest Schedule - Share Units (RSU)
Vest DateVest Quantity
[DATE]XXXX
[DATE]XXXX
[DATE]XXXX
 [DATE]
XXXX

Notwithstanding anything to the contrary in this agreement, upon a Change in Control, and whether a Separation from Service occurs or not, all Units granted hereunder shall vest as of the date of such Change in Control event.
3.                  Restrictions on Transfer»
The Units may not be sold, assigned, transferred or pledged, other than by will or the laws of descent and distribution, and any such attempted transfer shall be void.
4.                  Forfeiture; Early Vesting»
Except as noted in Section 2 with respect to a Change in Control, if Participant has a Separation from Service prior to vesting of the Units identified in Section 2, all of Participant’s rights to all of the unvested Units shall be immediately and irrevocably forfeited.  Upon forfeiture, Participant will no longer have any rights relating to the unvested Units. 



5.                  Miscellaneous»
(a)                Issuance of Shares.  Within 60 days following the Participant’s Distribution Date, the Company shall cause to be issued and delivered to the Participant a certificate or certificates evidencing Shares registered in the name of the Participant (or in the name of the Participant’s legal representatives, beneficiaries or heirs, as the case may be) or to instruct the Company’s transfer agent to electronically deliver such shares to the respective Participant.  The number of Shares issued shall equal the number of Units vested, reduced as necessary to cover applicable withholding obligations in accordance with Section 5(c) hereof.  If it is administratively impracticable to issue Shares within the time frame described above because issuances of Shares are prohibited or restricted pursuant to the policies of the Company that are reasonably designed to ensure compliance with applicable securities laws or stock exchange rules, then such issuance shall occur as soon as administratively practicable.  Notwithstanding the foregoing in this Section 5(a), if the Participant’s Distribution Date results from the occurrence of a Change in Control that would result in the extinguishment or unavailability of the Shares, then, in connection with such Change in Control, the Committee may, in its sole discretion, provide for the replacement of the delivery of the Shares with the delivery of other rights or property, including, without limitation, cash, in accordance with the foregoing provisions of this Section 5(a) and in a manner consistent with Section 4(c) of the Plan.
(b)               Rights as Shareholder.  Units are not actual Shares, but rather, represent a right to receive Shares according to the terms and conditions set forth herein and the terms of the Plan.  Accordingly, the issuance of a Unit shall not entitle the Participant to any of the rights or benefits generally accorded to stockholders unless and until a Share is actually issued under Section 5(a) hereof. 
(c)                Taxes.  Participant acknowledges that Participant will consult with his/her personal tax advisor regarding the applicable federal, state, local or foreign tax consequences that arise in connection with this Agreement.  In order to comply with all applicable federal, state, local or foreign income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that all applicable federal, state, local or foreign payroll, withholding, income or other taxes, which are Participant’s sole and absolute responsibility, are withheld or collected from Participant, if and to the extent required by applicable law.
(d)               Subject to Plan.  This Award is subject to the terms and conditions of the Plan, but the terms of the Plan shall not be considered an enlargement of any benefits under this Agreement.  In addition, this Award is subject to the rules and regulations promulgated pursuant to the Plan, now or hereafter in effect.  A copy of the Plan will be furnished upon request of the Participant.  In the event that any provision of this Award conflicts with or is inconsistent in any respect with the terms of the Plan, the terms of the Plan shall control.
(e)                No Right to Continued Service.  This Agreement shall not confer on the Participant any right with respect to continuance of service to the Company, nor will it interfere in any way with the right of the Company or its shareholders to terminate such service at any time.
(f)                 Confidentiality. This Agreement, including, without limitation, the grant made hereunder, constitute confidential information and Participant agrees not to use or divulge such confidential information, or permit others to use or divulge such confidential information, for any reason; providedhowever, Employee may divulge such confidential information to his/her tax, accounting or legal advisor strictly for purposes of receiving professional advice or to exercise his/her rights hereunder. This confidentiality provision is not exclusive of any other obligation of confidentiality of Participant, including, without limitation, any obligation of confidentiality set forth in a separate confidentiality agreement between Participant and the Company.
(g)                Governing Law.  The validity, construction and effect of the Plan and this Agreement, and any rules and regulations relating to the Plan and this Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Utah.
(h)               Severability.  If any provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify this Agreement under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or this Agreement, such provision shall be stricken as to such jurisdiction or this Agreement, and the remainder of this Agreement shall remain in full force and effect.
(i)               No Trust or Fund Created.  Neither the Plan nor this Agreement shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate (as defined in Rule 12b-2 promulgated under the Exchange Act) and Participant or any other person.
(j)                 Section 409A Provisions.  If a payment has become payable on account of the Participant’s Separation from Service, and if such Participant is determined to be a Specified Employee, such payment shall not be paid before the date which is six months after such Specified Employee’s Separation From Service (or, if earlier, the date of death of such Specified Employee).  Following any applicable six month delay of payment, all such delayed payments shall be made to the Specified Employee in a lump sum on the earliest possible payment date.



(k)                 Headings.  Headings are given to the Sections and subsections of this Agreement solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Agreement or any provision thereof.
[Signature page follows]
 
 
 
 
 
 
 
 
 
 
 




IN WITNESS WHEREOF, the Company and Participant have executed this Agreement on the date set forth in the first paragraph.
 NATURE’S SUNSHINE PRODUCTS, INC.


By:        
                                                                      
            Joseph W. Baty                                     
Its:        Executive Vice President, CFO & Treasurer

PARTICIPANT


                                                                                   
NAME, an individual


EX-10.3 3 formpsuawardagreement-2022.htm EX-10.3 Document

[GRANT NAME]
NATURE'S SUNSHINE PRODUCTS, INC.
AMENDED AND RESTATED 2012 STOCK INCENTIVE PLAN
PERFORMANCE STOCK UNIT AWARD AGREEMENT
This PERFORMANCE STOCK UNIT AWARD AGREEMENT (this “Agreement”) is made effective as of [DATE], by and between Nature’s Sunshine Products, Inc., a Utah corporation (the “Company”), and [NAME], an individual (“Participant”).
1.                  Award»
The Company hereby grants to Participant a restricted stock unit award covering [XXXXXX] shares (the “Shares”) of Common Stock of the Company according to the terms and conditions set forth herein and in the Nature’s Sunshine Products, Inc. Amended and Restated 2012 Stock Incentive Plan (the “Plan”).  Each restricted stock unit (a “Unit”) represents the right to receive one Share, subject to the vesting requirements of this Agreement and the terms of the Plan. The Units are granted under Section 6(c) of the Plan. A copy of the Plan will be furnished upon request of Participant.
For purposes of this Agreement, the following terms shall have the definitions set forth below:
(a)        “Grant Date” shall mean [DATE].           
(b)        “Change in Control” shall mean any one of the transactions or events described in subparagraphs (i) through (v) below, provided any such transaction or event must also constitute a “change in control event” as defined in Treasury Regulation §1.409A-3(i)(5).
(i)      approval by the stockholders of the Company of a plan of complete dissolution or liquidation of the Company;
(ii)     consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company or any of its subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination:  (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the ultimate parent corporation that directly or indirectly has beneficial ownership of at least 90% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company Voting Securities (as defined in subparagraph (iv)) that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation) is or becomes the beneficial owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation), and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors (as defined in subparagraph (v)) at the time of the approval by the Company’s board of directors (the “Board”) of the execution of the initial agreement providing for such Business Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”);
(iii)    consummation of a sale of all or substantially all of the Company’s business and/or assets to a person or entity which is not a subsidiary;
(iv)    any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more (an “Acquiring Person”) of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided, however, that the event described in this subparagraph (iv) shall not be deemed to be a Change in Control Event by virtue of any of the following acquisitions:  (A) by the Company or any subsidiary, (B) by any employee benefit plan (or related trust) sponsored or maintained by the Company or any subsidiary, (C) by any underwriter temporarily holding securities pursuant to an offering of such securities, or (D) pursuant to a Non-Qualifying Transaction, as defined in subparagraph (ii); or
(v)     during any period not longer than two consecutive years, individuals who at the beginning of such period constituted the Board (the “Incumbent Directors”) cease for any reason to constitute at least a majority thereof, provided that any person becoming a director subsequent to the beginning of such period whose election or



nomination for election was approved by a vote of a least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director, provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director.
(c)        “Disability” shall mean a determination by the Company that the Participant is, by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, unable to engage in any substantial gainful activity.
(d)       “Distribution Date” as to any particular Unit shall mean the earliest to occur of the following events:  (i) the Participant’s Separation from Service; (ii) the Participant’s Disability; (iii) a Change in Control; or (iv) with respect to the Vesting Schedule.
(e)        “Separation from Service” shall mean a complete severance of the Participant’s relationship as an employee, officer, consultant, independent contractor, advisor, or director of the Company; provided, however, that a Participant may have a Separation from Service upon resignation or removal as a director even if the director then becomes an officer or employee of the Company. For the sake of clarity, a Separation of Service shall not be deemed to have occurred unless such separation qualifies as a “separation of service” as determined under Section 409A of the Internal Revenue Code.
(f)        “Specified Employee” shall mean an individual who meets the definition of “specified employee,” as defined in Section 409A(a)(2)(B)(i) of the  Internal Revenue Code.
2.                  Vesting
Except as otherwise provided in this Agreement, the Units shall vest as follows: Achieved upon Compensation Committee certification of trailing four-quarter adjusted EBITDA, subject to any Compensation Committee-approved adjustments consistent with past practices. The adjusted EBITDA targets are as follows: [XXXX]. All EBITDA targets must be achieved prior to [XXXXX]; provided, however, that the Units will not expire until thirty days following the filing of the Form 10K for the year ending [XXXXX]. Achievement of the targets is weighted with [XXXXXXX]. For each target, half of the allocated award vests upon the certification that a target has been achieved and the second half vests after an additional 12-month period. All unachieved adjusted EBITDA targets will be adjusted by any incremental acquired adjusted EBITDA in the event of a merger or acquisition.
Notwithstanding anything to the contrary in this agreement, upon a Change in Control, and whether a Separation from Service occurs or not, all earned but unvested Units, and the Units related to the next unearned adjusted EBITDA target up to the adjusted EBITDA target of [XXXX], shall vest as of the date of such Change in Control event. For the sake of clarity, in the event of a Change in Control, any Units that would otherwise vest only upon the achievement of the adjusted EBITDA target of [XXXX] will not be subject to the acceleration described in this paragraph, but nonetheless may vest if such target is achieved prior to the Change in Control.
3.                  Restrictions on Transfer»
The Units may not be sold, assigned, transferred or pledged, other than by will or the laws of descent and distribution, and any such attempted transfer shall be void.
4.                  Forfeiture; Early Vesting»
Except as noted in Section 2 with respect to a Change in Control, if Participant has a Separation from Service prior to vesting of the Units identified in Section 2, all of Participant’s rights to all of the unvested Units shall be immediately and irrevocably forfeited, except that all achieved but unvested Units will vest upon a Separation of Service without Cause.  Upon forfeiture, Participant will no longer have any rights relating to the unvested Units.
5.                  Miscellaneous»
(a)                Issuance of Shares.  Within 60 days following the Participant’s Distribution Date, the Company shall cause to be issued and delivered to the Participant a certificate or certificates evidencing Shares registered in the name of the Participant (or in the name of the Participant’s legal representatives, beneficiaries or heirs, as the case may be) or to instruct the Company’s transfer agent to electronically deliver such shares to the respective Participant.  The number of Shares issued shall equal the number of Units vested, reduced as necessary to cover applicable withholding obligations in accordance with Section 5(c) hereof.  If it is administratively impracticable to issue Shares within the time frame described above because issuances of Shares are prohibited or restricted pursuant to the policies of the Company that are reasonably designed to ensure compliance with applicable securities laws or stock exchange rules, then such issuance shall occur as soon as administratively practicable.  Notwithstanding the foregoing in this Section 5(a), if the Participant’s Distribution Date results from the occurrence of a Change in Control



that would result in the extinguishment or unavailability of the Shares, then, in connection with such Change in Control, the Committee may, in its sole discretion, provide for the replacement of the delivery of the Shares with the delivery of other rights or property, including, without limitation, cash, in accordance with the foregoing provisions of this Section 5(a) and in a manner consistent with Section 4(c) of the Plan.
(b)               Rights as Shareholder.  Units are not actual Shares, but rather, represent a right to receive Shares according to the terms and conditions set forth herein and the terms of the Plan.  Accordingly, the issuance of a Unit shall not entitle the Participant to any of the rights or benefits generally accorded to stockholders unless and until a Share is actually issued under Section 5(a) hereof. 
(c)                Taxes.  Participant acknowledges that Participant will consult with his/her personal tax advisor regarding the applicable federal, state, local or foreign tax consequences that arise in connection with this Agreement.  In order to comply with all applicable federal, state, local or foreign income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that all applicable federal, state, local or foreign payroll, withholding, income or other taxes, which are Participant’s sole and absolute responsibility, are withheld or collected from Participant, if and to the extent required by applicable law.
(d)               Subject to Plan.  This Award is subject to the terms and conditions of the Plan, but the terms of the Plan shall not be considered an enlargement of any benefits under this Agreement.  In addition, this Award is subject to the rules and regulations promulgated pursuant to the Plan, now or hereafter in effect.  A copy of the Plan will be furnished upon request of the Participant.  In the event that any provision of this Award conflicts with or is inconsistent in any respect with the terms of the Plan, the terms of the Plan shall control.
(e)                No Right to Continued Service.  This Agreement shall not confer on the Participant any right with respect to continuance of service to the Company, nor will it interfere in any way with the right of the Company or its shareholders to terminate such service at any time.
(f)                 Confidentiality. This Agreement, including, without limitation, the grant made hereunder, constitute confidential information and Participant agrees not to use or divulge such confidential information, or permit others to use or divulge such confidential information, for any reason; providedhowever, Employee may divulge such confidential information to his/her tax, accounting or legal advisor strictly for purposes of receiving professional advice or to exercise his/her rights hereunder. This confidentiality provision is not exclusive of any other obligation of confidentiality of Participant, including, without limitation, any obligation of confidentiality set forth in a separate confidentiality agreement between Participant and the Company.
(g)                Governing Law.  The validity, construction and effect of the Plan and this Agreement, and any rules and regulations relating to the Plan and this Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Utah.
(h)               Severability.  If any provision of this Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify this Agreement under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or this Agreement, such provision shall be stricken as to such jurisdiction or this Agreement, and the remainder of this Agreement shall remain in full force and effect.
(i)               No Trust or Fund Created.  Neither the Plan nor this Agreement shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate (as defined in Rule 12b-2 promulgated under the Exchange Act) and Participant or any other person.
(j)                 Section 409A Provisions.  If a payment has become payable on account of the Participant’s Separation from Service, and if such Participant is determined to be a Specified Employee, such payment shall not be paid before the date which is six months after such Specified Employee’s Separation From Service (or, if earlier, the date of death of such Specified Employee).  Following any applicable six month delay of payment, all such delayed payments shall be made to the Specified Employee in a lump sum on the earliest possible payment date.
(k)                 Headings.  Headings are given to the Sections and subsections of this Agreement solely as a convenience to facilitate reference.  Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Agreement or any provision thereof.
[Signature page follows]
 




IN WITNESS WHEREOF, the Company and Participant have executed this Agreement on the date set forth in the first paragraph.

NATURE’S SUNSHINE PRODUCTS, INC.


By:     
                                                                         
            Joseph W. Baty                                     
Its:        Executive Vice President, CFO & Treasurer
 
PARTICIPANT


                                                                                    
NAME, an individual

EX-31.1 4 natr2022630-ex311.htm EX-31.1 Document

Exhibit 31.1
 
CERTIFICATIONS
 
I, Terrence O. Moorehead, certify that:
 
1.              I have reviewed this Quarterly Report on Form 10-Q of Nature’s Sunshine Products, Inc. (“the registrant”);
 
2.             Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.             Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.             The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)         Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)        Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.          The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)        Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:August 9, 2022/s/ Terrence O. Moorehead
 Terrence O. Moorehead
 President and Chief Executive Officer


EX-31.2 5 natr2022630-ex312.htm EX-31.2 Document

Exhibit 31.2
 
CERTIFICATIONS
 
I, Joseph W. Baty, certify that:
 
1.             I have reviewed this Quarterly Report on Form 10-Q of Nature’s Sunshine Products, Inc. (the “registrant”);
 
2.             Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.             Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.             The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)        Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)        Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)         Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)        Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.             The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)        All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)        Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:August 9, 2022/s/ Joseph W. Baty
 Joseph W. Baty
 Executive Vice President, Chief Financial Officer and Treasurer


EX-32.1 6 natr2022630-ex321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Nature’s Sunshine Products, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Terrence O. Moorehead, President and Chief Executive Officer of the Company, certify, pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:
 
(1)                   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)                   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:August 9, 2022/s/ Terrence O. Moorehead
 Terrence O. Moorehead
 President and Chief Executive Officer


EX-32.2 7 natr2022630-ex322.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Nature’s Sunshine Products, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph W. Baty, Executive Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:
 
(1)                   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)                   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:August 9, 2022/s/ Joseph W. Baty
 Joseph W. Baty
 Executive Vice President, Chief Financial Officer and Treasurer


EX-101.SCH 8 natr-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Investment Securities - Trading link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Investment Securities - Trading (Details) link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Revolving Credit Facility and Other Obligations link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Revolving Credit Facility and Other Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2111105 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2114106 - Disclosure - Capital Transactions link:presentationLink link:calculationLink link:definitionLink 2315303 - Disclosure - Capital Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Capital Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Capital Transactions - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Capital Transactions - RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2119107 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2421409 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2122108 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2423410 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2124109 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2126110 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2427412 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2128111 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2329305 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2430413 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2131112 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2432414 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 natr-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 natr-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 natr-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock options (in shares) Dilutive Securities Excluded from Computation of Earnings Represents potentially dilutive securities excluded from diluted per share amounts. It includes performance-based options to purchase shares of common stock which will not vest until certain earnings metrics have been achieved. Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Related Party Transactions [Abstract] Related Party Transactions [Abstract] Value-added tax assessments and other civil litigation Value Added Tax Assessments And Other Civil Litigation [Member] Represents information pertaining to value added tax assessments and other civil litigation in which the entity is involved. Asia Asia Segment [Member] Asia Segment [Member] Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Deferred income tax assets Deferred Income Tax Assets, Net Latin America and Other Latin America And Other Segment [Member] Latin America And Other Segment [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Investment securities - trading Debt Securities, Trading, and Equity Securities, FV-NI Time-Based Restricted Stock Units (RSUs) Time-Based Restricted Stock Units (RSUs) [Member] Time-Based Restricted Stock Units (RSUs) [Member] Personal care Personal Care Products [Member] Represents the information pertaining to personal care products of the entity. Notes Receivable Notes Receivable [Member] Non-Income Tax Contingencies Non Income Tax [Member] Represents information pertaining to non-income tax matters, including value-added taxes. Realized and unrealized gains (losses) on investments Gain (Loss) on Investments Number of monthly payments Debt Instrument, Number of Monthly Payments Debt Instrument, Number of Monthly Payments Debt Instrument [Axis] Debt Instrument [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Current portion of note payable Long-Term Debt and Lease Obligation, Current Provision for losses Loss Contingency, Loss in Period Restructuring Reserve Restructuring Reserve Foreign currency translation loss (net of tax) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Fair Value Measurement [Domain] Fair Value Measurement [Domain] Margin on variable rate Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] General health General Health Products [Member] Represents information pertaining to general health products of the entity. Exercised (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Non-cash lease expense Operating Lease, Non-Cash Lease Expense Operating Lease, Non-Cash Lease Expense Purchase of trading investment securities Payments for Purchase of Securities, Operating Activities Net income attributable to common shareholders Net Income (Loss) Attributable to Parent Stock options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award performance period Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period Discount for lack of marketability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability Equity Component [Domain] Equity Component [Domain] Principal payments of related party borrowing Repayments of Related Party Debt Total assets measured at fair value on a recurring basis Assets, Fair Value Disclosure Ownership [Axis] Ownership [Axis] Related party transaction, rate Related Party Transaction, Rate Estimate of possible loss Loss Contingency, Estimate of Possible Loss Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] China Joint Venture China Joint Venture [Member] China Joint Venture SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Number of separate increases Line Of Credit Facility, Number Of Separate Increases Line Of Credit Facility, Number Of Separate Increases Net sales: Segment Reporting Information, Revenue for Reportable Segment [Abstract] Share based compensation potential compensation expense to be recognized Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Long-term line of credit Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Level 1 - Quoted Prices in Active Markets for Identical Assets Fair Value, Inputs, Level 1 [Member] Schedule of assets per segment Schedule of Segment Reporting Information, by Segment1 [Table Text Block] Schedule of Segment Reporting Information, by Segment1 Award Type [Axis] Award Type [Axis] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Deferred compensation payable Increase (Decrease) in Deferred Compensation Current portion of operating lease liabilities Operating Lease, Liability, Current Total contribution margin Contribution Margin Represents the amount of contribution margin which consists of net sales revenue less cost of sales and volume incentives expense. Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Legal Entity [Axis] Legal Entity [Axis] Subsidiaries Subsidiaries [Member] Total liabilities Liabilities Geographical [Axis] Geographical [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving credit facility Revolving Credit Facility [Member] Document Type Document Type Weighted Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Revolving Credit Facility and Other Obligations Long-Term Debt [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Forfeited or canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] Restricted Stock Units outstanding, beginning balance (in dollars per share) Restricted Stock Units outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) Accrued liabilities Increase (Decrease) in Accrued Liabilities Potential increase in maximum borrowing capacity Line Of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings Line Of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings Document Period End Date Document Period End Date Operating income margin, three (as a percent) Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, Three Represents the three operating margin percentage to be achieved for the vesting of stock options. Total assets Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Basic and diluted net income per common share: Earnings Per Share [Abstract] Operating income margin, one (as a percent) Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, One Represents the first operating margin percentage to be achieved for the vesting of stock options. Operating income margin, two (as a percent) Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, Two Represents the second operating margin percentage to be achieved for the vesting of stock options. Accrued liabilities Accrued Liabilities, Current Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Line of Credit Line of Credit [Member] Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other Prepaid Expense and Other Assets, Current Segments [Domain] Segments [Domain] Net Income Per Share Earnings Per Share [Text Block] Europe Europe Segment [Member] Europe Segment [Member] Deferred compensation payable Deferred Compensation Liability, Classified, Noncurrent Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Weighted-average period over which the remaining compensation cost is expected to be recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Gross profit Gross Profit Entity Registrant Name Entity Registrant Name CHINA CHINA Net Sales and Operating Income Targets Net Sales and Operating Income Targets [Member] Net Sales and Operating Income Targets [Member] Entity Address, City or Town Entity Address, City or Town Fosun Pharma Member Fosun Pharma [Member] Fosun Pharma Minimum number of claims that the Company's insurance coverage may not be sufficient to cover Minimum Number of Claims Companies Insurance Coverage May Not Cover Represents the minimum number of claims the Company's insurance coverage may not be sufficient to cover. Operating expenses: Operating Expenses [Abstract] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Raw materials Inventory, Raw Materials, Net of Reserves Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Periodic payment Debt Instrument, Periodic Payment, Principal Title of Individual [Axis] Title of Individual [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Provision (benefit) for income taxes, as a percentage of income before income taxes Effective Income Tax Rate Reconciliation, Percent Proceeds from revolving credit facility Proceeds from Lines of Credit Use of Estimates Use of Estimates, Policy [Policy Text Block] NSP China Natures Sunshine Products, China [Member] Natures Sunshine Products, China [Member] Performance-Based Restricted Stock Units (RSUs) Performance-Based Restricted Stock Units (RSUs) [Member] Performance-Based Restricted Stock Units (RSUs) [Member] Accounts payable Increase (Decrease) in Accounts Payable LIBOR London Interbank Offered Rate (LIBOR) [Member] Additional number of shares authorized under the plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Investment Securities - Trading Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Credit Facility [Domain] Credit Facility [Domain] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic earnings (loss) per share attributable to common shareholders (in dollars per share) Earnings Per Share, Basic Counterparty Name [Domain] Counterparty Name [Domain] Director Director [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Vesting [Domain] Vesting [Domain] Ownership [Domain] Ownership [Domain] Entity Interactive Data Current Entity Interactive Data Current Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Capital Transactions Shareholders' Equity and Share-Based Payments [Text Block] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Contract with customer, contract term Contract With Customer, Contract Term Contract With Customer, Contract Term Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Payments of cash dividends Payments of Dividends Retained Earnings Retained Earnings [Member] Segment information Segment Reporting Information [Line Items] Unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash dividends Dividends, common stock, cash Dividends, Common Stock, Cash Litigation Status [Domain] Litigation Status [Domain] Common Stock Common Stock [Member] Number of business segments Number of Reportable Segments Repurchase of common stock Payments for Repurchase of Common Stock Statement [Table] Statement [Table] Principal payments of long-term debt Repayments of Other Long-Term Debt Issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Document Quarterly Report Document Quarterly Report Refund period Revenue from Contract with Customer, Refund Period Revenue from Contract with Customer, Refund Period Current assets: Assets, Current [Abstract] Long-term portion of operating lease liabilities Operating Lease, Liability, Noncurrent Proceeds from sale of trading investment securities Proceeds from Sale of Securities, Operating Activities Statistical Measurement [Axis] Statistical Measurement [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Accounts receivable, net of allowance for doubtful accounts of $525 and $143, respectively Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Recurring basis Fair Value, Recurring [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Restricted Stock Units outstanding, beginning balance (in shares) Restricted Stock Units outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, general and administrative expenses Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Repurchase of common stock Repurchase of common stock Stock Repurchased During Period, Value Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Weight management Weight Management Products [Member] Represents information pertaining to weight management products of the entity. Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating income Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Accrued Severance and Rent Costs Accrued Severance and Rent Costs [Member] Accrued Severance and Rent Costs [Member] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Deferred income tax liabilities Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate intrinsic values of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Cost of sales Cost of Goods and Services Sold Share-based compensation expense Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Number of principal categories of products Number of Principal Categories of Products Number of Principal Categories of Products Weighted average diluted common shares outstanding (in shares) Diluted weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Schedule of composition of inventories Schedule of Inventory, Current [Table Text Block] Commitments and contingencies Loss Contingencies [Line Items] Common stock, dividends (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Common stock, no par value, 50,000 shares authorized, 19,259 and 19,724 shares issued and outstanding, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Exercised (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2012 Stock Incentive Plan 2012 Incentive Plan [Member] Represents the information pertaining to 2012 incentive plan. Restriction period for issuance of shares Restriction Period for Issuance of Shares Represents the restriction period before shares will be issued related to a share-based compensation plan. Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net income (loss) attributable to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Lease liabilities Increase (Decrease) In Operating Lease, Liabilities Increase (Decrease) In Operating Lease, Liabilities Accrued volume incentives and service fees Increase (Decrease) in Accrued Volume Incentives and Service Fees This element represents the net increase or decrease in payables that are related to accrued volume incentives, during the reporting period. Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Deferred revenue Contract with Customer, Liability, Current Minimum withholding requirements (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Minimum Withholding Requirements Represents the minimum number of shares paid on behalf of the entity's employees per statutory withholding requirements. Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax Stock Issued During Period, Value, Stock Options and Restricted Stock Exercised Value of stock issued as a result of the exercise of stock options and issuance of restricted stock units. Fair value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities South Korea KOREA, REPUBLIC OF Nonvested subject to restriction period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested Subject to Restriction Period, Number The number of non-vested equity-based payment instruments subject to restriction period, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Schedule of reportable business segment information Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Investment securities - trading Trading securities portfolio Debt Securities, Trading, Restricted Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Annual commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Counterparty Name [Axis] Counterparty Name [Axis] Dilutive shares excluded from diluted-per-share amounts: Dilutive Securities Excluded from Computation of Earnings Per Share [Abstract] Options outstanding (in shares) Options outstanding at the beginning of the period (in shares) Options outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Anti-dilutive shares excluded from diluted-per-share amounts: Antidilutive Securities Excluded from Computation of Dilutive Earnings Per Share [Abstract] Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares) Stock Issued During Period, Shares, Stock Options and Restricted Stock Exercised Number of share options (or share units) exercised, and issuance of restricted stock units during the current period. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net Volume incentives Volume Incentives This element represents the expenses that are related to incentives on volume sales, during the reporting period by the entity. Stock options Share-Based Payment Arrangement, Option [Member] Title of Individual [Domain] Title of Individual [Domain] Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other loss, net Other income (loss), net Other Nonoperating Income (Expense) Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Digestive Digestive Products [Member] Represents information pertaining to digestive products of the entity. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Income taxes payable Accrued Income Taxes, Current Maximum Maximum [Member] Schedule of revenue generated by each of the Company's product lines Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of consolidated net sales revenue by geographical locations Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Cash paid for income taxes, net of refunds Income Taxes Paid, Net Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Increase (decrease) in noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Entity Small Business Entity Small Business Measurement Basis [Axis] Measurement Basis [Axis] Company's Joint Venture Partner Company's Joint Venture Partner [Member] Company's Joint Venture Partner [Member] Liability related to unrecognized tax benefits Increase (Decrease) in Liability Related to Unrecognized Tax Positions This element represents the net changes in liability that are related to gross amount of unrecognized tax benefits (tax reductions recognized in financial reports but excluded from tax returns), which pertain to uncertain tax positions taken in tax returns, as of the ending balance sheet date, which excludes amounts that pertain to examined tax returns. Measurement Frequency [Domain] Measurement Frequency [Domain] Dividends declared per common share (in dollars per share) Cash dividend (in dollars per share) Common Stock, Dividends, Per Share, Declared Schedule of the company's hierarchy for assets measured at fair value on a recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Forfeited or canceled (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Canceled Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Canceled Weighted Average Grant Date Fair Value Tax benefit from the exercise of stock options Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Immune Immunity Products [Member] Represents information pertaining to immunity products of the entity. Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Joint venture ownership, noncontrolling party Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Principal payments of revolving credit facility Repayments of Lines of Credit Long-term debt Debt Instrument [Line Items] Segment Information Segment Reporting Disclosure [Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Customer Loyalty Program, Loyalty Points Customer Loyalty Program, Loyalty Points Customer Loyalty Program, Loyalty Points Debt securities, trading, realized gains (losses) Debt Securities, Trading, Realized Gain (Loss) Noncontrolling Interest [Table] Noncontrolling Interest [Table] Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Total Estimate of Fair Value Measurement [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accrued volume incentives and service fees Accrued Volume Incentive and Service Fees This element represents the liability that is related to incentives that are payable, due to volume sales. Forfeited or canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Banc of America Leasing and Capital Credit Agreement Banc of America Leasing and Capital, LLC, Credit Agreement [Member] Banc of America Leasing and Capital, LLC, Credit Agreement Diluted shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories Total inventories Inventory, Net North America North America Segment [Member] North America Segment [Member] Accounts payable Accounts Payable, Current Restructuring charges Restructuring Charges Other assets Increase (Decrease) in Other Operating Assets Entity Filer Category Entity Filer Category Performance based stock options operating income margins Performance Based Stock Options Vesting Upon Achieving Operating Income Margins [Member] Represents the performance based stock options, which vest upon achieving operating income margins. Weighted average basic common shares outstanding (in shares) Basic weighted average shares outstanding (in shares) Basic weighted-average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic United States UNITED STATES Bank of America Credit Agreement Bank of America Credit Agreement [Member] Bank of America Credit Agreement [Member] Indicative Index Indicative Index [Member] Indicative Index Accrued liabilities Loss Contingency Accrual Share-based compensation expense Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Options outstanding at the beginning of the period (in dollars per share) Options outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Schedule of consolidated property, plant and equipment by geographical locations Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Net sales Total net sales revenue Revenue from Contract with Customer, Excluding Assessed Tax Income taxes payable Increase (Decrease) in Income Taxes Payable Cover [Abstract] Pending Litigation Pending Litigation [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 - Significant Unobservable Inputs Fair Value, Inputs, Level 3 [Member] Related party notes payable Notes Payable, Related Parties, Current Taiwan TAIWAN Work in progress Inventory, Work in Process, Net of Reserves Revenue Recognition Revenue from Contract with Customer [Text Block] Notes receivable, related parties, current Notes Receivable, Related Parties, Current Segment Reporting [Abstract] Segment Reporting [Abstract] Options outstanding at the beginning of the period (in dollars per share) Options outstanding at the beginning of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Noncontrolling Interest Noncontrolling Interest [Member] Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Payments related to tax withholding for net-share settled equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and shareholders’ equity Liabilities and Equity Foreign exchange losses Foreign Currency Transaction Gain (Loss), Unrealized Related Party [Axis] Related Party [Axis] Stock repurchase program, remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock-based awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Time-based stock options Time Based Stock Options [Member] Represents the time-based stock options, which vest over differing periods. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Level 2 - Significant Other Observable Inputs Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Vesting [Axis] Vesting [Axis] Diluted earnings (loss) per share attributable to common shareholders (in dollars per share) Earnings Per Share, Diluted Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Loss on sale of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Joint venture ownership Noncontrolling Interest, Ownership Percentage by Parent Total current liabilities Liabilities, Current Long-term note payable Notes Payable, Noncurrent Liability related to unrecognized tax benefits Unrecognized Tax Benefits Schedule of restricted stock unit activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Contribution margin: Contribution Margin [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Product and Service [Axis] Product and Service [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Credit Facility [Axis] Credit Facility [Axis] Related party transaction, amount Related Party Transaction, Amounts of Transaction Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Potential increase in maximum borrowing capacity, per occurrence Line of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings, Minimum Per Occurrence Line of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings, Minimum Per Occurrence Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized under the plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Common stock, no par value (in dollars per share) Common Stock, No Par Value Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other Other Countries [Member] Represents information related to all other international countries. Potentially dilutive shares included in the calculation of diluted earnings per share Weighted Average Number of Shares Outstanding, Diluted, Adjustment Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity [Domain] Entity [Domain] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] City Area Code City Area Code Assets Assets [Abstract] Unvested stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Line of credit, outstanding, current Line of Credit, Current CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted-average grant date fair value (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Other liabilities Other Liabilities, Noncurrent Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cardiovascular Cardiovascular Products [Member] Represents information pertaining to cardiovascular products of the entity. EX-101.PRE 12 natr-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 natr-20220630_g1.jpg GRAPHIC begin 644 natr-20220630_g1.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
6 Months Ended
Jun. 30, 2022
Jul. 22, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-34483  
Entity Registrant Name NATURE’S SUNSHINE PRODUCTS, INC.  
Entity Incorporation, State or Country Code UT  
Entity Tax Identification Number 87-0327982  
Entity Address, Address Line One 2901 Bluegrass Boulevard  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Lehi  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84043  
City Area Code 801  
Local Phone Number 341-7900  
Title of 12(b) Security Common Stock, no par value  
Trading Symbol NATR  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   19,224,999
Entity Central Index Key 0000275053  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 56,344 $ 86,184
Accounts receivable, net of allowance for doubtful accounts of $525 and $143, respectively 10,540 8,871
Inventories 70,643 60,852
Prepaid expenses and other 9,618 8,760
Total current assets 147,145 164,667
Property, plant and equipment, net 49,099 50,857
Operating lease right-of-use assets 18,060 18,349
Investment securities - trading 743 964
Deferred income tax assets 7,794 13,590
Other assets 10,218 10,447
Total assets 233,059 258,874
Current liabilities:    
Accounts payable 9,423 9,702
Accrued volume incentives and service fees 23,199 23,131
Accrued liabilities 26,842 31,600
Deferred revenue 1,829 3,694
Related party notes payable 0 302
Income taxes payable 2,227 2,647
Current portion of operating lease liabilities 4,336 4,350
Current portion of note payable 1,263 1,244
Total current liabilities 69,119 76,670
Long-term portion of operating lease liabilities 15,871 15,919
Long-term note payable 537 1,174
Deferred compensation payable 743 964
Deferred income tax liabilities 1,212 1,566
Other liabilities 1,098 1,177
Total liabilities 88,580 97,470
Shareholders’ equity:    
Common stock, no par value, 50,000 shares authorized, 19,259 and 19,724 shares issued and outstanding, respectively 121,623 133,382
Retained earnings 32,591 35,025
Noncontrolling interest 3,902 3,202
Accumulated other comprehensive loss (13,637) (10,205)
Total shareholders’ equity 144,479 161,404
Total liabilities and shareholders’ equity $ 233,059 $ 258,874
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 525 $ 143
Common stock, no par value (in dollars per share) $ 0 $ 0
Common stock, shares outstanding (in shares) 19,259,000 19,724,000
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 19,259,000 19,724,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Net sales $ 104,161 $ 108,978 $ 214,655 $ 211,399
Cost of sales 29,471 28,463 63,931 55,442
Gross profit 74,690 80,515 150,724 155,957
Operating expenses:        
Volume incentives 32,069 35,443 66,171 69,698
Selling, general and administrative 36,866 35,586 77,489 69,138
Operating income 5,755 9,486 7,064 17,121
Other loss, net (442) 529 (756) (1,404)
Income before provision for income taxes 5,313 10,015 6,308 15,717
Provision for income taxes 4,361 3,221 8,042 4,771
Net income (loss) 952 6,794 (1,734) 10,946
Net income attributable to noncontrolling interests 436 254 700 390
Net income attributable to common shareholders $ 516 $ 6,540 $ (2,434) $ 10,556
Basic and diluted net income per common share:        
Basic earnings (loss) per share attributable to common shareholders (in dollars per share) $ 0.03 $ 0.33 $ (0.12) $ 0.53
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share) $ 0.03 $ 0.32 $ (0.12) $ 0.52
Weighted average basic common shares outstanding (in shares) 19,386 19,999 19,479 19,897
Weighted average diluted common shares outstanding (in shares) 19,594 20,503 19,479 20,340
Dividends declared per common share (in dollars per share)     $ 0 $ 1.00
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 952 $ 6,794 $ (1,734) $ 10,946
Foreign currency translation loss (net of tax) (2,457) (45) (3,432) (166)
Total comprehensive income (loss) $ (1,505) $ 6,749 $ (5,166) $ 10,780
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Retained Earnings
Noncontrolling Interest
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020   19,697      
Beginning balance at Dec. 31, 2020 $ 157,234 $ 139,311 $ 26,030 $ 1,848 $ (9,955)
Increase (Decrease) in Shareholders' Equity          
Share-based compensation expense 1,005 $ 1,005      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)   218      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (914) $ (914)      
Cash dividends (19,858)   (19,858)    
Net income (loss) 4,152   4,016 136  
Other comprehensive loss (121)       (121)
Ending balance (in shares) at Mar. 31, 2021   19,915      
Ending balance at Mar. 31, 2021 141,498 $ 139,402 10,188 1,984 (10,076)
Beginning balance (in shares) at Dec. 31, 2020   19,697      
Beginning balance at Dec. 31, 2020 $ 157,234 $ 139,311 26,030 1,848 (9,955)
Increase (Decrease) in Shareholders' Equity          
Repurchase of common stock (in shares) (77)        
Repurchase of common stock $ (1,500)        
Net income (loss) 10,946        
Ending balance (in shares) at Jun. 30, 2021   19,990      
Ending balance at Jun. 30, 2021 147,153 $ 138,308 16,728 2,238 (10,121)
Beginning balance (in shares) at Mar. 31, 2021   19,915      
Beginning balance at Mar. 31, 2021 141,498 $ 139,402 10,188 1,984 (10,076)
Increase (Decrease) in Shareholders' Equity          
Share-based compensation expense 1,066 $ 1,066      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)   152      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (660) $ (660)      
Repurchase of common stock (in shares)   (77)      
Repurchase of common stock (1,500) $ (1,500)      
Net income (loss) 6,794   6,540 254  
Other comprehensive loss (45)       (45)
Ending balance (in shares) at Jun. 30, 2021   19,990      
Ending balance at Jun. 30, 2021 $ 147,153 $ 138,308 16,728 2,238 (10,121)
Beginning balance (in shares) at Dec. 31, 2021 19,724 19,724      
Beginning balance at Dec. 31, 2021 $ 161,404 $ 133,382 35,025 3,202 (10,205)
Increase (Decrease) in Shareholders' Equity          
Share-based compensation expense 801 $ 801      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)   218      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (795) $ (795)      
Repurchase of common stock (in shares)   (451)      
Repurchase of common stock (7,971) $ (7,971)      
Net income (loss) (2,686)   (2,950) 264  
Other comprehensive loss (975)       (975)
Ending balance (in shares) at Mar. 31, 2022   19,491      
Ending balance at Mar. 31, 2022 $ 149,778 $ 125,417 32,075 3,466 (11,180)
Beginning balance (in shares) at Dec. 31, 2021 19,724 19,724      
Beginning balance at Dec. 31, 2021 $ 161,404 $ 133,382 35,025 3,202 (10,205)
Increase (Decrease) in Shareholders' Equity          
Repurchase of common stock (in shares) (741)        
Repurchase of common stock $ (12,000)        
Net income (loss) $ (1,734)        
Ending balance (in shares) at Jun. 30, 2022 19,259 19,259      
Ending balance at Jun. 30, 2022 $ 144,479 $ 121,623 32,591 3,902 (13,637)
Beginning balance (in shares) at Mar. 31, 2022   19,491      
Beginning balance at Mar. 31, 2022 149,778 $ 125,417 32,075 3,466 (11,180)
Increase (Decrease) in Shareholders' Equity          
Share-based compensation expense 540 $ 540      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)   58      
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (334) $ (334)      
Repurchase of common stock (in shares)   (290)      
Repurchase of common stock (4,000) $ (4,000)      
Net income (loss) 952   516 436  
Other comprehensive loss $ (2,457)       (2,457)
Ending balance (in shares) at Jun. 30, 2022 19,259 19,259      
Ending balance at Jun. 30, 2022 $ 144,479 $ 121,623 $ 32,591 $ 3,902 $ (13,637)
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) - $ / shares
3 Months Ended 6 Months Ended
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]      
Cash dividend (in dollars per share) $ 1.00 $ 0 $ 1.00
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (1,734) $ 10,946
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Provision for doubtful accounts 417 0
Depreciation and amortization 5,451 5,541
Non-cash lease expense 2,785 2,626
Share-based compensation expense 1,341 2,071
Loss on sale of property, plant and equipment 0 12
Deferred income taxes 5,338 1,753
Purchase of trading investment securities (19) (24)
Proceeds from sale of trading investment securities 69 175
Realized and unrealized gains (losses) on investments 170 (67)
Foreign exchange losses 803 1,572
Changes in assets and liabilities:    
Accounts receivable (2,801) (2,755)
Inventories (11,910) (3,777)
Prepaid expenses and other current assets (1,357) (918)
Other assets (33) (108)
Accounts payable (80) 1,079
Accrued volume incentives and service fees 1,045 483
Accrued liabilities (4,001) (5,473)
Deferred revenue (1,718) (111)
Lease liabilities (2,503) (2,487)
Income taxes payable (386) 261
Liability related to unrecognized tax benefits 0 (87)
Deferred compensation payable (220) 0
Net cash provided by (used in) operating activities (9,343) 10,712
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (3,757) (2,898)
Net cash used in investing activities (3,757) (2,898)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of cash dividends 0 (19,858)
Principal payments of long-term debt (618) (698)
Proceeds from revolving credit facility 15,645 0
Principal payments of revolving credit facility (15,645) 0
Principal payments of related party borrowing (300) 0
Payments related to tax withholding for net-share settled equity awards (1,129) (1,574)
Repurchase of common stock (11,971) (1,500)
Net cash used in financing activities (14,018) (23,630)
Effect of exchange rates on cash and cash equivalents (2,722) (1,351)
Net decrease in cash and cash equivalents (29,840) (17,167)
Cash and cash equivalents at the beginning of the period 86,184 92,069
Cash and cash equivalents at the end of the period 56,344 74,902
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes, net of refunds 4,173 2,582
Cash paid for interest $ 113 $ 111
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Basis of Presentation
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
 
We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.
 
Principles of Consolidation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.
 
These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.

The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions.

Noncontrolling Interests

Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.7 million for the three and six months ended June 30, 2022, respectively. Net income attributable to the noncontrolling interests was $0.3 million and $0.4 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, noncontrolling interests were $3.9 million and $3.2 million, respectively.

Restructuring Related Accruals and Expenses

We recorded $0 and $0.3 million of restructuring related expenses during the three and six months ended June 30, 2022, respectively. We recorded $0 and $48,000 of restructuring related expenses during the three and six months ended June 30, 2021, respectively. Accrued severance and restructuring related costs were $5,000 and $0.2 million as of June 30, 2022 and December 31, 2021, respectively.

Recent Accounting Pronouncements
 
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the
potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
 
The composition of inventories is as follows (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Raw materials$27,680 $22,494 
Work in progress1,930 1,746 
Finished goods41,033 36,612 
Total inventories$70,643 $60,852 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Investment Securities - Trading
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investment Securities - Trading Investment Securities - Trading
 
Our trading securities portfolio totaled $0.7 million at June 30, 2022, and $1.0 million at December 31, 2021, and generated losses of $0.1 million and gains of $0.1 million for the three months ended June 30, 2022 and 2021, respectively, and losses of $0.2 million and gains of $0.1 million for the six months ended June 30, 2022 and 2021, respectively.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Revolving Credit Facility and Other Obligations
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Revolving Credit Facility and Other Obligations Revolving Credit Facility and Other Obligations
On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022 the credit agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each. The amendment to the credit agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (3.10 percent as of June 30, 2022), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. At June 30, 2022 and December 31, 2021, there was no outstanding balance under the Credit Agreement.

The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of June 30, 2022, we were in compliance with the debt covenants set forth in the Credit Agreement.

On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in 36 monthly payments, of $0.1 million. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of June 30, 2022, there was $1.8 million outstanding balance under the Capital Credit Agreement, of which $1.3 million was classified as current.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income Per Share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
 
Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.
Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net income (loss) attributable to common shareholders$516 $6,540 $(2,434)$10,556 
Basic weighted average shares outstanding19,386 19,999 19,479 19,897 
Basic earnings (loss) per share attributable to common shareholders$0.03 $0.33 $(0.12)$0.53 
Diluted shares outstanding:    
Basic weighted-average shares outstanding19,386 19,999 19,479 19,897 
Stock-based awards208 504 — 443 
Diluted weighted-average shares outstanding19,594 20,503 19,479 20,340 
Diluted earnings (loss) per share attributable to common shareholders$0.03 $0.32 $(0.12)$0.52 
Dilutive shares excluded from diluted-per-share amounts:    
Stock options341 563 — 563 
Anti-dilutive shares excluded from diluted-per-share amounts:    
Stock options25 — 341 (1)— 
_________________________________________

(1)     As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.

Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Capital Transactions
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Capital Transactions Capital Transactions
 
Dividends

On March 10, 2021, we announced a special non-recurring cash dividend of $1.00 per common share in an aggregate amount of $19.9 million that was paid on April 5, 2021, to shareholders of record on March 29, 2021. In accordance with the provisions of our 2012 Stock Incentive Plan (the "2012 Incentive Plan"), as a result of the special dividend we are required to make the participant's original grant whole by preventing either dilution or enlargement of the benefits or potential benefits intended by the original grant. The 2012 Incentive Plan provides our Compensation Committee with the discretion to meet this requirement. See further discussion in the Share-Based Compensation section of this Note.

The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors.
Share Repurchase Program

On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the six months ended June 30, 2022 and 2021, we repurchased 741,000 and 77,000 shares of our common stock for $12.0 million and $1.5 million, respectively. At June 30, 2022, the remaining balance available for repurchases under the program was $25.6 million.

Share-Based Compensation
 
During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.
 
Stock Options
 
Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.
 
Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Exercise
Price Per Share
Weighted Average
Grant Date
Fair Value
Options outstanding at December 31, 2021172 $12.13 $5.05 
Granted— — — 
Forfeited or canceled— — — 
Exercised(29)9.17 3.92 
Options outstanding at June 30, 2022143 $12.72 $5.28 

There was no share-based compensation expense for the three- and six-month periods ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, there was no unrecognized share-based compensation expense related to the grants described above.

At June 30, 2022, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 143,000 shares of common stock was $41,000. At December 31, 2021, the aggregate intrinsic value of outstanding and exercisable options to purchase 172,000 shares of common stock was $1.1 million.

For the six-month periods ended June 30, 2022 and 2021, we issued 29,000 and 50,000 shares of common stock upon the exercise of stock options at an average exercise price of $9.17 and $12.00 per share, respectively. The aggregate intrinsic value of options exercised during the six-month periods ended June 30, 2022 and 2021, was $0.3 million and $0.4 million, respectively. For the six-month periods ended June 30, 2022 and 2021, the Company recognized $0.1 million and $0.2 million of tax benefits from the exercise of stock options, respectively.

As of June 30, 2022 and December 31, 2021, we did not have any unvested performance-based stock options outstanding.
 
Restricted Stock Units
 
Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2022 and December 31, 2021, there were 68,000 and 88,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period.

Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Grant Date
Fair Value
Restricted Stock Units outstanding at December 31, 2021830 $9.46 
Granted164 8.87 
Forfeited(68)5.39 
Issued(329)7.50 
Restricted Stock Units outstanding at June 30, 2022597 10.84 
 
During the six-month period ended June 30, 2022, we granted 164,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $6.01 per share and vest upon achieving share-priced targets over a three-year period from the grant date.

Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.9 percent for a common share.

Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50.1 percent, and a risk-free rate of 3.3 percent.

Share-based compensation expense related to time-based RSUs for the three-month periods ended June 30, 2022 and 2021, was approximately $0.3 million and $0.6 million, respectively. Share-based compensation expense related to time-based RSUs for the six-month periods ended June 30, 2022 and 2021, was approximately $0.9 million and $1.0 million, respectively. As of June 30, 2022 and December 31, 2021, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.4 million and $1.6 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.3 years.
 
Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2022 and 2021, was $0.2 million and $0.5 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2022 and 2021, was $0.5 million and $0.9 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would, and expect to, recognize up to $2.4 million of potential share-based compensation expense.
The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 80,000 and 121,000 shares for the six-month periods ended June 30, 2022 and 2021, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Segment Information Segment Information
 
We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.

Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.

Reportable business segment information is as follows (dollar amounts in thousands):

 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
Asia$47,382 $43,536 $93,492 $79,291 
Europe17,099 21,455 38,876 43,655 
North America34,082 37,372 70,063 75,134 
Latin America and Other5,598 6,615 12,224 13,319 
Total net sales104,161 108,978 214,655 211,399 
Contribution margin (1):    
Asia21,432 18,463 43,371 33,782 
Europe6,595 6,588 10,968 13,384 
North America12,300 16,259 25,019 31,699 
Latin America and Other2,294 3,762 5,195 7,394 
Total contribution margin42,621 45,072 84,553 86,259 
Selling, general and administrative expenses (2)36,866 35,586 77,489 69,138 
Operating income5,755 9,486 7,064 17,121 
Other income (loss), net(442)529 (756)(1,404)
Income before provision for income taxes$5,313 $10,015 $6,308 $15,717 
_________________________________________

(1)    Contribution margin consists of net sales less cost of sales and volume incentives expense.

(2)    Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses.
From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
United States$31,483 $34,378 $64,712 $69,298 
South Korea14,465 17,546 28,118 32,355 
Taiwan11,933 4,730 21,683 7,499 
Other46,280 52,324 100,142 102,247 
 $104,161 $108,978 $214,655 $211,399 
Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Asia    
General health$12,319 $12,698 $25,305 $23,990 
Immune781 382 2,125 585 
Cardiovascular13,242 12,260 26,872 22,163 
Digestive10,990 7,747 20,026 14,618 
Personal care2,083 5,290 4,626 7,814 
Weight management7,967 5,159 14,538 10,121 
 47,382 43,536 93,492 79,291 
Europe    
General health$7,328 $9,667 $16,524 $19,139 
Immune1,443 1,818 4,074 3,834 
Cardiovascular2,150 2,836 4,783 5,828 
Digestive4,481 5,567 10,072 11,107 
Personal care1,209 999 2,442 2,425 
Weight management488 568 981 1,322 
 17,099 21,455 38,876 43,655 
North America    
General health$14,954 $16,349 $30,268 $32,619 
Immune4,061 4,101 8,933 8,975 
Cardiovascular3,893 4,010 7,735 8,235 
Digestive9,044 10,016 17,638 19,479 
Personal care1,389 1,834 3,564 3,653 
Weight management741 1,062 1,925 2,173 
 34,082 37,372 70,063 75,134 
Latin America and Other    
General health$1,597 $1,873 $3,415 $3,848 
Immune755 697 1,516 1,508 
Cardiovascular455 425 812 903 
Digestive2,551 3,001 5,392 5,872 
Personal care80 398 721 743 
Weight management160 221 368 445 
 5,598 6,615 12,224 13,319 
 $104,161 $108,978 $214,655 $211,399 

From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
 June 30,
2022
December 31,
2021
Property, plant and equipment:  
United States$45,036 $46,595 
Other4,063 4,262 
Total property, plant and equipment, net$49,099 $50,857 
Total assets per segment is set forth below (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Assets:  
Asia$91,762 $104,659 
Europe14,771 15,486 
North America119,018 131,207 
Latin America and Other7,508 7,522 
Total assets$233,059 $258,874 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
 
For the three months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 82.1 percent and 32.2 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 127.5 percent and 30.4 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2022, was primarily attributed to recording a valuation allowance against deferred tax assets which are expected to expire before utilization.

The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2021, was primarily attributed to transfer pricing adjustments and foreign losses during those periods that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items.

The difference between the effective tax rate for the three and six months ended June 30, 2022 compared to June 30, 2021 is primarily caused by recording a valuation allowance in the current period against deferred tax assets which are expected to expire before utilization.

Our U.S. federal income tax returns for 2018 through 2020 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2016 through 2021.
 
As of June 30, 2022 and December 31, 2021, we do not have any amounts accrued for unrecognized tax positions.
 
Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
 
Legal Proceedings
 
We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim.
 
Non-Income Tax Contingencies
 
We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are
recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.8 million.
 
Other Litigation
 
We are a party to various other legal proceedings and disputes in the United States and foreign jurisdictions. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.5 million, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, but either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.4 million.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions Related Party TransactionsDuring the three and six months ended June 30, 2022 and 2021, our joint venture in China, owned 80 percent by us and 20 percent by a wholly owned subsidiary of Fosun Pharma, did not borrow any amounts from the Company or our joint venture partner. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from the Company were $0 and $1.2 million, respectively. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from our joint venture partner were $0 and $0.3 million, respectively. These notes were payable in less than one year and bore interest of 3.0 percent. The notes between NSP China and the Company eliminated in consolidation. In March 2022 the outstanding principal and interest amounts were repaid.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
 
The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
 
Level 1: Quoted market prices in active markets for identical assets or liabilities.
 
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
 
Level 3: Unobservable inputs that are not corroborated by market data.
 
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2022 (dollar amounts in thousands):
 
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$743 $— $— $743 
Total assets measured at fair value on a recurring basis$743 $— $— $743 
 
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2021 (dollar amounts in thousands):
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$964 $— $— $964 
Total assets measured at fair value on a recurring basis$964 $— $— $964 
 
Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets.
 
For the six months ended June 30, 2022 and for the year ended December 31, 2021, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3).
 
The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the six months ended June 30, 2022 and 2021, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue Recognition
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Revenue Recognition

Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year.

A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive.

From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation.

Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales.

Contract Liabilities - Customer Loyalty Programs

Historically, we have offered loyalty point programs which allowed customers to earn loyalty points on personal orders. Loyalty points were recorded as contract liabilities in deferred revenue. These programs were accounted for as a reduction in the transaction price and generally recognized as points that were redeemed for additional products. During the year ended December 31, 2020 these programs were discontinued. As of June 30, 2022, there were no outstanding loyalty points.
Disaggregation of Revenue

Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category.

Practical Expedients and Exemptions

We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.

We generally expense volume incentives when incurred because the amortization period would have been one year or less.

All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Basis of Presentation (Policies)
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
 
We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.
Principles of Consolidation
Principles of Consolidation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.
 
These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.
Use of Estimates
Use of Estimates

The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.
The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the
potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Tables)
6 Months Ended
Jun. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of composition of inventories The composition of inventories is as follows (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Raw materials$27,680 $22,494 
Work in progress1,930 1,746 
Finished goods41,033 36,612 
Total inventories$70,643 $60,852 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income Per Share (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS
Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net income (loss) attributable to common shareholders$516 $6,540 $(2,434)$10,556 
Basic weighted average shares outstanding19,386 19,999 19,479 19,897 
Basic earnings (loss) per share attributable to common shareholders$0.03 $0.33 $(0.12)$0.53 
Diluted shares outstanding:    
Basic weighted-average shares outstanding19,386 19,999 19,479 19,897 
Stock-based awards208 504 — 443 
Diluted weighted-average shares outstanding19,594 20,503 19,479 20,340 
Diluted earnings (loss) per share attributable to common shareholders$0.03 $0.32 $(0.12)$0.52 
Dilutive shares excluded from diluted-per-share amounts:    
Stock options341 563 — 563 
Anti-dilutive shares excluded from diluted-per-share amounts:    
Stock options25 — 341 (1)— 
_________________________________________

(1)     As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Capital Transactions (Tables)
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Schedule of stock option activity Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Exercise
Price Per Share
Weighted Average
Grant Date
Fair Value
Options outstanding at December 31, 2021172 $12.13 $5.05 
Granted— — — 
Forfeited or canceled— — — 
Exercised(29)9.17 3.92 
Options outstanding at June 30, 2022143 $12.72 $5.28 
Schedule of restricted stock unit activity Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):
 Number of
Shares
Weighted Average
Grant Date
Fair Value
Restricted Stock Units outstanding at December 31, 2021830 $9.46 
Granted164 8.87 
Forfeited(68)5.39 
Issued(329)7.50 
Restricted Stock Units outstanding at June 30, 2022597 10.84 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Schedule of reportable business segment information
Reportable business segment information is as follows (dollar amounts in thousands):

 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
Asia$47,382 $43,536 $93,492 $79,291 
Europe17,099 21,455 38,876 43,655 
North America34,082 37,372 70,063 75,134 
Latin America and Other5,598 6,615 12,224 13,319 
Total net sales104,161 108,978 214,655 211,399 
Contribution margin (1):    
Asia21,432 18,463 43,371 33,782 
Europe6,595 6,588 10,968 13,384 
North America12,300 16,259 25,019 31,699 
Latin America and Other2,294 3,762 5,195 7,394 
Total contribution margin42,621 45,072 84,553 86,259 
Selling, general and administrative expenses (2)36,866 35,586 77,489 69,138 
Operating income5,755 9,486 7,064 17,121 
Other income (loss), net(442)529 (756)(1,404)
Income before provision for income taxes$5,313 $10,015 $6,308 $15,717 
_________________________________________

(1)    Contribution margin consists of net sales less cost of sales and volume incentives expense.
(2)    Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses.
Schedule of consolidated net sales revenue by geographical locations
From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Net sales:    
United States$31,483 $34,378 $64,712 $69,298 
South Korea14,465 17,546 28,118 32,355 
Taiwan11,933 4,730 21,683 7,499 
Other46,280 52,324 100,142 102,247 
 $104,161 $108,978 $214,655 $211,399 
Schedule of revenue generated by each of the Company's product lines
Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Asia    
General health$12,319 $12,698 $25,305 $23,990 
Immune781 382 2,125 585 
Cardiovascular13,242 12,260 26,872 22,163 
Digestive10,990 7,747 20,026 14,618 
Personal care2,083 5,290 4,626 7,814 
Weight management7,967 5,159 14,538 10,121 
 47,382 43,536 93,492 79,291 
Europe    
General health$7,328 $9,667 $16,524 $19,139 
Immune1,443 1,818 4,074 3,834 
Cardiovascular2,150 2,836 4,783 5,828 
Digestive4,481 5,567 10,072 11,107 
Personal care1,209 999 2,442 2,425 
Weight management488 568 981 1,322 
 17,099 21,455 38,876 43,655 
North America    
General health$14,954 $16,349 $30,268 $32,619 
Immune4,061 4,101 8,933 8,975 
Cardiovascular3,893 4,010 7,735 8,235 
Digestive9,044 10,016 17,638 19,479 
Personal care1,389 1,834 3,564 3,653 
Weight management741 1,062 1,925 2,173 
 34,082 37,372 70,063 75,134 
Latin America and Other    
General health$1,597 $1,873 $3,415 $3,848 
Immune755 697 1,516 1,508 
Cardiovascular455 425 812 903 
Digestive2,551 3,001 5,392 5,872 
Personal care80 398 721 743 
Weight management160 221 368 445 
 5,598 6,615 12,224 13,319 
 $104,161 $108,978 $214,655 $211,399 
Schedule of consolidated property, plant and equipment by geographical locations
From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
 June 30,
2022
December 31,
2021
Property, plant and equipment:  
United States$45,036 $46,595 
Other4,063 4,262 
Total property, plant and equipment, net$49,099 $50,857 
Schedule of assets per segment
Total assets per segment is set forth below (dollar amounts in thousands):
June 30,
2022
December 31,
2021
Assets:  
Asia$91,762 $104,659 
Europe14,771 15,486 
North America119,018 131,207 
Latin America and Other7,508 7,522 
Total assets$233,059 $258,874 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of the company's hierarchy for assets measured at fair value on a recurring basis
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2022 (dollar amounts in thousands):
 
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$743 $— $— $743 
Total assets measured at fair value on a recurring basis$743 $— $— $743 
 
The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2021 (dollar amounts in thousands):
 Level 1Level 2Level 3 
 Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
Total
Investment securities - trading$964 $— $— $964 
Total assets measured at fair value on a recurring basis$964 $— $— $964 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Basis of Presentation (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Noncontrolling Interest [Line Items]          
Increase (decrease) in noncontrolling interest $ 400,000 $ 300,000 $ 700,000 $ 400,000  
Noncontrolling interest 3,902,000   3,902,000   $ 3,202,000
Restructuring charges 0 $ 0 300,000 $ 48,000  
Accrued Severance and Rent Costs          
Noncontrolling Interest [Line Items]          
Restructuring Reserve $ 5,000   $ 5,000   $ 200,000
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 27,680 $ 22,494
Work in progress 1,930 1,746
Finished goods 41,033 36,612
Total inventories $ 70,643 $ 60,852
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Investment Securities - Trading (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]          
Trading securities portfolio $ 743   $ 743   $ 964
Debt securities, trading, realized gains (losses) $ (100) $ 100 $ 200 $ 100  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Revolving Credit Facility and Other Obligations (Details)
Jun. 23, 2022
USD ($)
borrowing
Nov. 19, 2020
USD ($)
payment
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Apr. 21, 2020
USD ($)
Jul. 11, 2017
USD ($)
Revolving credit facility | Bank of America Credit Agreement            
Long-term debt            
Maximum borrowing capacity           $ 25,000,000
Potential increase in maximum borrowing capacity $ 25,000,000          
Number of separate increases | borrowing 3          
Potential increase in maximum borrowing capacity, per occurrence $ 5,000,000          
Annual commitment fee 0.25%          
Long-term line of credit     $ 0 $ 0    
Revolving credit facility | LIBOR | Bank of America Credit Agreement            
Long-term debt            
Margin on variable rate 1.50%          
Effective interest rate     3.10%      
Line of Credit | Banc of America Leasing and Capital Credit Agreement            
Long-term debt            
Maximum borrowing capacity         $ 6,000,000  
Long-term line of credit   $ 3,700,000 $ 1,800,000      
Number of monthly payments | payment   36        
Periodic payment   $ 100,000        
Line of credit, outstanding, current     $ 1,300,000      
Line of Credit | Indicative Index | Banc of America Leasing and Capital Credit Agreement            
Long-term debt            
Effective interest rate     3.00%      
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]        
Net income (loss) attributable to common shareholders $ 516 $ 6,540 $ (2,434) $ 10,556
Basic weighted average shares outstanding (in shares) 19,386 19,999 19,479 19,897
Basic earnings (loss) per share attributable to common shareholders (in dollars per share) $ 0.03 $ 0.33 $ (0.12) $ 0.53
Diluted shares outstanding:        
Basic weighted-average shares outstanding (in shares) 19,386 19,999 19,479 19,897
Stock-based awards (in shares) 208 504 0 443
Diluted weighted-average shares outstanding (in shares) 19,594 20,503 19,479 20,340
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share) $ 0.03 $ 0.32 $ (0.12) $ 0.52
Dilutive shares excluded from diluted-per-share amounts:        
Stock options (in shares) 341 563 0 563
Anti-dilutive shares excluded from diluted-per-share amounts:        
Stock options (in shares) 25 0 341 0
Potentially dilutive shares included in the calculation of diluted earnings per share     0  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Capital Transactions - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
May 05, 2021
Apr. 05, 2021
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2015
Mar. 08, 2022
Dec. 31, 2021
Mar. 10, 2021
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common stock, dividends (in dollars per share)   $ 1.00                      
Dividends, common stock, cash   $ 19,900,000       $ 19,858,000              
Stock repurchase program, authorized amount                   $ 30,000,000   $ 15,000,000  
Repurchase of common stock (in shares)             741,000 77,000          
Repurchase of common stock     $ 4,000,000 $ 7,971,000 $ 1,500,000   $ 12,000,000 $ 1,500,000          
Stock repurchase program, remaining authorized repurchase amount     25,600,000       25,600,000            
2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares authorized under the plan (in shares)                         1,500,000
Additional number of shares authorized under the plan (in shares) 2,000,000               1,500,000        
Stock options                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share-based compensation expense     0   0   0 $ 0          
Unrecognized share-based compensation expense     $ 0       $ 0       $ 0    
Options outstanding (in shares)     143,000       143,000       172,000    
Aggregate intrinsic value, outstanding     $ 41,000       $ 41,000       $ 1,100,000    
Exercised (in shares)             29,000 50,000          
Exercised (in dollars per share)             $ 9.17 $ 12.00          
Aggregate intrinsic values of options exercised             $ 300,000 $ 400,000          
Tax benefit from the exercise of stock options             $ 100,000 200,000          
Weighted-average grant date fair value (in dollars per share)             $ 0            
Time-based stock options | Maximum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Vesting period             48 months            
Performance based stock options operating income margins                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Operating income margin, one (as a percent)             6.00%            
Operating income margin, two (as a percent)             8.00%            
Operating income margin, three (as a percent)             10.00%            
Unvested stock options outstanding (in shares)     0       0       0    
Performance based stock options operating income margins | Minimum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Award performance period             1 year            
Performance based stock options operating income margins | Maximum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Award performance period             1 year 3 months            
RSUs                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share-based compensation expense     $ 300,000   600,000   $ 900,000 $ 1,000,000          
Unrecognized share-based compensation expense     $ 1,400,000       $ 1,400,000       $ 1,600,000    
Discount for lack of marketability             12.90%            
Award performance period             3 years            
Weighted-average period over which the remaining compensation cost is expected to be recognized             3 months 18 days            
Minimum withholding requirements (in shares)             80,000 121,000          
RSUs | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Granted (in shares)             164,000            
RSUs | Minimum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Expected volatility (as a percent)             50.10%            
Risk-free interest rate (as a percent)             3.30%            
RSUs | Minimum | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Vesting period             12 months            
RSUs | Maximum | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Vesting period             36 months            
RSUs | Director | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Restriction period for issuance of shares             2 years            
Nonvested subject to restriction period (in shares)     68,000       68,000       88,000    
Time-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Vesting period             3 years            
Weighted-average grant date fair value (in dollars per share)             $ 13.87            
Performance-Based Restricted Stock Units (RSUs)                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share-based compensation expense     $ 200,000   $ 500,000   $ 500,000 $ 900,000          
Performance-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Weighted-average grant date fair value (in dollars per share)             $ 6.01            
Performance-Based Restricted Stock Units (RSUs) | Maximum                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share based compensation potential compensation expense to be recognized     $ 2,400,000       $ 2,400,000            
Performance-Based Restricted Stock Units (RSUs) | Net Sales and Operating Income Targets | 2012 Stock Incentive Plan                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Vesting period             3 years            
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Capital Transactions - Stock Option Activity (Details) - Stock options - $ / shares
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Number of Shares    
Options outstanding at the beginning of the period (in shares) 172,000  
Granted (in shares) 0  
Forfeited or canceled (in shares) 0  
Exercised (in shares) (29,000) (50,000)
Options outstanding at the end of the period (in shares) 143,000  
Weighted Average Exercise Price Per Share    
Options outstanding at the beginning of the period (in dollars per share) $ 12.13  
Granted (in dollars per share) 0  
Forfeited or canceled (in dollars per share) 0  
Exercised (in dollars per share) 9.17 $ 12.00
Options outstanding at the end of the period (in dollars per share) 12.72  
Weighted Average Grant Date Fair Value    
Options outstanding at the beginning of the period (in dollars per share) 5.05  
Granted (in dollars per share) 0  
Forfeited or canceled (in dollars per share) 0  
Exercised (in dollars per share) 3.92  
Options outstanding at the beginning of the period (in dollars per share) $ 5.28  
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs
6 Months Ended
Jun. 30, 2022
$ / shares
shares
Number of Shares  
Restricted Stock Units outstanding, beginning balance (in shares) | shares 830,000
Granted (in shares) | shares 164,000
Forfeited (in shares) | shares (68,000)
Issued (in shares) | shares (329,000)
Restricted Stock Units outstanding, ending balance (in shares) | shares 597,000
Weighted Average Grant Date Fair Value  
Restricted Stock Units outstanding, beginning balance (in dollars per share) | $ / shares $ 9.46
Granted (in dollars per share) | $ / shares 8.87
Forfeited (in dollars per share) | $ / shares 5.39
Issued (in dollars per share) | $ / shares 7.50
Restricted Stock Units outstanding, ending balance (in dollars per share) | $ / shares $ 10.84
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Segment information          
Number of business segments | segment     4    
Net sales:          
Total net sales revenue $ 104,161 $ 108,978 $ 214,655 $ 211,399  
Contribution margin:          
Total contribution margin 42,621 45,072 84,553 86,259  
Selling, general and administrative expenses 36,866 35,586 77,489 69,138  
Operating income 5,755 9,486 7,064 17,121  
Other income (loss), net (442) 529 (756) (1,404)  
Income before provision for income taxes 5,313 10,015 6,308 15,717  
Total property, plant and equipment, net 49,099   49,099   $ 50,857
Total assets 233,059   233,059   258,874
Asia          
Net sales:          
Total net sales revenue 47,382 43,536 93,492 79,291  
Contribution margin:          
Total contribution margin 21,432 18,463 43,371 33,782  
Total assets 91,762   91,762   104,659
Asia | General health          
Net sales:          
Total net sales revenue 12,319 12,698 25,305 23,990  
Asia | Immune          
Net sales:          
Total net sales revenue 781 382 2,125 585  
Asia | Cardiovascular          
Net sales:          
Total net sales revenue 13,242 12,260 26,872 22,163  
Asia | Digestive          
Net sales:          
Total net sales revenue 10,990 7,747 20,026 14,618  
Asia | Personal care          
Net sales:          
Total net sales revenue 2,083 5,290 4,626 7,814  
Asia | Weight management          
Net sales:          
Total net sales revenue 7,967 5,159 14,538 10,121  
Europe          
Net sales:          
Total net sales revenue 17,099 21,455 38,876 43,655  
Contribution margin:          
Total contribution margin 6,595 6,588 10,968 13,384  
Total assets 14,771   14,771   15,486
Europe | General health          
Net sales:          
Total net sales revenue 7,328 9,667 16,524 19,139  
Europe | Immune          
Net sales:          
Total net sales revenue 1,443 1,818 4,074 3,834  
Europe | Cardiovascular          
Net sales:          
Total net sales revenue 2,150 2,836 4,783 5,828  
Europe | Digestive          
Net sales:          
Total net sales revenue 4,481 5,567 10,072 11,107  
Europe | Personal care          
Net sales:          
Total net sales revenue 1,209 999 2,442 2,425  
Europe | Weight management          
Net sales:          
Total net sales revenue 488 568 981 1,322  
North America          
Net sales:          
Total net sales revenue 34,082 37,372 70,063 75,134  
Contribution margin:          
Total contribution margin 12,300 16,259 25,019 31,699  
Total assets 119,018   119,018   131,207
North America | General health          
Net sales:          
Total net sales revenue 14,954 16,349 30,268 32,619  
North America | Immune          
Net sales:          
Total net sales revenue 4,061 4,101 8,933 8,975  
North America | Cardiovascular          
Net sales:          
Total net sales revenue 3,893 4,010 7,735 8,235  
North America | Digestive          
Net sales:          
Total net sales revenue 9,044 10,016 17,638 19,479  
North America | Personal care          
Net sales:          
Total net sales revenue 1,389 1,834 3,564 3,653  
North America | Weight management          
Net sales:          
Total net sales revenue 741 1,062 1,925 2,173  
Latin America and Other          
Net sales:          
Total net sales revenue 5,598 6,615 12,224 13,319  
Contribution margin:          
Total contribution margin 2,294 3,762 5,195 7,394  
Total assets 7,508   7,508   7,522
Latin America and Other | General health          
Net sales:          
Total net sales revenue 1,597 1,873 3,415 3,848  
Latin America and Other | Immune          
Net sales:          
Total net sales revenue 755 697 1,516 1,508  
Latin America and Other | Cardiovascular          
Net sales:          
Total net sales revenue 455 425 812 903  
Latin America and Other | Digestive          
Net sales:          
Total net sales revenue 2,551 3,001 5,392 5,872  
Latin America and Other | Personal care          
Net sales:          
Total net sales revenue 80 398 721 743  
Latin America and Other | Weight management          
Net sales:          
Total net sales revenue 160 221 368 445  
CHINA          
Contribution margin:          
Selling, general and administrative expenses 3,900 3,700 8,800 6,500  
United States          
Net sales:          
Total net sales revenue 31,483 34,378 64,712 69,298  
Contribution margin:          
Total property, plant and equipment, net 45,036   45,036   46,595
South Korea          
Net sales:          
Total net sales revenue 14,465 17,546 28,118 32,355  
Taiwan          
Net sales:          
Total net sales revenue 11,933 4,730 21,683 7,499  
Other          
Net sales:          
Total net sales revenue 46,280 $ 52,324 100,142 $ 102,247  
Contribution margin:          
Total property, plant and equipment, net $ 4,063   $ 4,063   $ 4,262
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Income Tax Disclosure [Abstract]          
Provision (benefit) for income taxes, as a percentage of income before income taxes 82.10% 32.20% 127.50% 30.40%  
Liability related to unrecognized tax benefits $ 0   $ 0   $ 0
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Details)
6 Months Ended
Jun. 30, 2022
USD ($)
claim
Dec. 31, 2021
USD ($)
Value-added tax assessments and other civil litigation    
Commitments and contingencies    
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim 1  
Provision for losses $ 0  
Non-Income Tax Contingencies    
Commitments and contingencies    
Accrued liabilities 200,000 $ 200,000
Minimum | Value-added tax assessments and other civil litigation    
Commitments and contingencies    
Estimate of possible loss 0  
Minimum | Non-Income Tax Contingencies    
Commitments and contingencies    
Estimate of possible loss 0  
Maximum | Value-added tax assessments and other civil litigation    
Commitments and contingencies    
Estimate of possible loss 400,000  
Maximum | Non-Income Tax Contingencies    
Commitments and contingencies    
Estimate of possible loss 2,800,000  
Pending Litigation    
Commitments and contingencies    
Accrued liabilities $ 500,000 $ 500,000
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
China Joint Venture          
Related Party Transaction [Line Items]          
Joint venture ownership 80.00% 80.00% 80.00% 80.00%  
China Joint Venture | Fosun Pharma Member          
Related Party Transaction [Line Items]          
Joint venture ownership, noncontrolling party 20.00% 20.00% 20.00% 20.00%  
China Joint Venture | Subsidiaries | Notes Receivable          
Related Party Transaction [Line Items]          
Related party transaction, amount $ 0 $ 0 $ 0 $ 0  
NSP China | Subsidiaries          
Related Party Transaction [Line Items]          
Notes receivable, related parties, current 0   0   $ 1,200,000
NSP China | Subsidiaries | Company's Joint Venture Partner          
Related Party Transaction [Line Items]          
Notes receivable, related parties, current $ 0   $ 0   $ 300,000
NSP China | Subsidiaries | Notes Receivable          
Related Party Transaction [Line Items]          
Related party transaction, rate     3.00%    
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements (Details) - Recurring basis - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Total    
Fair value    
Investment securities - trading $ 743 $ 964
Total assets measured at fair value on a recurring basis 743 964
Level 1 - Quoted Prices in Active Markets for Identical Assets    
Fair value    
Investment securities - trading 743 964
Total assets measured at fair value on a recurring basis 743 964
Level 2 - Significant Other Observable Inputs    
Fair value    
Investment securities - trading 0 0
Total assets measured at fair value on a recurring basis 0 0
Level 3 - Significant Unobservable Inputs    
Fair value    
Investment securities - trading 0 0
Total assets measured at fair value on a recurring basis $ 0 $ 0
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue Recognition - Narrative (Details)
6 Months Ended
Jun. 30, 2022
segment
product_category
loyalty_point
Disaggregation of Revenue [Line Items]  
Refund period 90 days
Customer Loyalty Program, Loyalty Points | loyalty_point 0
Number of principal categories of products | product_category 6
Number of business segments | segment 4
Maximum  
Disaggregation of Revenue [Line Items]  
Contract with customer, contract term 1 year
XML 54 natr-20220630_htm.xml IDEA: XBRL DOCUMENT 0000275053 2022-01-01 2022-06-30 0000275053 2022-07-22 0000275053 2022-06-30 0000275053 2021-12-31 0000275053 2022-04-01 2022-06-30 0000275053 2021-04-01 2021-06-30 0000275053 2021-01-01 2021-06-30 0000275053 us-gaap:CommonStockMember 2021-12-31 0000275053 us-gaap:RetainedEarningsMember 2021-12-31 0000275053 us-gaap:NoncontrollingInterestMember 2021-12-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000275053 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000275053 2022-01-01 2022-03-31 0000275053 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000275053 us-gaap:CommonStockMember 2022-03-31 0000275053 us-gaap:RetainedEarningsMember 2022-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2022-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000275053 2022-03-31 0000275053 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000275053 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000275053 us-gaap:CommonStockMember 2022-06-30 0000275053 us-gaap:RetainedEarningsMember 2022-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2022-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000275053 us-gaap:CommonStockMember 2020-12-31 0000275053 us-gaap:RetainedEarningsMember 2020-12-31 0000275053 us-gaap:NoncontrollingInterestMember 2020-12-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000275053 2020-12-31 0000275053 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000275053 2021-01-01 2021-03-31 0000275053 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000275053 us-gaap:CommonStockMember 2021-03-31 0000275053 us-gaap:RetainedEarningsMember 2021-03-31 0000275053 us-gaap:NoncontrollingInterestMember 2021-03-31 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000275053 2021-03-31 0000275053 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000275053 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000275053 us-gaap:CommonStockMember 2021-06-30 0000275053 us-gaap:RetainedEarningsMember 2021-06-30 0000275053 us-gaap:NoncontrollingInterestMember 2021-06-30 0000275053 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000275053 2021-06-30 0000275053 natr:AccruedSeveranceandRentCostsMember 2022-06-30 0000275053 natr:AccruedSeveranceandRentCostsMember 2021-12-31 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2017-07-11 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2022-06-23 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-06-23 2022-06-23 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-06-30 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2022-06-23 2022-06-23 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2021-12-31 0000275053 us-gaap:RevolvingCreditFacilityMember natr:BankofAmericaCreditAgreementMember 2022-06-30 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-04-21 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-11-19 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember natr:IndicativeIndexMember 2022-06-30 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2020-11-19 2020-11-19 0000275053 us-gaap:LineOfCreditMember natr:BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember 2022-06-30 0000275053 2021-04-05 2021-04-05 0000275053 2021-03-10 0000275053 2022-03-08 0000275053 natr:A2012IncentivePlanMember 2012-12-31 0000275053 natr:A2012IncentivePlanMember 2015-01-01 2015-12-31 0000275053 natr:A2012IncentivePlanMember 2021-05-05 2021-05-05 0000275053 srt:MaximumMember natr:TimeBasedStockOptionsMember 2022-01-01 2022-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2022-01-01 2022-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2021-12-31 0000275053 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2022-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0000275053 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2021-12-31 0000275053 natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2022-06-30 0000275053 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-06-30 0000275053 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2021-12-31 0000275053 us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2021-12-31 0000275053 us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember natr:A2012IncentivePlanMember 2022-06-30 0000275053 natr:TimeBasedRestrictedStockUnitsRSUsMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember natr:A2012IncentivePlanMember 2022-01-01 2022-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember natr:A2012IncentivePlanMember natr:NetSalesandOperatingIncomeTargetsMember 2022-01-01 2022-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0000275053 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0000275053 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember 2022-04-01 2022-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember 2021-04-01 2021-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember 2022-01-01 2022-06-30 0000275053 natr:PerformanceBasedRestrictedStockUnitsRSUsMember 2021-01-01 2021-06-30 0000275053 srt:MaximumMember natr:PerformanceBasedRestrictedStockUnitsRSUsMember 2022-06-30 0000275053 srt:MinimumMember natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2022-01-01 2022-06-30 0000275053 srt:MaximumMember natr:PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember 2022-01-01 2022-06-30 0000275053 natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 country:CN 2022-04-01 2022-06-30 0000275053 country:CN 2022-01-01 2022-06-30 0000275053 country:CN 2021-04-01 2021-06-30 0000275053 country:CN 2021-01-01 2021-06-30 0000275053 country:US 2022-04-01 2022-06-30 0000275053 country:US 2021-04-01 2021-06-30 0000275053 country:US 2022-01-01 2022-06-30 0000275053 country:US 2021-01-01 2021-06-30 0000275053 country:KR 2022-04-01 2022-06-30 0000275053 country:KR 2021-04-01 2021-06-30 0000275053 country:KR 2022-01-01 2022-06-30 0000275053 country:KR 2021-01-01 2021-06-30 0000275053 country:TW 2022-04-01 2022-06-30 0000275053 country:TW 2021-04-01 2021-06-30 0000275053 country:TW 2022-01-01 2022-06-30 0000275053 country:TW 2021-01-01 2021-06-30 0000275053 natr:OtherCountriesMember 2022-04-01 2022-06-30 0000275053 natr:OtherCountriesMember 2021-04-01 2021-06-30 0000275053 natr:OtherCountriesMember 2022-01-01 2022-06-30 0000275053 natr:OtherCountriesMember 2021-01-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:AsiaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:AsiaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:AsiaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:AsiaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:EuropeSegmentMember 2022-04-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:EuropeSegmentMember 2021-04-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:EuropeSegmentMember 2022-01-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:EuropeSegmentMember 2021-01-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:NorthAmericaSegmentMember 2022-04-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:NorthAmericaSegmentMember 2021-04-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:NorthAmericaSegmentMember 2022-01-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:NorthAmericaSegmentMember 2021-01-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:GeneralHealthProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:GeneralHealthProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:ImmunityProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:ImmunityProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:CardiovascularProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:CardiovascularProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:DigestiveProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:DigestiveProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:PersonalCareProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:PersonalCareProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-04-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-04-01 2021-06-30 0000275053 natr:WeightManagementProductsMember natr:LatinAmericaAndOtherSegmentMember 2022-01-01 2022-06-30 0000275053 natr:WeightManagementProductsMember natr:LatinAmericaAndOtherSegmentMember 2021-01-01 2021-06-30 0000275053 country:US 2022-06-30 0000275053 country:US 2021-12-31 0000275053 natr:OtherCountriesMember 2022-06-30 0000275053 natr:OtherCountriesMember 2021-12-31 0000275053 natr:AsiaSegmentMember 2022-06-30 0000275053 natr:AsiaSegmentMember 2021-12-31 0000275053 natr:EuropeSegmentMember 2022-06-30 0000275053 natr:EuropeSegmentMember 2021-12-31 0000275053 natr:NorthAmericaSegmentMember 2022-06-30 0000275053 natr:NorthAmericaSegmentMember 2021-12-31 0000275053 natr:LatinAmericaAndOtherSegmentMember 2022-06-30 0000275053 natr:LatinAmericaAndOtherSegmentMember 2021-12-31 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2022-06-30 0000275053 natr:NonIncomeTaxMember 2022-06-30 0000275053 natr:NonIncomeTaxMember 2021-12-31 0000275053 srt:MinimumMember natr:NonIncomeTaxMember 2022-06-30 0000275053 srt:MaximumMember natr:NonIncomeTaxMember 2022-06-30 0000275053 us-gaap:PendingLitigationMember 2021-12-31 0000275053 us-gaap:PendingLitigationMember 2022-06-30 0000275053 natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2022-01-01 2022-06-30 0000275053 srt:MinimumMember natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2022-06-30 0000275053 srt:MaximumMember natr:ValueAddedTaxAssessmentsAndOtherCivilLitigationMember 2022-06-30 0000275053 natr:ChinaJointVentureMember 2022-06-30 0000275053 natr:ChinaJointVentureMember 2021-06-30 0000275053 natr:ChinaJointVentureMember natr:FosunPharmaMember 2021-06-30 0000275053 natr:ChinaJointVentureMember natr:FosunPharmaMember 2022-06-30 0000275053 natr:ChinaJointVentureMember us-gaap:NotesReceivableMember srt:SubsidiariesMember 2022-01-01 2022-06-30 0000275053 natr:ChinaJointVentureMember us-gaap:NotesReceivableMember srt:SubsidiariesMember 2022-04-01 2022-06-30 0000275053 natr:ChinaJointVentureMember us-gaap:NotesReceivableMember srt:SubsidiariesMember 2021-01-01 2021-06-30 0000275053 natr:ChinaJointVentureMember us-gaap:NotesReceivableMember srt:SubsidiariesMember 2021-04-01 2021-06-30 0000275053 natr:NaturesSunshineProductsChinaMember srt:SubsidiariesMember 2022-06-30 0000275053 natr:NaturesSunshineProductsChinaMember srt:SubsidiariesMember 2021-12-31 0000275053 natr:NaturesSunshineProductsChinaMember srt:SubsidiariesMember natr:CompanysJointVenturePartnerMember 2022-06-30 0000275053 natr:NaturesSunshineProductsChinaMember srt:SubsidiariesMember natr:CompanysJointVenturePartnerMember 2021-12-31 0000275053 natr:NaturesSunshineProductsChinaMember us-gaap:NotesReceivableMember srt:SubsidiariesMember 2022-01-01 2022-06-30 0000275053 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000275053 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000275053 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000275053 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0000275053 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000275053 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000275053 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000275053 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000275053 srt:MaximumMember 2022-01-01 2022-06-30 shares iso4217:USD iso4217:USD shares natr:borrowing pure natr:payment natr:segment natr:claim natr:loyalty_point natr:product_category 0000275053 false 2022 Q2 --12-31 P1Y P1Y3M 10-Q true 2022-06-30 false 001-34483 NATURE’S SUNSHINE PRODUCTS, INC. UT 87-0327982 2901 Bluegrass Boulevard Suite 100 Lehi UT 84043 801 341-7900 Common Stock, no par value NATR NASDAQ Yes Yes Accelerated Filer true false false 19224999 56344000 86184000 525000 143000 10540000 8871000 70643000 60852000 9618000 8760000 147145000 164667000 49099000 50857000 18060000 18349000 743000 964000 7794000 13590000 10218000 10447000 233059000 258874000 9423000 9702000 23199000 23131000 26842000 31600000 1829000 3694000 0 302000 2227000 2647000 4336000 4350000 1263000 1244000 69119000 76670000 15871000 15919000 537000 1174000 743000 964000 1212000 1566000 1098000 1177000 88580000 97470000 0 0 50000000 50000000 19259000 19259000 19724000 19724000 121623000 133382000 32591000 35025000 3902000 3202000 -13637000 -10205000 144479000 161404000 233059000 258874000 104161000 108978000 29471000 28463000 74690000 80515000 32069000 35443000 36866000 35586000 5755000 9486000 -442000 529000 5313000 10015000 4361000 3221000 952000 6794000 436000 254000 516000 6540000 0.03 0.33 0.03 0.32 19386000 19999000 19594000 20503000 214655000 211399000 63931000 55442000 150724000 155957000 66171000 69698000 77489000 69138000 7064000 17121000 -756000 -1404000 6308000 15717000 8042000 4771000 -1734000 10946000 700000 390000 -2434000 10556000 -0.12 0.53 -0.12 0.52 19479000 19897000 19479000 20340000 0 1.00 952000 6794000 -2457000 -45000 -1505000 6749000 -1734000 10946000 -3432000 -166000 -5166000 10780000 19724000 133382000 35025000 3202000 -10205000 161404000 801000 801000 218000 -795000 -795000 451000 7971000 7971000 -2950000 264000 -2686000 -975000 -975000 19491000 125417000 32075000 3466000 -11180000 149778000 540000 540000 58000 -334000 -334000 290000 4000000 4000000 516000 436000 952000 -2457000 -2457000 19259000 121623000 32591000 3902000 -13637000 144479000 19697000 139311000 26030000 1848000 -9955000 157234000 1005000 1005000 218000 -914000 -914000 1.00 19858000 19858000 4016000 136000 4152000 -121000 -121000 19915000 139402000 10188000 1984000 -10076000 141498000 1066000 1066000 152000 -660000 -660000 77000 1500000 1500000 6540000 254000 6794000 -45000 -45000 19990000 138308000 16728000 2238000 -10121000 147153000 -1734000 10946000 417000 0 5451000 5541000 2785000 2626000 1341000 2071000 0 -12000 5338000 1753000 19000 24000 69000 175000 -170000 67000 -803000 -1572000 2801000 2755000 11910000 3777000 1357000 918000 33000 108000 -80000 1079000 1045000 483000 -4001000 -5473000 -1718000 -111000 -2503000 -2487000 -386000 261000 0 -87000 -220000 0 -9343000 10712000 3757000 2898000 -3757000 -2898000 0 19858000 618000 698000 15645000 0 15645000 0 300000 0 1129000 1574000 11971000 1500000 -14018000 -23630000 -2722000 -1351000 -29840000 -17167000 86184000 92069000 56344000 74902000 4173000 2582000 113000 111000 Basis of Presentation<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.7 million for the three and six months ended June 30, 2022, respectively. Net income attributable to the noncontrolling interests was $0.3 million and $0.4 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021, noncontrolling interests were $3.9 million and $3.2 million, respectively. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Related Accruals and Expenses</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $0 and $0.3 million of restructuring related expenses during the three and six months ended June 30, 2022, respectively. We recorded $0 and $48,000 of restructuring related expenses during the three and six months ended June 30, 2021, respectively. Accrued severance and restructuring related costs were $5,000 and $0.2 million as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the </span></div>potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements. Basis of Presentation<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2022, and for the three and six-month periods ended June 30, 2022 and 2021. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2022.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors, and those differences could have a material effect on our financial position and results of operations.</span></div>The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. 400000 700000 300000 400000 3900000 3200000 0 300000 0 48000 5000 200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the </span></div>potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements. Inventories<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of inventories is as follows (dollar amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,643 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of inventories is as follows (dollar amounts in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,494 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,643 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 27680000 22494000 1930000 1746000 41033000 36612000 70643000 60852000 Investment Securities - Trading<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trading securities portfolio totaled $0.7 million at June 30, 2022, and $1.0 million at December 31, 2021, and generated losses of $0.1 million and gains of $0.1 million for the three months ended June 30, 2022 and 2021, respectively, and losses of $0.2 million and gains of $0.1 million for the six months ended June 30, 2022 and 2021, respectively.</span></div> 700000 1000000 -100000 100000 200000 100000 Revolving Credit Facility and Other Obligations<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022 the credit agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each. The amendment to the credit agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (3.10 percent as of June 30, 2022), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. At June 30, 2022 and December 31, 2021, there was no outstanding balance under the Credit Agreement. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of June 30, 2022, we were in compliance with the debt covenants set forth in the Credit Agreement.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in 36 monthly payments, of $0.1 million. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of June 30, 2022, there was $1.8 million outstanding balance under the Capital Credit Agreement, of which $1.3 million was classified as current.</span></div> 25000000 25000000 3 5000000 0.015 0.031 0.0025 0 0 6000000 3700000 0.0300 36 100000 1800000 1300000 Net Income Per Share<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,434)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings (loss) per share attributable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings (loss) per share attributable to common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dilutive shares excluded from diluted-per-share amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-dilutive shares excluded from diluted-per-share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.</span></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2022 and 2021 (dollar and share amounts in thousands, except for per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,434)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,556 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings (loss) per share attributable to common shareholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,897 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,594 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings (loss) per share attributable to common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dilutive shares excluded from diluted-per-share amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-dilutive shares excluded from diluted-per-share amounts:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)     As a result of the net loss for the six months ended June 30, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the six months ended June 30, 2022 include 341 restricted stock units.</span></div> 516000 6540000 -2434000 10556000 19386000 19999000 19479000 19897000 0.03 0.33 -0.12 0.53 19386000 19999000 19479000 19897000 208000 504000 0 443000 19594000 20503000 19479000 20340000 0.03 0.32 -0.12 0.52 341000 563000 0 563000 25000 0 341000 0 0 341000 Capital Transactions<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dividends</span></div><div style="text-indent:27.35pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 10, 2021, we announced a special non-recurring cash dividend of $1.00 per common share in an aggregate amount of $19.9 million that was paid on April 5, 2021, to shareholders of record on March 29, 2021. In accordance with the provisions of our 2012 Stock Incentive Plan (the "2012 Incentive Plan"), as a result of the special dividend we are required to make the participant's original grant whole by preventing either dilution or enlargement of the benefits or potential benefits intended by the original grant. The 2012 Incentive Plan provides our Compensation Committee with the discretion to meet this requirement. See further discussion in the Share-Based Compensation section of this Note.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Share Repurchase Program</span></div><div><span><br/></span></div><div style="text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the six months ended June 30, 2022 and 2021, we repurchased 741,000 and 77,000 shares of our common stock for $12.0 million and $1.5 million, respectively. At June 30, 2022, the remaining balance available for repurchases under the program was $25.6 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There was no share-based compensation expense for the three- and six-month periods ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, there was no unrecognized share-based compensation expense related to the grants described above.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2022, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 143,000 shares of common stock was $41,000. At December 31, 2021, the aggregate intrinsic value of outstanding and exercisable options to purchase 172,000 shares of common stock was $1.1 million.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six-month periods ended June 30, 2022 and 2021, we issued 29,000 and 50,000 shares of common stock upon the exercise of stock options at an average exercise price of $9.17 and $12.00 per share, respectively. The aggregate intrinsic value of options exercised during the six-month periods ended June 30, 2022 and 2021, was $0.3 million and $0.4 million, respectively. For the six-month periods ended June 30, 2022 and 2021, the Company recognized $0.1 million and $0.2 million of tax benefits from the exercise of stock options, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we did not have any unvested performance-based stock options outstanding.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2022 and December 31, 2021, there were 68,000 and 88,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six-month period ended June 30, 2022, we granted 164,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $6.01 per share and vest upon achieving share-priced targets over a three-year period from the grant date.</span></div><div style="padding-left:36pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.9 percent for a common share.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of 50.1 percent, and a risk-free rate of 3.3 percent.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense related to time-based RSUs for the three-month periods ended June 30, 2022 and 2021, was approximately $0.3 million and $0.6 million, respectively. Share-based compensation expense related to time-based RSUs for the six-month periods ended June 30, 2022 and 2021, was approximately $0.9 million and $1.0 million, respectively. As of June 30, 2022 and December 31, 2021, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $1.4 million and $1.6 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.3 years.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2022 and 2021, was $0.2 million and $0.5 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2022 and 2021, was $0.5 million and $0.9 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would, and expect to, recognize up to $2.4 million of potential share-based compensation expense. </span></div>The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 80,000 and 121,000 shares for the six-month periods ended June 30, 2022 and 2021, respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above. 1.00 19900000 15000000 30000000 741000 77000 12000000 1500000 25600000 1500000 1500000 2000000 P48M 0.06 0.08 0.10 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 172000 12.13 5.05 0 0 0 0 0 0 29000 9.17 3.92 143000 12.72 5.28 0 0 0 0 0 0 143000 41000 172000 1100000 29000 50000 9.17 12.00 300000 400000 100000 200000 0 0 P12M P36M P2Y 68000 88000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity for the six-month period ended June 30, 2022, is as follows (amounts in thousands, except per share information):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 830000 9.46 164000 8.87 68000 5.39 329000 7.50 597000 10.84 164000 13.87 P3Y 6.01 P3Y 0.129 P3Y 0.501 0.033 300000 600000 900000 1000000 1400000 1600000 P0Y3M18D 200000 500000 500000 900000 2400000 80000 121000 Segment Information<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reportable business segment information is as follows (dollar amounts in thousands):</span></div><div style="text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution margin (1):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contribution margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,866 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,064 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)    Contribution margin consists of net sales less cost of sales and volume incentives expense.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)    Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,455 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,876 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,655 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets per segment is set forth below (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,874 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reportable business segment information is as follows (dollar amounts in thousands):</span></div><div style="text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,082 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution margin (1):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contribution margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,621 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,866 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,064 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,015 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)    Contribution margin consists of net sales less cost of sales and volume incentives expense.</span></div>(2)    Service fees in China totaled $3.9 million and $8.8 million for the three and six-month periods ended June 30, 2022, respectively, compared to $3.7 million and $6.5 million for the three and six-month periods ended June 30, 2021. These service fees are included in selling, general and administrative expenses. 47382000 43536000 93492000 79291000 17099000 21455000 38876000 43655000 34082000 37372000 70063000 75134000 5598000 6615000 12224000 13319000 104161000 108978000 214655000 211399000 21432000 18463000 43371000 33782000 6595000 6588000 10968000 13384000 12300000 16259000 25019000 31699000 2294000 3762000 5195000 7394000 42621000 45072000 84553000 86259000 36866000 35586000 77489000 69138000 5755000 9486000 7064000 17121000 -442000 529000 -756000 -1404000 5313000 10015000 6308000 15717000 3900000 8800000 3700000 6500000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2022 and 2021, as follows (dollar amounts in thousands):</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:55.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 31483000 34378000 64712000 69298000 14465000 17546000 28118000 32355000 11933000 4730000 21683000 7499000 46280000 52324000 100142000 102247000 104161000 108978000 214655000 211399000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales generated by each of our product lines is set forth below (dollar amounts in thousands):</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,538 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,492 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,291 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,074 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,099 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,455 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,876 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,655 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,082 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General health</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immune</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Digestive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personal care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weight management</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,224 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,161 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,978 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12319000 12698000 25305000 23990000 781000 382000 2125000 585000 13242000 12260000 26872000 22163000 10990000 7747000 20026000 14618000 2083000 5290000 4626000 7814000 7967000 5159000 14538000 10121000 47382000 43536000 93492000 79291000 7328000 9667000 16524000 19139000 1443000 1818000 4074000 3834000 2150000 2836000 4783000 5828000 4481000 5567000 10072000 11107000 1209000 999000 2442000 2425000 488000 568000 981000 1322000 17099000 21455000 38876000 43655000 14954000 16349000 30268000 32619000 4061000 4101000 8933000 8975000 3893000 4010000 7735000 8235000 9044000 10016000 17638000 19479000 1389000 1834000 3564000 3653000 741000 1062000 1925000 2173000 34082000 37372000 70063000 75134000 1597000 1873000 3415000 3848000 755000 697000 1516000 1508000 455000 425000 812000 903000 2551000 3001000 5392000 5872000 80000 398000 721000 743000 160000 221000 368000 445000 5598000 6615000 12224000 13319000 104161000 108978000 214655000 211399000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,857 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 45036000 46595000 4063000 4262000 49099000 50857000 <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets per segment is set forth below (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,059 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,874 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 91762000 104659000 14771000 15486000 119018000 131207000 7508000 7522000 233059000 258874000 Income Taxes<div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 82.1 percent and 32.2 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2022 and 2021, our provision for income taxes, as a percentage of income before income taxes was 127.5 percent and 30.4 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2022, was primarily attributed to recording a valuation allowance against deferred tax assets which are expected to expire before utilization.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2021, was primarily attributed to transfer pricing adjustments and foreign losses during those periods that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the effective tax rate for the three and six months ended June 30, 2022 compared to June 30, 2021 is primarily caused by recording a valuation allowance in the current period against deferred tax assets which are expected to expire before utilization.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. federal income tax returns for 2018 through 2020 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2016 through 2021.</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, we do not have any amounts accrued for unrecognized tax positions.</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.</span></div> 0.821 0.322 1.275 0.304 0 0 Commitments and Contingencies<div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim.</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Income Tax Contingencies</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.8 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>We are a party to various other legal proceedings and disputes in the United States and foreign jurisdictions. As of June 30, 2022 and December 31, 2021, accrued liabilities were $0.5 million, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, but either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.4 million. 1 200000 200000 0 2800000 500000 500000 0 0 400000 Related Party TransactionsDuring the three and six months ended June 30, 2022 and 2021, our joint venture in China, owned 80 percent by us and 20 percent by a wholly owned subsidiary of Fosun Pharma, did not borrow any amounts from the Company or our joint venture partner. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from the Company were $0 and $1.2 million, respectively. As of June 30, 2022 and December 31, 2021 outstanding borrowings by NSP China from our joint venture partner were $0 and $0.3 million, respectively. These notes were payable in less than one year and bore interest of 3.0 percent. The notes between NSP China and the Company eliminated in consolidation. In March 2022 the outstanding principal and interest amounts were repaid. 0.80 0.80 0.20 0.20 0 0 0 0 0 1200000 0 300000 0.03 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are not corroborated by market data.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2022 (dollar amounts in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities - trading</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2021 (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities - trading</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment securities - trading</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and for the year ended December 31, 2021, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3).</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the six months ended June 30, 2022 and 2021, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.</span></div> <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2022 (dollar amounts in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities - trading</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2021 (dollar amounts in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:46.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities - trading</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 743000 0 0 743000 743000 0 0 743000 964000 0 0 964000 964000 0 0 964000 Revenue Recognition<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities - Customer Loyalty Programs</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have offered loyalty point programs which allowed customers to earn loyalty points on personal orders. Loyalty points were recorded as contract liabilities in deferred revenue. These programs were accounted for as a reduction in the transaction price and generally recognized as points that were redeemed for additional products. During the year ended December 31, 2020 these programs were discontinued. As of June 30, 2022, there were no outstanding loyalty points.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expense volume incentives when incurred because the amortization period would have been one year or less.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.</span></div> P90D 0 6 4 P1Y EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &R)"54'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !LB0E5[.4O%.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2@,Q$(=?17+?G=T41,,V%\53"X(%Q5M(IFUP\X=D9+=O;W9MMX@^@)!+9G[Y MYAM(IZ/0(>%S"A$36H7-,!HM(? MZH# F^86')(RBA1,P"HN1"8[HX5.J"BD,][H!1\_4S_#C ;LT:&G#&W= I/3 MQ'@:^PZN@ E&F%S^+J!9B'/U3^S< 79.CMDNJ6$8ZF$UY\H.+;QM-R_SNI7U MF9376%YE*^@4<621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &R)"57T)/^W\@4 ,0? 8 >&PO=V]R:W-H965T&UL MM9GO;]HX&,?_%8M)TYU4FMBA!3:*1&E[XVYCC- [[4[WPDT,1$MBSG&@_>_/ M3B"AE?,01:,O2A+R?/''CW]\;0]V7/Q(UHQ)]!R%<7+36DNY^6!9B;=F$4TN M^8;%ZILE%Q&5ZE:LK&0C&/6SH"BTB&U?6Q$-XM9PD#V;B>& IS(,8C83*$FC MB(J76Q;RW4T+MPX/YL%J+?4#:SC8T!5SF7S^//@.V2HVND49XX_Z%O)OY-R]8E8B'SI):@ZF/+QBP,M9(JQW][ MT5;QFSKP^/J@_I#!*Y@GFK Q#_\*?+F^:?5:R&=+FH9RSG>?V![H2NMY/$RR M_VB7O]OIM)"7)I)'^V!5@BB(\T_ZO*^(HP %:@X@^P#R)@!7_8*S#\AJSLI+ MEF'=44F' \%W2.BWE9J^R.HFBU8T0:S3Z$JAO@U4G!R.^98)-%,90VV4K*E@ MR<"22EA_;7E[D=M'B)"#&%ORJ.4U22D^DY8"7],WI*I%#M[E]3#>4*';."[HP? MD@WUV$U+];:$B2UK#=^_P]?V1Q/>3Q)[!=LI8#N0^O".>ZGJIQ(M7C;,1 J' M8[O]S80$1C5$NBJ0KNHA?4NID$R$+VC.-EQ($QXL)45JJI0Q&-40[[K NZZ' M-V,BX+[NA4@-!L;DP4I%OZOL>&!\0\YNP=FMV3(%5?-(-@U4YQ'66M(P,282 M#&L(V"L >V"A[F,9R!?T$(0,3=/HB0D3&*QAV[CM=#H]QP0'AC:$ZQ=P_3IP M<[8*]#"JTCBED;&-PCK3T>)Q?O_^78_@[D<7N8]3]]-D>H]F\Z]WC^.%>Y&7 M>#(=7YJJ !1O6 78+F=;NTXE3&*/"]5PJ6[#%\B5JK!DWT,1/2/:Z;=LAW7[/.$3!P4UY M2'"_19O8>^QN:\PI*D;V-T&Z9L):A2NN5IR+94^$9Z4*HI M?>F4,.A-8/K%CAOI84DW#23+BXAMV\A\#K^$2\.$8%PJ6'PK#S>4M9#%HSP;=![)D;-JQ9,6"=PTSATDUAV 2]!9WQ M1-(0_1ULJL=E6+'7L3O&^1B.:TI:^BD,FZ"LH8[4ZK\:#!;HV=B(=0X3A4L7 MA6$+])E[*E^S-8\A&W5"Q.G@=K=?,=Z_&;:HQ'-64LS0_I);YF<22 MB7Q_4J_#Z0'P_"0TO"06H9'KU/5FD79@!47QN'GA,[(\YB24 )^ M+F9D/8?M(:7M(;5LCQO1,$2W::*^3LPMMMG&$1S6%*\T.Z26V;F/F%CI'OF; M4I!KY0>B#8W-.84%*S=6X+BFH*77(;!5.>1QS50>(;R&^T9P7%.\TO.06EM' MKR=T-]O/1U]3J1QLK"=/(_%/LC5KC(U?8BT'>(^(9U^OS^PMB;&TO>0 M6CM(8S64"F7P)K'/GM$?S)Q&6,I6?Z1[95\9;3D,3<=")=$E*2?9I]]1 M\DKEHD*2+\]& MY_CD@L9F0&/Q=\X?U=XQ,J[<"_'-G'Q:G(T"HX@7?*[-% S^;?@%+PHS$^CX MOIUTM+NG&;A__#+['XWSX,P]4_Q"%/_D"[TZ&Z4CM.!+5A?Z3CQ^Y%N'(C/? M7!2J^8L>M[;!",UKI46Y'0P*RKQJ_[.G;2#V!N!P8 #9#B _.H!N!]#&T599 MX]8ETVQZ*L4CDL8:9C,'36R:T>!-7IG'.-,2?LUAG)Y>W%Q?7EW/KBX1',UN M/G^Z//\")Q_./Y]?7URAV<>KJR\S=(R^SB[1;T>_HR.45^C+2M2*50MU.M&@ MPOAT_ \YW[9.<^ M:>:C0^[74O)*(Z84U^K$Y4\[0>B>P&39B5JS.3\;01HI+C=\-'W[!L?!>Y=W MOVBR5[[2G:_4-_OT@JD5@J>&YN: ?Z_S#2O >>=3;*>*FZE,*=A,HYB&X>ED ML^^.;97&..VL7ND,=SI#K\[S^5S4( NJQ)R#QON"CU$%%4TL$2N@[K!JSA%4 M,+00];U>U@44@^T0,#F*2-2X>81#.H9)U)HWM:)X=CG::HGV7,!!% 8]1VVK M-$VPV\]HYV?D]?-3M8'H"YESYQ.(K%LF01S2GC#;*@[2B+B5Q3MEL5?9K>1K MEB\0?P):**Z:< J]XM(E-+8D9+ (>CIMHS2) [?,9"?6 "@Y\1-* \%@LCVLX&0YR9D)^'KFL:)BY%>.@@UAP,)64-A%%BL."R#4D%5!+2[8 3YR8"NS\LK++893% M ^4-[R$7>]5>\B6'-;L E,Y%R9%F3Y[ ;B=[)33)^I78885IE UD&.[XB+U( MFMZ8K/>I(X[Z2:ST=YJ%X!N,F,;9H1B MJSJ[S>A UX [ZF$_]E[$[RTIITJ;9R1.0])7:9M16 A#A:/#'O9S;U?D)(GW$@>5* M;("%E,9]^2ZK:&"QDKU=H)]R#OEF07C#[2 :B?OURVD5#JQ=TF&/_ CVYC9; MG$IMML49QOTTDXQGQ\ZQSX>"JL'D542L';2.,AUH-TD&-^*&VJ[A0+\R^C37!]HFU 66W MP ZCP1:8= PC?H:Y6N!#:\"Q/R.XCS.7513' WH[FA$_S=HV^)!"!\Z"K-\* MNZQP,E2!.YP1/\[:DG!(H4VH-(W2/L@<9ED2#I4"VJ&,!MYF>+9BDJ]$L>!2 MO7V3$IR\;_;"^MG9$U,O&'^V)_Y5L[WVO2,D/4!(49:0CDJ+^3?8]@O3=Z - M*VH^1E$P#H( *1,>:$%KO1(R_YZH M2OU4;2N6&JP)3M$.=(9AF/2;&9==C,-@ %RT@RSU0]8JL^V.\>>V)%NOFB]"]T%J4S>&* M,Q!O#.#WI8 V9WMB/C+M/BI._P-02P,$% @ ;(D)5-A6-GMM.R_?I=.R5J(120UH?&'_<W MDNI>IP"&/&13A6\[%TG?"ZP@X! ; MRT#QL80A<&Z)4,;O-:=7+6F!F^U']C/G';W,J(:AY#]88M*^]]DC"7UZ,!K?8.1U<#JZ&8S(]'X]OIV1_0A4(DX)A,>4'Y!.YFX[(_MX!V2-, MD-M4%IJ*1/=\@YHLLQ^OUS\MUP]?6/]K(8Y(,S@D81"&-?#A;O@(8H0W'+RQ M#?-KOL W-=0 ;E)#Y)R<,4%%S"@G$ZF9VW4_!S-M%.Z]7W56 M2^Y6/;>MQQ.=TQCZ'A:'B01!8S,R\X%F(96Y>0)\NH';9[_G+3 MY_.81JM9Q6S);U7R6SOE#V66X*+"DO@.SC=DTDYU1ID@,> M9RGN[(,Z[:UGNH(GRG=%;.EN5[K;[]#MI&F"1Z\V6%Q,+)SZWDSE M<=@^#H*GRNL"NV%K,W#+0*>R6H'Y>^)_C<$;NGO M5OJ[[]?/M"Y>U]Y]:^[K FMS[V^&PO=V]R:W-H965T&ULO5E=;]LV%/TK MA%<,'9#$)/6=)0822]TR+!^HT_9AV(-L,;902?1$VLG^_:YD199)2DL[8R^Q MI)Q[R7-X>7EL73SS\JM8,2;12YX5XG*TDG)]/AZ+Q8KEL3CC:U; ?YYXF<<2 M;LOE6*Q+%B=U4)Z-*<;N.(_38C2YJ)\]E),+OI%96K"'$HE-GL?EW]Q:=:U11F7/^M;JY22Y'N)H1R]A"5BEB^-BR*5KL/N.71HA. .0Q!] F@*H!=D^ U018;QW!;@+LMX[@- $U M]?&.>RU<&,MX,,W7] -W?3^]L(G:)/LQ"]?_<3$JNX9 *E!7I< M\8V(BT2Z9BH5M>R)5 49&PQ! ?#L>[ _%C MD*75AKYJS@QT?EOHT??/?J!&%9;*%:=S^K) M=U,L>,[03,:20:.0Z(^KN9 E;/0_34N]2V:;DU7=[URLXP6['$%[$ZS4RXDXD_]7'?A M3G?8P/94J@:4;[N6PE1'N59@*;DB'>4XMDW-/-V6ISO(\Y>2"X'6)7]*I8FF MJPWJV6Z %9HZRL<.458JU%'$P1ZU%9XFF!,XGIFHUQ+U!EO)_9J5L4R+)6(O M8'@$$^99QMHZFFQ@(X.ALVXO7RM M""R*W4"I.P,*MH2ZO724ZQ)UJT8&5. &OKGJ@I9K,,AU!F84:NX$+5D!]9
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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 284 243 1 false 52 0 false 10 false false R1.htm 0001001 - Document - Cover Page Sheet http://naturessunshine.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYPARENTHETICAL CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) Statements 7 false false R8.htm 1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101101 - Disclosure - Basis of Presentation Sheet http://naturessunshine.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 2104102 - Disclosure - Inventories Sheet http://naturessunshine.com/role/Inventories Inventories Notes 10 false false R11.htm 2107103 - Disclosure - Investment Securities - Trading Sheet http://naturessunshine.com/role/InvestmentSecuritiesTrading Investment Securities - Trading Notes 11 false false R12.htm 2109104 - Disclosure - Revolving Credit Facility and Other Obligations Sheet http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligations Revolving Credit Facility and Other Obligations Notes 12 false false R13.htm 2111105 - Disclosure - Net Income Per Share Sheet http://naturessunshine.com/role/NetIncomePerShare Net Income Per Share Notes 13 false false R14.htm 2114106 - Disclosure - Capital Transactions Sheet http://naturessunshine.com/role/CapitalTransactions Capital Transactions Notes 14 false false R15.htm 2119107 - Disclosure - Segment Information Sheet http://naturessunshine.com/role/SegmentInformation Segment Information Notes 15 false false R16.htm 2122108 - Disclosure - Income Taxes Sheet http://naturessunshine.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2124109 - Disclosure - Commitments and Contingencies Sheet http://naturessunshine.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 17 false false R18.htm 2126110 - Disclosure - Related Party Transactions Sheet http://naturessunshine.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 2128111 - Disclosure - Fair Value Measurements Sheet http://naturessunshine.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 2131112 - Disclosure - Revenue Recognition Sheet http://naturessunshine.com/role/RevenueRecognition Revenue Recognition Notes 20 false false R21.htm 2202201 - Disclosure - Basis of Presentation (Policies) Sheet http://naturessunshine.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 21 false false R22.htm 2305301 - Disclosure - Inventories (Tables) Sheet http://naturessunshine.com/role/InventoriesTables Inventories (Tables) Tables http://naturessunshine.com/role/Inventories 22 false false R23.htm 2312302 - Disclosure - Net Income Per Share (Tables) Sheet http://naturessunshine.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://naturessunshine.com/role/NetIncomePerShare 23 false false R24.htm 2315303 - Disclosure - Capital Transactions (Tables) Sheet http://naturessunshine.com/role/CapitalTransactionsTables Capital Transactions (Tables) Tables http://naturessunshine.com/role/CapitalTransactions 24 false false R25.htm 2320304 - Disclosure - Segment Information (Tables) Sheet http://naturessunshine.com/role/SegmentInformationTables Segment Information (Tables) Tables http://naturessunshine.com/role/SegmentInformation 25 false false R26.htm 2329305 - Disclosure - Fair Value Measurements (Tables) Sheet http://naturessunshine.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://naturessunshine.com/role/FairValueMeasurements 26 false false R27.htm 2403401 - Disclosure - Basis of Presentation (Details) Sheet http://naturessunshine.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://naturessunshine.com/role/BasisofPresentationPolicies 27 false false R28.htm 2406402 - Disclosure - Inventories (Details) Sheet http://naturessunshine.com/role/InventoriesDetails Inventories (Details) Details http://naturessunshine.com/role/InventoriesTables 28 false false R29.htm 2408403 - Disclosure - Investment Securities - Trading (Details) Sheet http://naturessunshine.com/role/InvestmentSecuritiesTradingDetails Investment Securities - Trading (Details) Details http://naturessunshine.com/role/InvestmentSecuritiesTrading 29 false false R30.htm 2410404 - Disclosure - Revolving Credit Facility and Other Obligations (Details) Sheet http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails Revolving Credit Facility and Other Obligations (Details) Details http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligations 30 false false R31.htm 2413405 - Disclosure - Net Income Per Share (Details) Sheet http://naturessunshine.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Details http://naturessunshine.com/role/NetIncomePerShareTables 31 false false R32.htm 2416406 - Disclosure - Capital Transactions - Narrative (Details) Sheet http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails Capital Transactions - Narrative (Details) Details 32 false false R33.htm 2417407 - Disclosure - Capital Transactions - Stock Option Activity (Details) Sheet http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails Capital Transactions - Stock Option Activity (Details) Details 33 false false R34.htm 2418408 - Disclosure - Capital Transactions - RSU Activity (Details) Sheet http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails Capital Transactions - RSU Activity (Details) Details 34 false false R35.htm 2421409 - Disclosure - Segment Information (Details) Sheet http://naturessunshine.com/role/SegmentInformationDetails Segment Information (Details) Details http://naturessunshine.com/role/SegmentInformationTables 35 false false R36.htm 2423410 - Disclosure - Income Taxes (Details) Sheet http://naturessunshine.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://naturessunshine.com/role/IncomeTaxes 36 false false R37.htm 2425411 - Disclosure - Commitments and Contingencies (Details) Sheet http://naturessunshine.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://naturessunshine.com/role/CommitmentsandContingencies 37 false false R38.htm 2427412 - Disclosure - Related Party Transactions (Details) Sheet http://naturessunshine.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://naturessunshine.com/role/RelatedPartyTransactions 38 false false R39.htm 2430413 - Disclosure - Fair Value Measurements (Details) Sheet http://naturessunshine.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://naturessunshine.com/role/FairValueMeasurementsTables 39 false false R40.htm 2432414 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 40 false false All Reports Book All Reports natr-20220630.htm formpsuawardagreement-2022.htm formrsuawardagreement-2022.htm natr-20220630.xsd natr-20220630_cal.xml natr-20220630_def.xml natr-20220630_lab.xml natr-20220630_pre.xml natr2022630-ex311.htm natr2022630-ex312.htm natr2022630-ex321.htm natr2022630-ex322.htm natr-20220630_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "natr-20220630.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 284, "dts": { "calculationLink": { "local": [ "natr-20220630_cal.xml" ] }, "definitionLink": { "local": [ "natr-20220630_def.xml" ] }, "inline": { "local": [ "natr-20220630.htm" ] }, "labelLink": { "local": [ "natr-20220630_lab.xml" ] }, "presentationLink": { "local": [ "natr-20220630_pre.xml" ] }, "schema": { "local": [ "natr-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 400, "entityCount": 1, "hidden": { "http://naturessunshine.com/20220630": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 7 }, "keyCustom": 30, "keyStandard": 213, "memberCustom": 27, "memberStandard": 24, "nsprefix": "natr", "nsuri": "http://naturessunshine.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://naturessunshine.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Inventories", "role": "http://naturessunshine.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Investment Securities - Trading", "role": "http://naturessunshine.com/role/InvestmentSecuritiesTrading", "shortName": "Investment Securities - Trading", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Revolving Credit Facility and Other Obligations", "role": "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligations", "shortName": "Revolving Credit Facility and Other Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111105 - Disclosure - Net Income Per Share", "role": "http://naturessunshine.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114106 - Disclosure - Capital Transactions", "role": "http://naturessunshine.com/role/CapitalTransactions", "shortName": "Capital Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119107 - Disclosure - Segment Information", "role": "http://naturessunshine.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122108 - Disclosure - Income Taxes", "role": "http://naturessunshine.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124109 - Disclosure - Commitments and Contingencies", "role": "http://naturessunshine.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126110 - Disclosure - Related Party Transactions", "role": "http://naturessunshine.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128111 - Disclosure - Fair Value Measurements", "role": "http://naturessunshine.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131112 - Disclosure - Revenue Recognition", "role": "http://naturessunshine.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation (Policies)", "role": "http://naturessunshine.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Inventories (Tables)", "role": "http://naturessunshine.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Net Income Per Share (Tables)", "role": "http://naturessunshine.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315303 - Disclosure - Capital Transactions (Tables)", "role": "http://naturessunshine.com/role/CapitalTransactionsTables", "shortName": "Capital Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Segment Information (Tables)", "role": "http://naturessunshine.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329305 - Disclosure - Fair Value Measurements (Tables)", "role": "http://naturessunshine.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Basis of Presentation (Details)", "role": "http://naturessunshine.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Inventories (Details)", "role": "http://naturessunshine.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesTradingRestricted", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Investment Securities - Trading (Details)", "role": "http://naturessunshine.com/role/InvestmentSecuritiesTradingDetails", "shortName": "Investment Securities - Trading (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtSecuritiesTradingRealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i6664400f5c0f4f89b87611c960387b5d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i3ebfa6f8567e40d1a2a760accb7bbea4_I20170711", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Revolving Credit Facility and Other Obligations (Details)", "role": "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails", "shortName": "Revolving Credit Facility and Other Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i3ebfa6f8567e40d1a2a760accb7bbea4_I20170711", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Net Income Per Share (Details)", "role": "http://naturessunshine.com/role/NetIncomePerShareDetails", "shortName": "Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "id43a42217b544ac8b9c3a88d7603dc7c_D20210405-20210405", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Capital Transactions - Narrative (Details)", "role": "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "shortName": "Capital Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "id43a42217b544ac8b9c3a88d7603dc7c_D20210405-20210405", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "if56ba20f195b410abf307642660cc883_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Capital Transactions - Stock Option Activity (Details)", "role": "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails", "shortName": "Capital Transactions - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i037f2bf593424ebbb2463130670b9500_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i4e4a9f0f3dc04c34a02ebda1cbc6bca4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Capital Transactions - RSU Activity (Details)", "role": "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails", "shortName": "Capital Transactions - RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i4e4a9f0f3dc04c34a02ebda1cbc6bca4_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421409 - Disclosure - Segment Information (Details)", "role": "http://naturessunshine.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "natr:ContributionMargin", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - Income Taxes (Details)", "role": "http://naturessunshine.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i79c8cba193ea4e74a98bf3afbbad5531_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "natr:MinimumNumberOfClaimsCompaniesInsuranceCoverageMayNotCover", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - Commitments and Contingencies (Details)", "role": "http://naturessunshine.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i79c8cba193ea4e74a98bf3afbbad5531_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "natr:MinimumNumberOfClaimsCompaniesInsuranceCoverageMayNotCover", "reportCount": 1, "unique": true, "unitRef": "claim", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "ieb1f2cbeb45641b98084cebf4b44042a_I20220630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427412 - Disclosure - Related Party Transactions (Details)", "role": "http://naturessunshine.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i8697b921ad014f26a575cfc1149b9240_D20220401-20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i54e4c0f522f94857b635e5a330232a19_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430413 - Disclosure - Fair Value Measurements (Details)", "role": "http://naturessunshine.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i54e4c0f522f94857b635e5a330232a19_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "natr:RevenuefromContractwithCustomerRefundPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432414 - Disclosure - Revenue Recognition - Narrative (Details)", "role": "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails", "shortName": "Revenue Recognition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "natr:RevenuefromContractwithCustomerRefundPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i2deb8b0665634023b0cf089d0c54b39e_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iaee4a7c87e224eaab7c67198aea6c998_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i8fd528aa5314405493f5b3e4bfe0312c_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i8fd528aa5314405493f5b3e4bfe0312c_D20210101-20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL)", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYPARENTHETICAL", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "i8fd528aa5314405493f5b3e4bfe0312c_D20210101-20210331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation", "role": "http://naturessunshine.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "natr-20220630.htm", "contextRef": "iba7a91683c6046e69a790f361f4316ad_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TAIWAN", "terseLabel": "Taiwan" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://naturessunshine.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "natr_A2012IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2012 incentive plan.", "label": "2012 Incentive Plan [Member]", "terseLabel": "2012 Stock Incentive Plan" } } }, "localname": "A2012IncentivePlanMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "domainItemType" }, "natr_AccruedSeveranceandRentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Severance and Rent Costs [Member]", "label": "Accrued Severance and Rent Costs [Member]", "terseLabel": "Accrued Severance and Rent Costs" } } }, "localname": "AccruedSeveranceandRentCostsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "natr_AccruedVolumeIncentiveandServiceFees": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the liability that is related to incentives that are payable, due to volume sales.", "label": "Accrued Volume Incentive and Service Fees", "terseLabel": "Accrued volume incentives and service fees" } } }, "localname": "AccruedVolumeIncentiveandServiceFees", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "natr_AntidilutiveSecuritiesExcludedFromComputationOfDilutiveEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Dilutive Earnings Per Share [Abstract]", "terseLabel": "Anti-dilutive shares excluded from diluted-per-share amounts:" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfDilutiveEarningsPerShareAbstract", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "natr_AsiaSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asia Segment [Member]", "label": "Asia Segment [Member]", "terseLabel": "Asia" } } }, "localname": "AsiaSegmentMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Banc of America Leasing and Capital, LLC, Credit Agreement", "label": "Banc of America Leasing and Capital, LLC, Credit Agreement [Member]", "terseLabel": "Banc of America Leasing and Capital Credit Agreement" } } }, "localname": "BancOfAmericaLeasingAndCapitalLLCCreditAgreementMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "natr_BankofAmericaCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank of America Credit Agreement [Member]", "label": "Bank of America Credit Agreement [Member]", "terseLabel": "Bank of America Credit Agreement" } } }, "localname": "BankofAmericaCreditAgreementMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "natr_CardiovascularProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to cardiovascular products of the entity.", "label": "Cardiovascular Products [Member]", "terseLabel": "Cardiovascular" } } }, "localname": "CardiovascularProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_ChinaJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "China Joint Venture", "label": "China Joint Venture [Member]", "terseLabel": "China Joint Venture" } } }, "localname": "ChinaJointVentureMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "natr_CompanysJointVenturePartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company's Joint Venture Partner [Member]", "label": "Company's Joint Venture Partner [Member]", "terseLabel": "Company's Joint Venture Partner" } } }, "localname": "CompanysJointVenturePartnerMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "natr_ContractWithCustomerContractTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Contract Term", "label": "Contract With Customer, Contract Term", "terseLabel": "Contract with customer, contract term" } } }, "localname": "ContractWithCustomerContractTerm", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "natr_ContributionMargin": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/SegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of contribution margin which consists of net sales revenue less cost of sales and volume incentives expense.", "label": "Contribution Margin", "terseLabel": "Total contribution margin" } } }, "localname": "ContributionMargin", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "natr_ContributionMarginAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contribution Margin [Abstract]", "terseLabel": "Contribution margin:" } } }, "localname": "ContributionMarginAbstract", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "natr_CustomerLoyaltyProgramLoyaltyPoints": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Loyalty Program, Loyalty Points", "label": "Customer Loyalty Program, Loyalty Points", "terseLabel": "Customer Loyalty Program, Loyalty Points" } } }, "localname": "CustomerLoyaltyProgramLoyaltyPoints", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "integerItemType" }, "natr_DebtInstrumentNumberOfMonthlyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number of Monthly Payments", "label": "Debt Instrument, Number of Monthly Payments", "terseLabel": "Number of monthly payments" } } }, "localname": "DebtInstrumentNumberOfMonthlyPayments", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "integerItemType" }, "natr_DigestiveProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to digestive products of the entity.", "label": "Digestive Products [Member]", "terseLabel": "Digestive" } } }, "localname": "DigestiveProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities Excluded from Computation of Earnings Per Share [Abstract]", "terseLabel": "Dilutive shares excluded from diluted-per-share amounts:" } } }, "localname": "DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "natr_DilutiveSecuritiesExcludedfromComputationofEarnings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents potentially dilutive securities excluded from diluted per share amounts. It includes performance-based options to purchase shares of common stock which will not vest until certain earnings metrics have been achieved.", "label": "Dilutive Securities Excluded from Computation of Earnings", "terseLabel": "Stock options (in shares)" } } }, "localname": "DilutiveSecuritiesExcludedfromComputationofEarnings", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "natr_EuropeSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe Segment [Member]", "label": "Europe Segment [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeSegmentMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_FosunPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fosun Pharma", "label": "Fosun Pharma [Member]", "terseLabel": "Fosun Pharma Member" } } }, "localname": "FosunPharmaMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "natr_GeneralHealthProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to general health products of the entity.", "label": "General Health Products [Member]", "terseLabel": "General health" } } }, "localname": "GeneralHealthProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_ImmunityProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to immunity products of the entity.", "label": "Immunity Products [Member]", "terseLabel": "Immune" } } }, "localname": "ImmunityProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_IncreaseDecreaseInLiabilityRelatedToUnrecognizedTaxPositions": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the net changes in liability that are related to gross amount of unrecognized tax benefits (tax reductions recognized in financial reports but excluded from tax returns), which pertain to uncertain tax positions taken in tax returns, as of the ending balance sheet date, which excludes amounts that pertain to examined tax returns.", "label": "Increase (Decrease) in Liability Related to Unrecognized Tax Positions", "terseLabel": "Liability related to unrecognized tax benefits" } } }, "localname": "IncreaseDecreaseInLiabilityRelatedToUnrecognizedTaxPositions", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "natr_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Liabilities", "label": "Increase (Decrease) In Operating Lease, Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "natr_IncreaseDecreaseinAccruedVolumeIncentivesandServiceFees": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the net increase or decrease in payables that are related to accrued volume incentives, during the reporting period.", "label": "Increase (Decrease) in Accrued Volume Incentives and Service Fees", "terseLabel": "Accrued volume incentives and service fees" } } }, "localname": "IncreaseDecreaseinAccruedVolumeIncentivesandServiceFees", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "natr_IndicativeIndexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicative Index", "label": "Indicative Index [Member]", "terseLabel": "Indicative Index" } } }, "localname": "IndicativeIndexMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "natr_LatinAmericaAndOtherSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Latin America And Other Segment [Member]", "label": "Latin America And Other Segment [Member]", "terseLabel": "Latin America and Other" } } }, "localname": "LatinAmericaAndOtherSegmentMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseFromAdditionalBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings", "terseLabel": "Potential increase in maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseFromAdditionalBorrowings", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "natr_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseFromAdditionalBorrowingsMinimumPerOccurrence": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings, Minimum Per Occurrence", "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase From Additional Borrowings, Minimum Per Occurrence", "terseLabel": "Potential increase in maximum borrowing capacity, per occurrence" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseFromAdditionalBorrowingsMinimumPerOccurrence", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "natr_LineOfCreditFacilityNumberOfSeparateIncreases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Number Of Separate Increases", "label": "Line Of Credit Facility, Number Of Separate Increases", "terseLabel": "Number of separate increases" } } }, "localname": "LineOfCreditFacilityNumberOfSeparateIncreases", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "integerItemType" }, "natr_MinimumNumberOfClaimsCompaniesInsuranceCoverageMayNotCover": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the minimum number of claims the Company's insurance coverage may not be sufficient to cover.", "label": "Minimum Number of Claims Companies Insurance Coverage May Not Cover", "terseLabel": "Minimum number of claims that the Company's insurance coverage may not be sufficient to cover" } } }, "localname": "MinimumNumberOfClaimsCompaniesInsuranceCoverageMayNotCover", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "natr_NaturesSunshineProductsChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Natures Sunshine Products, China [Member]", "label": "Natures Sunshine Products, China [Member]", "verboseLabel": "NSP China" } } }, "localname": "NaturesSunshineProductsChinaMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "natr_NetSalesandOperatingIncomeTargetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sales and Operating Income Targets [Member]", "label": "Net Sales and Operating Income Targets [Member]", "terseLabel": "Net Sales and Operating Income Targets" } } }, "localname": "NetSalesandOperatingIncomeTargetsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "natr_NonIncomeTaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to non-income tax matters, including value-added taxes.", "label": "Non Income Tax [Member]", "terseLabel": "Non-Income Tax Contingencies" } } }, "localname": "NonIncomeTaxMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "natr_NorthAmericaSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "North America Segment [Member]", "label": "North America Segment [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaSegmentMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_NumberofPrincipalCategoriesofProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Principal Categories of Products", "label": "Number of Principal Categories of Products", "terseLabel": "Number of principal categories of products" } } }, "localname": "NumberofPrincipalCategoriesofProducts", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "integerItemType" }, "natr_OperatingLeaseNonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Non-Cash Lease Expense", "label": "Operating Lease, Non-Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseNonCashLeaseExpense", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "natr_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to all other international countries.", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_PerformanceBasedRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-Based Restricted Stock Units (RSUs) [Member]", "label": "Performance-Based Restricted Stock Units (RSUs) [Member]", "terseLabel": "Performance-Based Restricted Stock Units (RSUs)" } } }, "localname": "PerformanceBasedRestrictedStockUnitsRSUsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "natr_PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the performance based stock options, which vest upon achieving operating income margins.", "label": "Performance Based Stock Options Vesting Upon Achieving Operating Income Margins [Member]", "terseLabel": "Performance based stock options operating income margins" } } }, "localname": "PerformanceBasedStockOptionsVestingUponAchievingOperatingIncomeMarginsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "natr_PersonalCareProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to personal care products of the entity.", "label": "Personal Care Products [Member]", "terseLabel": "Personal care" } } }, "localname": "PersonalCareProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "natr_RestrictionPeriodForIssuanceOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the restriction period before shares will be issued related to a share-based compensation plan.", "label": "Restriction Period for Issuance of Shares", "terseLabel": "Restriction period for issuance of shares" } } }, "localname": "RestrictionPeriodForIssuanceOfShares", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "natr_RevenuefromContractwithCustomerRefundPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Refund Period", "label": "Revenue from Contract with Customer, Refund Period", "terseLabel": "Refund period" } } }, "localname": "RevenuefromContractwithCustomerRefundPeriod", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "natr_ScheduleOfSegmentReportingInformationBySegment1TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Segment Reporting Information, by Segment1", "label": "Schedule of Segment Reporting Information, by Segment1 [Table Text Block]", "terseLabel": "Schedule of assets per segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegment1TableTextBlock", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Performance Period", "terseLabel": "Award performance period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMinimumWithholdingRequirements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the minimum number of shares paid on behalf of the entity's employees per statutory withholding requirements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Minimum Withholding Requirements", "terseLabel": "Minimum withholding requirements (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMinimumWithholdingRequirements", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSubjectToRestrictionPeriodNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments subject to restriction period, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested Subject to Restriction Period, Number", "terseLabel": "Nonvested subject to restriction period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedSubjectToRestrictionPeriodNumber", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the first operating margin percentage to be achieved for the vesting of stock options.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, One", "terseLabel": "Operating income margin, one (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsOne", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the three operating margin percentage to be achieved for the vesting of stock options.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, Three", "terseLabel": "Operating income margin, three (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsThree", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the second operating margin percentage to be achieved for the vesting of stock options.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Operating Margins, Two", "terseLabel": "Operating income margin, two (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOperatingMarginsTwo", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "natr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrCanceledWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Canceled Weighted Average Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Or Canceled Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited or canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedOrCanceledWeightedAverageGrantDateFairValue", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "natr_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Lack of Marketability", "terseLabel": "Discount for lack of marketability" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsDiscountforLackofMarketability", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "natr_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised, and issuance of restricted stock units during the current period.", "label": "Stock Issued During Period, Shares, Stock Options and Restricted Stock Exercised", "terseLabel": "Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockExercised", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "natr_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options and issuance of restricted stock units.", "label": "Stock Issued During Period, Value, Stock Options and Restricted Stock Exercised", "terseLabel": "Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockExercised", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "natr_TimeBasedRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]", "label": "Time-Based Restricted Stock Units (RSUs) [Member]", "terseLabel": "Time-Based Restricted Stock Units (RSUs)" } } }, "localname": "TimeBasedRestrictedStockUnitsRSUsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "natr_TimeBasedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the time-based stock options, which vest over differing periods.", "label": "Time Based Stock Options [Member]", "terseLabel": "Time-based stock options" } } }, "localname": "TimeBasedStockOptionsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "natr_ValueAddedTaxAssessmentsAndOtherCivilLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to value added tax assessments and other civil litigation in which the entity is involved.", "label": "Value Added Tax Assessments And Other Civil Litigation [Member]", "terseLabel": "Value-added tax assessments and other civil litigation" } } }, "localname": "ValueAddedTaxAssessmentsAndOtherCivilLitigationMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "natr_VolumeIncentives": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the expenses that are related to incentives on volume sales, during the reporting period by the entity.", "label": "Volume Incentives", "terseLabel": "Volume incentives" } } }, "localname": "VolumeIncentives", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "natr_WeightManagementProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to weight management products of the entity.", "label": "Weight Management Products [Member]", "terseLabel": "Weight management" } } }, "localname": "WeightManagementProductsMember", "nsuri": "http://naturessunshine.com/20220630", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r43", "r45", "r98", "r99", "r243", "r264" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r220", "r222", "r223", "r224", "r242", "r263", "r304", "r305", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r489", "r492", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CommitmentsandContingenciesDetails", "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r220", "r222", "r223", "r224", "r242", "r263", "r304", "r305", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r489", "r492", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CommitmentsandContingenciesDetails", "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r174", "r222", "r223", "r283", "r286", "r443", "r488", "r490" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r174", "r222", "r223", "r283", "r286", "r443", "r488", "r490" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r204", "r220", "r222", "r223", "r224", "r242", "r263", "r294", "r304", "r305", "r334", "r335", "r336", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r489", "r492", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CommitmentsandContingenciesDetails", "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails", "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r204", "r220", "r222", "r223", "r224", "r242", "r263", "r294", "r304", "r305", "r334", "r335", "r336", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r489", "r492", "r513", "r514" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CommitmentsandContingenciesDetails", "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails", "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r44", "r45", "r98", "r99", "r243", "r264" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r175", "r176", "r283", "r287", "r491", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r175", "r176", "r283", "r287", "r491", "r500", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r302", "r421", "r422", "r425" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Subsidiaries" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r180", "r424" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33", "r430" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r181", "r182" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $525 and $143, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r15", "r460", "r476" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r48", "r49", "r50", "r477", "r497", "r498" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r47", "r50", "r56", "r57", "r58", "r102", "r103", "r104", "r377", "r418", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r23", "r183", "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Stock options (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r93", "r156", "r163", "r170", "r186", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r371", "r379", "r398", "r428", "r430", "r458", "r475" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r31", "r93", "r186", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r371", "r379", "r398", "r428", "r430" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r388" ], "calculation": { "http://naturessunshine.com/role/FairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r88" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r80", "r88", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r80", "r403" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r216", "r225", "r503" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Common stock, dividends (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share (in dollars per share)", "verboseLabel": "Cash dividend (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYPARENTHETICAL", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r102", "r103", "r385" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock, no par value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r430" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, no par value, 50,000 shares authorized, 19,259 and 19,724 shares issued\u00a0and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r53", "r55", "r63", "r370", "r383", "r468", "r484" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r91", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r272", "r273", "r284" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r70", "r443" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r13", "r15", "r16", "r92", "r100", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r258", "r259", "r260", "r261", "r414", "r459", "r461", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Margin on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r257", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r92", "r100", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r258", "r259", "r260", "r261", "r414" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Periodic payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r92", "r100", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r266", "r267", "r268", "r269", "r412", "r413", "r414", "r415", "r473" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesTradingRealizedGainLoss": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading, Realized Gain (Loss)", "terseLabel": "Debt securities, trading, realized gains (losses)" } } }, "localname": "DebtSecuritiesTradingRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InvestmentSecuritiesTradingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesTradingRestricted": { "auth_ref": [ "r440", "r501", "r502" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading, Restricted", "terseLabel": "Investment securities - trading", "verboseLabel": "Trading securities portfolio" } } }, "localname": "DebtSecuritiesTradingRestricted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://naturessunshine.com/role/InvestmentSecuritiesTradingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation payable" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r347", "r348" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r86", "r94", "r355", "r360", "r361", "r362" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r347", "r348" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r86", "r151" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends", "terseLabel": "Dividends, common stock, cash" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r64", "r107", "r108", "r109", "r110", "r111", "r116", "r119", "r125", "r126", "r127", "r131", "r132", "r386", "r387", "r469", "r485" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings (loss) per share attributable to common shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r64", "r107", "r108", "r109", "r110", "r111", "r119", "r125", "r126", "r127", "r131", "r132", "r386", "r387", "r469", "r485" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128", "r129", "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r403" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Provision (benefit) for income taxes, as a percentage of income before income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period over which the remaining compensation cost is expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Share based compensation potential compensation expense to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Tax benefit from the exercise of stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r56", "r57", "r58", "r102", "r103", "r104", "r106", "r112", "r114", "r134", "r187", "r265", "r270", "r342", "r343", "r344", "r356", "r357", "r385", "r405", "r406", "r407", "r408", "r409", "r411", "r418", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r248", "r258", "r259", "r397" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Total" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r388", "r389", "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of the company's hierarchy for assets measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r248", "r258", "r259", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r389", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r248", "r258", "r259", "r388", "r394" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r388", "r389", "r390", "r391", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r248", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r248", "r295", "r296", "r301", "r303", "r389", "r431" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 - Quoted Prices in Active Markets for Identical Assets" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r248", "r258", "r259", "r295", "r296", "r301", "r303", "r389", "r432" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 - Significant Other Observable Inputs" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r248", "r258", "r259", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r389", "r433" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 - Significant Unobservable Inputs" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r248", "r258", "r259", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r392", "r395" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r87", "r401", "r402" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Foreign exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r72", "r86", "r184" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Realized and unrealized gains (losses) on investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on sale of property, plant and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r68", "r93", "r156", "r162", "r166", "r169", "r172", "r186", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r398" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r60", "r156", "r162", "r166", "r169", "r172", "r456", "r465", "r470", "r486" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r95", "r351", "r353", "r354", "r358", "r363", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r113", "r114", "r154", "r349", "r359", "r364", "r487" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r85", "r442" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation payable" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r120", "r121", "r122", "r127", "r308" ], "calculation": { "http://naturessunshine.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Stock-based awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r78", "r82", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r24", "r190" ], "calculation": { "http://naturessunshine.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r30", "r430" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://naturessunshine.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://naturessunshine.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r26", "r190" ], "calculation": { "http://naturessunshine.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r25", "r190" ], "calculation": { "http://naturessunshine.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r185", "r457", "r471", "r499", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investment Securities - Trading" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InvestmentSecuritiesTrading" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r93", "r164", "r186", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r372", "r379", "r380", "r398", "r428", "r429" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r93", "r186", "r398", "r430", "r463", "r480" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r37", "r93", "r186", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r372", "r379", "r380", "r398", "r428", "r429", "r430" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r16", "r461", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "verboseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Annual commitment fee" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r13", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Line of credit, outstanding, current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "terseLabel": "Current portion of note payable" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Revolving Credit Facility and Other Obligations" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Long-term note payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r217", "r219", "r220", "r221", "r222", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and contingencies" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r217", "r219", "r220", "r221", "r222", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r217", "r218" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Accrued liabilities" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r220", "r222", "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimate of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyLossInPeriod": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.", "label": "Loss Contingency, Loss in Period", "terseLabel": "Provision for losses" } } }, "localname": "LossContingencyLossInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r217", "r219", "r220", "r221", "r222", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r42", "r93", "r186", "r228", "r232", "r233", "r234", "r237", "r238", "r398", "r462", "r479" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Joint venture ownership, noncontrolling party" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Joint venture ownership" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Increase (decrease) in noncontrolling interest" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r42", "r69", "r369", "r378" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r80", "r84", "r87" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r51", "r54", "r58", "r61", "r87", "r93", "r105", "r107", "r108", "r109", "r110", "r113", "r114", "r123", "r156", "r162", "r166", "r169", "r172", "r186", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r387", "r398", "r466", "r482" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r51", "r54", "r58", "r113", "r114", "r375", "r382" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r107", "r108", "r109", "r110", "r116", "r117", "r124", "r127", "r156", "r162", "r166", "r169", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r102", "r103", "r104", "r270", "r368" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r32", "r97", "r423" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Related party notes payable" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.", "label": "Notes Receivable [Member]", "terseLabel": "Notes Receivable" } } }, "localname": "NotesReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesReceivableRelatedPartiesCurrent": { "auth_ref": [ "r19", "r97", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).", "label": "Notes Receivable, Related Parties, Current", "terseLabel": "Notes receivable, related parties, current" } } }, "localname": "NotesReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevenueRecognitionNarrativeDetails", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r156", "r162", "r166", "r169", "r172" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://naturessunshine.com/role/SegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r417" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r417" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r416" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r115", "r142", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r11" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r46", "r48", "r399", "r400", "r404" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation loss (net of tax)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r55", "r56", "r57", "r59", "r62", "r265", "r405", "r410", "r411", "r467", "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (loss), net", "verboseLabel": "Other loss, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.", "label": "Payments for Purchase of Securities, Operating Activities", "negatedLabel": "Purchase of trading investment securities" } } }, "localname": "PaymentsForPurchaseOfSecuritiesOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r76" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Payments of cash dividends" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r76" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Payments related to tax withholding for net-share settled equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r75", "r92" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfSecuritiesOperatingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from sale of investments in debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.", "label": "Proceeds from Sale of Securities, Operating Activities", "terseLabel": "Proceeds from sale of trading investment securities" } } }, "localname": "ProceedsFromSaleOfSecuritiesOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r51", "r54", "r58", "r79", "r93", "r105", "r113", "r114", "r156", "r162", "r166", "r169", "r172", "r186", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r370", "r374", "r376", "r382", "r383", "r387", "r398", "r470" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r202", "r430", "r472", "r481" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "verboseLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r65", "r189" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r302", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r421", "r425" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related party transaction, amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r302", "r421", "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party transaction, rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r302", "r421", "r425", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r419", "r420", "r422", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r77", "r92" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Principal payments of revolving credit facility" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r77" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedTerseLabel": "Principal payments of long-term debt" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r77" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedTerseLabel": "Principal payments of related party borrowing" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r86", "r205", "r209", "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r206", "r207", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r207", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r270", "r430", "r478", "r496", "r498" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r102", "r103", "r104", "r106", "r112", "r114", "r187", "r342", "r343", "r344", "r356", "r357", "r385", "r493", "r495" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r147", "r148", "r161", "r167", "r168", "r174", "r175", "r178", "r282", "r283", "r443" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total net sales revenue", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r285", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of consolidated property, plant and equipment by geographical locations" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of revenue generated by each of the Company's product lines" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of composition of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r67", "r175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of consolidated net sales revenue by geographical locations" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r156", "r159", "r165", "r200" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r156", "r159", "r165", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of reportable business segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r306", "r307", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r312", "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r143", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r172", "r178", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r208", "r213", "r488" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r143", "r145", "r146", "r156", "r160", "r166", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]", "terseLabel": "Net sales:" } } }, "localname": "SegmentReportingInformationRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://naturessunshine.com/role/SegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r85" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted Stock Units outstanding, ending balance (in shares)", "periodStartLabel": "Restricted Stock Units outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted Stock Units outstanding, ending balance (in dollars per share)", "periodStartLabel": "Restricted Stock Units outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted\u00a0Average Grant\u00a0Date Fair\u00a0Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional number of shares authorized under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic values of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited or canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding at the end of the period (in shares)", "periodStartLabel": "Options outstanding at the beginning of the period (in shares)", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Options outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted\u00a0Average Exercise Price\u00a0Per\u00a0Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsRSUActivityDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Unvested stock options outstanding (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding at the beginning of the period (in dollars per share)", "periodStartLabel": "Options outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted\u00a0Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r271", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "Capital Transactions" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r143", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r163", "r164", "r166", "r167", "r168", "r169", "r170", "r172", "r178", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r208", "r213", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r41", "r56", "r57", "r58", "r102", "r103", "r104", "r106", "r112", "r114", "r134", "r187", "r265", "r270", "r342", "r343", "r344", "r356", "r357", "r385", "r405", "r406", "r407", "r408", "r409", "r411", "r418", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r102", "r103", "r104", "r134", "r443" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r265", "r270", "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails", "http://naturessunshine.com/role/CapitalTransactionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture", "terseLabel": "Share-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r17", "r18", "r265", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r17", "r18", "r265", "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r57", "r93", "r102", "r103", "r104", "r106", "r112", "r186", "r187", "r270", "r342", "r343", "r344", "r356", "r357", "r368", "r369", "r381", "r385", "r398", "r405", "r406", "r411", "r418", "r494", "r495" ], "calculation": { "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r6", "r14", "r464" ], "calculation": { "http://naturessunshine.com/role/FairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Investment securities - trading" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r206", "r207", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r346", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Liability related to unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r135", "r136", "r137", "r138", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/RevolvingCreditFacilityandOtherObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CapitalTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Potentially dilutive shares included in the calculation of diluted earnings per share" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r127" ], "calculation": { "http://naturessunshine.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average diluted common shares outstanding (in shares)", "totalLabel": "Diluted weighted-average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Diluted shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r116", "r127" ], "calculation": { "http://naturessunshine.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Basic weighted-average shares outstanding (in shares)", "terseLabel": "Weighted average basic common shares outstanding (in shares)", "verboseLabel": "Basic weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://naturessunshine.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://naturessunshine.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r471": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r518": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r519": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r520": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r521": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 62 0000275053-22-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000275053-22-000017-xbrl.zip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